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Background: Each year, approximately 30,000 people have an out-of-hospital cardiac arrest (OHCA) that
is treated by UK ambulance services. Across all cases of OHCA, survival to hospital discharge is less than
10%. Acute coronary syndrome (ACS) is a common cause of OHCA.
Objectives: To explore factors that influence survival in patients who initially survive an OHCA attributable
to ACS.
Data source: Data collected by the Myocardial Ischaemia National Audit Project (MINAP) between 2003
and 2015.
Participants: Adult patients who had a first OHCA attributable to ACS and who were successfully
resuscitated and admitted to hospital.
Main outcome measures: Hospital mortality, neurological outcome at hospital discharge, and time to
all-cause mortality.
Methods: We undertook a cohort study using data from the MINAP registry. MINAP is a national audit
that collects data on patients admitted to English, Welsh and Northern Irish hospitals with myocardial
ischaemia. From the data set, we identified patients who had an OHCA. We used imputation to address
data missingness across the data set. We analysed data using multilevel logistic regression to identify
modifiable and non-modifiable factors that affect outcome.
Results: Between 2003 and 2015, 1,127,140 patient cases were included in the MINAP data set. Of
these, 17,604 OHCA cases met the study inclusion criteria. Overall hospital survival was 71.3%. Across
hospitals with at least 60 cases, hospital survival ranged from 34% to 89% (median 71.4%, interquartile
range 60.7–76.9%). Modelling, which adjusted for patient and treatment characteristics, could account for
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only 36.1% of this variability. For the primary outcome, the key modifiable factors associated with reduced
mortality were reperfusion treatment [primary percutaneous coronary intervention (pPCI) or thrombolysis]
and admission under a cardiologist. Admission to a high-volume cardiac arrest hospital did not influence
survival. Sensitivity analyses showed that reperfusion was associated with reduced mortality among
patients with a ST elevation myocardial infarction (STEMI), but there was no evidence of a reduction in
mortality in patients who did not present with a STEMI.
Limitations: This was an observational study, such that unmeasured confounders may have influenced study
findings. Differences in case identification processes at hospitals may contribute to an ascertainment bias.
Conclusions: In OHCA patients who have had a cardiac arrest attributable to ACS, there is evidence of
variability in survival between hospitals, which cannot be fully explained by variables captured in the
MINAP data set. Our findings provide some support for the current practice of transferring resuscitated
patients with a STEMI to a hospital that can deliver pPCI. In contrast, it may be reasonable to transfer
patients without a STEMI to the nearest appropriate hospital.
Future work: There is a need for clinical trials to examine the clinical effectiveness and cost-effectiveness
of invasive reperfusion strategies in resuscitated OHCA patients of cardiac cause who have not had
a STEMI.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
Each year, approximately 30,000 people have an out-of-hospital cardiac arrest (OHCA) that is treated byUK ambulance services. Cardiac arrest is often caused by a condition that affects blood supply to the
heart (e.g. a heart attack). At present, less than 1 in 10 OHCA patients survive to leave hospital following
OHCA, but this varies significantly across the country.
In this research study, we used data about OHCA patients from the Myocardial Ischaemia National Audit
Project (MINAP) registry to identify reasons why survival may vary. The MINAP registry collects data about
patients admitted to hospital who have had a heart attack or other condition that affects blood supply to
the heart. We used statistical techniques to try to identify which factors were associated with hospital
survival following OHCA.
We analysed information from 17,604 patients who had an OHCA between 2003 and 2015, and who
were included in the MINAP registry. The overall rate of patients who survived to leave hospital was 71%.
We found that survival rates by hospital did vary, but we could explain only some of this variation. Treatment
with a drug or procedure to reopen blocked blood vessels in the heart reduced the likelihood of dying in
hospital. However, these treatments require admission to a specialist hospital and seem to benefit only
patients who have a specific type of heart attack. Patients who did not have that type of heart attack did
not seem to benefit from admission to a specialist hospital, and could possibly be safely treated at the
nearest hospital.
This research study has helped us to better understand which patients, following OHCA, may benefit from
care in specialist hospitals, but the best treatment for some patients remains uncertain. It will be necessary
to conduct research in the future to help understand the best treatment for these patients.
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Scientific summary
Background
There are approximately 30,000 treated out-of-hospital cardiac arrests (OHCAs) in the UK each year.
Among these patients, 27.5% experience return of spontaneous circulation and 8.4% survive to hospital
discharge. Acute coronary syndrome (ACS) describes a spectrum of cardiac conditions, including unstable
angina pectoris and myocardial infarction (MI), that affect the coronary blood supply, thereby reducing
oxygen delivery to cardiac muscle. Coronary heart disease is a leading cause of death across Europe and is
a common cause of OHCA.
Previous studies have shown marked variability in survival, both between ambulance services and between
hospitals. Data from UK ambulance services show marked variability between ambulance services in the
percentage of patients who survive to hospital discharge (ranging from 2.5% to 12%), which cannot be
fully explained by case mix. At present, there are no UK data reporting OHCA survival variation between
hospitals, but international data show that, among OHCA patients admitted alive to hospital, survival by
hospital ranges from 14% to 59%. This may be partly attributable to variability in patient care.
One strategy to reduce variability in survival and clinical practice may be the establishment of regional
cardiac arrest centres. According to this strategy, the ambulance will, provided certain criteria are met,
bypass the local emergency department and transfer the patient directly to a regional centre. The rationale
behind this strategy is that the disadvantage of longer ambulance transport time is offset by expert care
at the regional centre through treatment by clinicians with greater exposure to the condition, improved
access to complementary clinical specialties and improved access to imaging and specialist interventions.
Such systems have been established in other disease areas [e.g. stroke, major trauma and ST elevation
myocardial infarction (STEMI)].
In 2010, the American Heart Association released a policy statement that described a need to establish
regionalised cardiac arrest care in the USA to improve patient outcome following OHCA. Subsequently,
the 2015 International Liaison Committee on Resuscitation recommended the establishment of regionalised
cardiac arrest care systems, but acknowledged that the supporting evidence was typically of low quality.
Importantly, none of the studies conducted to date has been undertaken in the UK setting.
Reducing variability in survival provides the opportunity to save more lives if outcomes can be improved to
reflect the best-performing systems.
Objectives
The aim of this research was to identify pre-hospital and in-hospital factors that affect survival in adult
patients who initially survive an OHCA attributable to ACS.
Methods
We conducted a retrospective cohort study to describe the epidemiology and outcomes among patients
admitted to hospital following successful resuscitation from OHCA caused by an ACS, and to identify
modifiable pre-hospital and in-hospital factors that affect outcomes in these patients.
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The data source was the Myocardial Ischaemia National Audit Project (MINAP) data set. MINAP is a national
audit commissioned by the Healthcare Quality Improvement Partnership, which collects data on patients
with myocardial ischaemia who are treated at a hospital in England, Wales or Northern Ireland. Data are
collected at the hospital level. The data set, as of 2014, contained > 1.25 million records. For each patient
record, a series of approximately 130 data points are collected, which cover the patient journey from the
onset of symptoms to hospital discharge. The data set includes data on patient demographics, past medical
history, pre-hospital interventions, in-hospital laboratory results, in-hospital drug therapy, in-hospital
interventions, discharge drugs and interventions, and the patient’s status at discharge.
Patients in the MINAP data set were eligible for inclusion in this study if they were an adult (aged ≥ 18 years)
who had an OHCA due to an ACS, and where initial resuscitation attempts were successful, leading to
admission to hospital. The exclusion criteria were second or subsequent cardiac arrest events and in-hospital
cardiac arrest.
The primary study outcome was all-cause in-hospital mortality. The secondary outcomes were neurological
outcome at hospital discharge and time to all-cause mortality. The time to all-cause mortality included only
patients who were discharged alive from hospital.
Modifiable and non-modifiable variables were categorised in four groups (demographic variables, medical
history variables, presenting characteristics of the OHCA variables and discharge care variables) to facilitate
data management and analysis.
For hospital-level data [distance to hospital, volume, primary percutaneous coronary intervention (pPCI) centre]
we categorised patients by the hospital to which they were first admitted. For hospital volume, we calculated
the number of OHCA cases per year at each hospital and categorised volume as low (1–10 cases), medium
(11–24 cases) or high (25–82 cases). Patients were then allocated a category based on the first hospital that
they attended. A pPCI centre was defined as a hospital that performed at least 100 pPCI procedures per year,
as per the British Cardiovascular Intervention Society recommendations for interventional centres (Banning AP,
Baumbach A, Blackman D, Curzen N, Devadathan S, Fraser D, et al. Percutaneous coronary intervention in the
UK: recommendations for good practice 2015. Heart 2015;101:1–13).
For reperfusion treatment, pPCI and thrombolysis were categorised by the time (early, late, unknown)
at which treatment was delivered. Early pPCI was defined as being within 90 minutes of hospital arrival.
Early thrombolysis was defined as being within 60 minutes of the call for help. Timings outside these
windows were considered late.
As a result of data missingness in the MINAP data set, we used imputation strategies to reduce the risk of
bias that may result from incomplete data. Data imputation was undertaken following case identification.
No outcomes were imputed. Our imputation strategy was informed by previous work on the MINAP
data set and included assigning appropriate imputation modelling strategies (binary logistic regression,
polytomous regression, predictive mean matching, default imputation) to specific variables. Convergence
was assessed by checking whether or not the imputation chains mixed well for all variables.
We report patient characteristic data for both the pre-imputation data set and the imputed data sets.
Continuous data are summarised as mean and standard deviation (SD), median and interquartile range
(IQR), and range. Categorical data are presented as number and percentage in each category. For each
outcome, we present unadjusted and adjusted analyses that include, for each variable, a point estimate,
95% confidence interval (CI) and p-value. Presented odds ratios (ORs) describe the odds of in-hospital
death or death/poor neurological outcome. Hazard ratios are used for the time to all-cause mortality
analysis. As such, for each analysis, a point estimate greater than one describes a worse outcome.
For the unadjusted analyses for the outcomes of in-hospital mortality and neurological outcome, we used
univariate random effects (RE) logistic regression models for each predictor variable, with a RE term for the
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hospital. For the adjusted analyses for the outcomes of in-hospital mortality and neurological outcome, we
included as many clinically relevant predictor variables in the model as possible, while avoiding including
two predictor variables that led to biased OR estimates due to multi-collinearity as a result of the two
predictors being highly correlated. We used a similar approach for the analysis of time to all-cause mortality,
except that a proportional hazards Cox regression RE model was used. We performed sensitivity analyses to
assess the robustness of the results due to the missing data methods used and assumptions made.
This study was secondary research that utilised an anonymised data set. Ethics approval was granted by the
University of Warwick Biomedical Research Ethics Committee. MINAP forms part of the National Institute for
Cardiovascular Outcomes Research, which is registered as a data controller under the Data Protection Act
1998 and has permission to collect and store patient identifiable information without consent in accordance
with section 251 of the National Health Service Act 2006 (Great Britain. National Health Service Act 2006.
Chapter 41. London: The Stationery Office; 2006).
Results
The data set provided by MINAP comprised 1,127,140 cases that were included in the audit between 2003
and 2015. Of these, 17,604 cases were identified as eligible for the study and included in the analysis of
our primary outcome. Analyses for neurological outcome and time to all-cause mortality comprised 15,286
and 12,483 patients, respectively.
In our patient cohort, most patients survived to hospital discharge (n = 12,557, 71.3%), but there was
variability in survival by hospital. Across the 94 hospitals that contributed at least 60 patient cases,
the survival rate ranged from 34% to 89% (median 71.4%, IQR 60.7–76.9%). For discharge with good
neurological outcome, 9041 (59.1%) of the 15,286 analysed patients survived to hospital discharge with
good neurological outcome. In the cohort of 12,483 patients who survived to hospital discharge, who
were included in the time to all-cause mortality analysis, 1926 (15.4%) died during the follow-up period.
The mean survival time was 84.3 months (95% CI 83.5 to 85.1 months).
Pre-imputation characteristics of patients included in the in-hospital mortality analysis show that most
patients were male (n = 13,188, 75.1%) and of white ethnicity (n = 14,343, 93.7%), with a mean age of
65.3 years (SD 13.2 years). Most patients were current or former smokers (n = 8883, 63.5%) and had at
least one comorbidity (n = 10,729, 60.9%). The commonest comorbidities were hypertension (n = 6389,
41.0%), hypercholesterolaemia (n = 3906, 25.9%) and previous acute myocardial infarction (AMI)
(n = 3092, 19.7%). Cardiac arrest events usually occurred before ambulance arrival (n = 10,533, 60.1%),
with a presenting rhythm of ventricular fibrillation (VF) or ventricular tachycardia (VT) (n = 14,778, 89.6%).
Most patients were admitted to the hospital during daytime hours (08.00–19.59 hours) (n = 11,741,
66.7%). The most common admission diagnosis was definite MI (anterior infarction: n = 3897, 27.0%;
other infarction site: n = 3639, 25.2%). ST-segment elevation/left bundle branch block were the most
common electrocardiographic findings (n = 12,220, 71.9%).
The median emergency medical service response time was 8 minutes (IQR 5–14 minutes). The median
distance between the patient’s home address and the admitting hospital was 8.1 km (IQR 3.9–15.8 km).
The patient distribution between low-volume (≤ 10 OHCA cases per year), medium-volume (11–24 OHCA
cases per year) and high-volume (25–82 OHCA cases per year) hospitals was 45.4% (n = 7984), 37.0%
(n = 6516) and 17.6% (n = 3104), respectively. The first hospital in which most patients (n = 9804, 55.7%)
were treated was classified as a pPCI centre.
Just over half of patients were admitted to the cardiac care unit (also referred to as the coronary care unit)
(n = 8872, 51.0%) and approximately one-third of patients were admitted to the intensive care unit
(n = 6154, 35.4%). Patients typically received aspirin or were already on aspirin (n = 14,126, 87.7%) and
underwent, a pre-hospital electrocardiogram (ECG) (n = 11,053, 75.7%). Reperfusion treatment (pPCI or
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thrombolysis) was delivered to 62.8% (n = 9540). Of these 9540 patients, the majority received pPCI (pPCI:
n = 6160, 64.6%; thrombolysis: n = 3380, 35.4%). Over the course of the study, there was an increase in
the use of reperfusion therapy. Across all groups, there was a move away from the use of thrombolysis to
pPCI over the study period. The time point at which the use of pPCI overtakes thrombolysis use is around
2008–9 and, thus, by the end of the study period, very few patients received thrombolysis.
The adjusted model for in-hospital mortality had an R2-value of 0.361, such that we could explain only
36.1% of the variability in the data. Factors associated with increased mortality included female sex,
increased age and increased deprivation. Ethnicity was not associated with hospital mortality.
Some comorbidities [heart failure, cerebrovascular disease, asthma or chronic obstructive pulmonary
disease (COPD) and peripheral vascular disease] were associated with an increased mortality, while
hypercholesterolaemia and hypertension were associated with reduced mortality. Cardiac arrest following
ambulance arrival and an initial cardiac arrest of VF/VT were associated with reduced mortality. Although
admission to a percutaneous coronary intervention (PCI) centre seemed to be associated with increased
mortality, early PCI and PCI where time was missing were associated with reduced mortality. Similarly,
early thrombolysis was associated with reduced mortality. Neither late PCI nor late thrombolysis influenced
survival. Each additional kilometre travelled to hospital appeared to be associated with a small decrease in
mortality. Hospital volume was not associated with mortality.
In sensitivity analyses, we found that in patients who did not present with a STEMI, night-time hospital
admission (between 20.00 and 07.59 hours) was associated with increased mortality and there was no
evidence of reduced mortality with the use of a reperfusion treatment.
The results of the adjusted analysis for neurological outcome were broadly similar to those reported for
the primary outcome (in-hospital mortality). However, there was an association between in-hospital ECG,
compared with pre-hospital ECG, and poorer outcome. In contrast to the primary outcome analysis,
neither transfer distance nor admission to a pPCI centre was associated with neurological outcome.
In the analysis of time to all-cause mortality, increased age and deprivation were predictive of increased
mortality, but ethnicity and sex were not associated with mortality. Only four medical history variables
(previous AMI, heart failure, diabetes mellitus, asthma or COPD) were associated with worse outcome.
None of the care pathway variables, such as reperfusion treatment, was associated with time to all-cause
mortality. The provision of coronary angiography, cardiology follow-up and cardiac rehabilitation was
associated with reduced risk of mortality. Similarly, discharge on beta-blockers or angiotensin-converting
enzyme inhibitor was associated with improved outcome. However, antiplatelet therapy on discharge did
not influence outcome.
Conclusions
Our study showed evidence of variability in survival between hospitals, such that survival in hospitals with
at least 60 cases ranged from 34% to 89% (median 71.4%, IQR 60.7–76.9%). The overall rate of patients
who survived was 71.3%. We could explain only 36.1% of this outcome variability through modelling of
variables in the MINAP data set. Similarly, there was variability between hospitals in relation to survival with
good neurological outcome, which ranged from 13% to 84% (median 58.9%, IQR 44.2–66.8%) across
hospitals with at least 60 cases.
The evaluation of modifiable factors in the patient journey produced conflicting results. There was no
evidence to suggest that increased transfer distances had a harmful effect, but hospital volume and
admission to a specialist services (pPCI centre) either had no effect or were associated with worse
outcomes. Early reperfusion, whether by thrombolysis or pPCI, was associated with improved outcome,
primarily in STEMI patients.
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Chapter 1 Introduction
Cardiac arrest and its epidemiology
Cardiac arrest describes the sudden cessation of heart function. Cardiac arrests may occur in the hospital
setting (in-hospital cardiac arrest) or outside the hospital [out-of-hospital cardiac arrest (OHCA)]. Cardiac
arrest is a time-critical condition, such that each minute of delay in initiating key treatments, such as chest
compressions and defibrillation, is associated with a significant decrease in survival.1,2 Survival following
cardiac arrest can be categorised as either return of spontaneous circulation (ROSC), which describes the
resumption of effective cardiac activity, or longer-term survival, often measured at discharge or 30 days
following the cardiac arrest event.
There are approximately 60,000 OHCAs in the UK each year, and treatment is delivered in approximately
half of cases.3,4 In 2014, there were 28,729 treated cardiac arrests in England that were reported to the
Out of Hospital Cardiac Arrest Outcomes project, based at the University of Warwick.5 This corresponds to
an incidence of 53.2 per 100,000 people. In this cohort, where data were available, 27.5% had a ROSC at
hospital transfer and 8.4% survived to hospital discharge. Neurological outcome and long-term survival is
not recorded in the data set, but other data demonstrate that hospital survivors often have a reasonable
long-term prognosis and quality of life.6–8
Acute coronary syndrome (ACS) describes a spectrum of cardiac conditions that affect the coronary blood
supply, thereby affecting oxygen delivery to cardiac muscle. ACS includes conditions such as unstable
angina pectoris, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction
(STEMI). Coronary heart disease is a leading cause of death across Europe, causing 1.8 million deaths per
year, which equates to approximately 20% of all European deaths.9 In the UK, coronary heart disease
causes 73,500 deaths each year and is responsible for 15% of male and 8% of female premature deaths,
which is defined as death in people aged < 75 years.10
Cardiac arrest represents the end point of all critical illnesses, including cardiovascular disease, trauma,
sepsis and stroke. Clinically, it can be difficult to accurately identify the cause of a cardiac arrest during
the resuscitation attempt. However, OHCAs are often sudden events that are likely to have been caused
by ACS. Until recently, international OHCA reporting guidelines recommended that the cause of OHCA
be categorised as one of cardiac disease, trauma, submersion, drug overdose, asphyxia, exsanguination or
any other non-cardiac cause.11,12 Based on this categorisation, 81.2% of English cardiac arrests to which a
cause is attributed are classified as due to a cardiac cause.5 This proportion is similar to that reported in
other studies.2,13–15 A systematic review of patients who underwent angiography following resuscitation
from OHCA without an obvious non-cardiac cause reported that 59–71% patients had evidence of
significant coronary artery disease.16
The cardiac arrest chain of survival
The cardiac arrest chain of survival describes the four key processes that are necessary for optimum recovery
from OHCA (Figure 1).18,19 Developed originally in 1991 by the American Heart Association, the chain was
updated in 2005 to reflect the importance of both cardiac arrest prevention and post-resuscitation
care.17,19,20 The process is conceptualised as a chain because any link that is missed, delayed or delivered
ineffectively reduces the likelihood of survival.
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For OHCA, the first three links [early access, early cardiopulmonary resuscitation (CPR) and early defibrillation]
are delivered in the pre-hospital setting and focus on the initial ROSC. This fourth link (post-resuscitation
care) describes care that is predominantly delivered in the hospital setting, which focuses on the restoration
of quality of life.
Hospital care plays a key role in patient outcome following cardiac arrest. After successful resuscitation
from cardiac arrest, patients develop post-cardiac-arrest syndrome, in which four separate, but inter-related,
physiological processes assault the cardiac arrest survivor.21 These process are post-cardiac-arrest brain injury,
post-cardiac-arrest myocardial dysfunction, a systemic ischaemia–reperfusion response and the underlying
cause of the original cardiac arrest event.
In a before-and-after study conducted in Norway, the implementation of a cardiac arrest care bundle
in patients with OHCA of cardiac aetiology admitted to the intensive care unit was associated with a
significant improvement in survival with good neurological outcome.22 The care bundle included the use
of therapeutic hypothermia, cardiac reperfusion therapy and physiological targets for blood glucose, blood
pressure and ventilation. In a multivariate analysis, the delivery of a standardised treatment bundle was the
strongest predictor of good outcome.
Variability in survival
The incidence of treated OHCA in the UK (53.2 per 100,000 person-years) is similar to that in North
America (54.6 per 100,000 person-years), although it is slightly higher than that in the rest of Europe
(35 per 100,000 person-years).5,23 However, the reported rates of ROSC (27.5%) and overall survival to
hospital discharge (8.4%) lag significantly behind those of other nations.
In Europe, the EuReCa One project captured OHCA data from 7146 patients who had an OHCA across
27 European countries in October 2014.24 The overall reported rate of ROSC was 28.6%, which is similar
to UK data, but there was marked variability even among countries contributing a large number of cases,
with reported ROSC rates ranging from < 10% to > 40%. Across the data set, the overall reported
hospital/30-day survival rate was 10.3%, with reported rates varying from 1.1% to 30.8%.
FIGURE 1 The chain of survival and relationship with different settings and objectives in the patient journey.
Adapted from European Resuscitation Council Guidelines for Resuscitation 2005 Section 1: Introduction, JP Nolan,
Resuscitation, 67, Supplement 1, S3–S6, 2005, with permission from Elsevier.17 CPR, cardiopulmonary resuscitation.
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High-performing health systems report OHCA hospital survival rates across all patients as exceeding 15%,
with survival in some subgroups exceeding 50%.25,26 Thus, it is likely that many UK OHCA deaths are
avoidable. However, these headline figures mask variability in survival that may result from both
ambulance service and hospital factors.
Ambulance-level variability
In the UK, there is evidence, as shown in Figure 2, of wide variability in ROSC and survival-to-discharge
rates across ambulance services.3 In 2011, the survival-to-discharge rate following OHCA by ambulance
service ranged from 2.5% to 12%.3 Although the number of cases was small, the variation was not
reduced through standardisation using the Utstein patient subgroup (witnessed arrest in a shockable
rhythm with bystander CPR), and neither was the variation in outcome associated with ambulance
response times.11,12 Such variation in outcome following OHCA across emergency medical service (EMS)
systems has also been observed in other countries.26–28
Hospital-level variability
In the UK, ambulance service data show variability in outcome in survival to discharge among ambulance
services with similar rates of ROSC (e.g. compare Great Western with Yorkshire and East of England
Ambulance Services in Figure 2).3 In the UK, conventional management for OHCA is that the patient will be
transferred to the nearest appropriate emergency department (ED) according to locally agreed protocols.
At present, there are no UK data reporting OHCA survival variation between hospitals. International data
from Sweden, Australia and North America show survival rates by hospital in OHCA patients admitted alive
to hospital, and these range from 14% to 59%.29–32 However, in the UK, there is evidence of variability in
practice. A recent survey of 208 UK intensive care units that treat cardiac arrest patients found that only
28 units could provide all of the interventions [24/7 primary percutaneous coronary intervention (pPCI),
ventilator care bundle, targeted temperature management and access to neurophysiology tests] recognised
as essential for the effective intensive care management of cardiac arrest patients.33 This availability is
important as the availability and delivery of key interventions is associated with improved hospital outcome.30,34
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FIGURE 2 Variability in OHCA survival rates across English ambulance services. The navy line corresponds to the
right vertical axis to describe the number of cardiac arrest calls per 1000 category A emergency calls. The black
and green bars correspond to the left vertical axis to describe ROSC (black bar) and survival to hospital discharge
(green bar) for services where data were available. Reproduced from Variability in cardiac arrest survival: the NHS
Ambulance Service Quality Indicators, GD Perkins and MW Cooke, Emergency Medicine Journal, vol. 29, pp. 3–5,
2011, with permission from BMJ Publishing Group Ltd.3
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One strategy to reduce variability in survival and clinical practice may be the establishment of regional
cardiac arrest centres. According to this strategy, the ambulance will, provided that certain criteria are met,
bypass the local ED and transfer the patient directly to a regional centre. The rational is that the disadvantage
of a longer ambulance transport time is offset by expert care at the regional setting through treatment by
clinicians with greater exposure to the condition, improved access to complementary clinical specialities and
improved access to imaging and specialist interventions.
Regionalised systems of care are already in place for conditions, such as stroke, STEMI and trauma. However,
recent systematic reviews in the clinical areas of stroke and trauma do not show improved outcome when
patients are taken directly to a specialist centre, rather to a non-specialist centre.35,36 In contrast, there is
evidence that treatment of STEMI patients with pPCI in a high-volume hospital is clinically effective and
cost-effective.37–39
In the context of cardiac arrest, the American Heart Association released a policy statement in 2010
describing a need to establish regionalised cardiac arrest care in the USA to improve patient outcome
following OHCA.40 In 2015, the International Liaison Committee on Resuscitation (ILCOR) review of evidence
led to a treatment recommendation that supported the establishment of regionalised cardiac arrest care
systems.41 However, in making this recommendation, ILCOR acknowledged that the supporting evidence
was of a low quality, that much of the evidence was retrospective and that there was inconsistency between
studies as to which hospital factors were associated with improved outcome.
Importantly, none of the studies conducted to date has been undertaken in the UK setting. A recently
published trial did demonstrate that it was feasible to undertake a randomised controlled trial comparing
transfer to a specialist centre and consideration of percutaneous coronary intervention centre (PCI) with
standard care in resuscitated OHCA patients without ST elevation on the electrocardiogram (ECG), and an
effectiveness trial is now being planned.42 As such, it is not currently possible to estimate the effects of
such a system of care in the UK, where environmental factors (e.g. disease prevalence, response times,
distances travelled), EMS systems (e.g. initial response time, ambulance staff skill mix, transfer time to
hospital) and hospital configurations vary.
Out-of-hospital cardiac arrest as a health and research priority
Out-of-hospital cardiac arrest is recognised as an important UK health priority.43 Reducing variability in
survival provides the opportunity to save more lives if outcomes can be improved to reflect the best
performing systems. The importance of OHCA as a health priority has been recognised in a series of
government publications.
In 2011, the National Audit Office report on transforming NHS ambulance services highlighted wide
variation in cost, methods of data collection and outcomes across ambulance services.44 In the same year,
OHCA survival was identified by the Department of Health as a key ambulance service quality indicator.45,46
More recently, the 2013 Department of Health Cardiovascular Disease Outcome Strategy described a
commitment to saving 1000 lives per year through improved health-care delivery to OHCA patients.47
It is, therefore, timely to evaluate the potential for regionalised cardiac arrest care to improve survival
from cardiac arrest.
INTRODUCTION
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Chapter 2 Research questions/objectives
This research aimed to answer the following question:
l In adult patients who initially survive an OHCA attributable to ACS, which pre-hospital and in-hospital
factors affect survival?
The specific objectives of this research were to:
1. describe the epidemiology and outcomes among patients admitted to hospital following successful
resuscitation from a cardiac arrest caused by ACS
2. identify the effect of modifiable factors that affect the outcomes of patients hospitalised following
resuscitation from an OHCA
3. develop recommendations for optimising pre-hospital and hospital organisation of services
4. develop a prioritised list of recommendations for further research in this area.
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Chapter 3 Methods
We conducted a retrospective cohort study using data from the Myocardial Ischaemia National AuditProject (MINAP) data set to describe the epidemiology and outcomes among patients admitted
to hospital following successful resuscitation from a cardiac arrest caused by an ACS, and to identify
modifiable pre-hospital and in-hospital factors that affect outcome in these patients.
The Myocardial Ischaemia National Audit Project
The MINAP is a national audit commissioned by the Healthcare Quality Improvement Partnership. MINAP
collects data on patients with myocardial ischaemia who are treated at a hospital in England, Wales or
Northern Ireland. Established in 1999, the project is managed by the National Institute for Cardiovascular
Outcomes Research (NICOR), based at University College London. Data are primarily collected for audit.
The full details of MINAP can be found on the project website and in its annual report.48,49
The Myocardial Ischaemia National Audit Project data set
As of 2014, the MINAP data set contained > 1.25 million records, with an additional 90,000 records being
uploaded each year. For each patient record, a series of data points are collected. These data points cover
the patient journey from the onset of symptoms to hospital discharge. The current data set includes
approximately 130 fields. This includes data on patient demographics, past medical history, pre-hospital
interventions, in-hospital laboratory results, in-hospital drug therapy, in-hospital interventions, discharge
drugs and interventions, and the patient’s status at discharge. A full list of the MINAP fields is included in
Appendix 1.
Four fields in the data set relate directly to cardiac arrest, namely the date/time of cardiac arrest (field 3.13),
cardiac arrest location (field 3.14), arrest presenting rhythm (field 3.15) and outcome of arrest (field 3.16).
One other field (field 3.10 – delay before treatment) has cardiac arrest as a listed response.
The MINAP data set can be linked to Office for National Statistics (ONS) data to provide additional
information on long-term mortality and deprivation.
Collection of the Myocardial Ischaemia National Audit data set
The MINAP data set is collected at the hospital level. In 2014, it was reported that all English, Welsh and
Northern Irish hospitals that admitted patients with myocardial ischaemia collected and uploaded data,
with the exception of Scarborough Hospital.48 MINAP is part of the national clinical audit programme,
such that hospital participation is mandated under section 26.1.2 of the service conditions of the NHS
standard contract.50
The precise process for collecting data, such as methods for identifying eligible cases and the personnel
involved in collecting and uploading data, varies between hospitals. This creates the potential for
ascertainment bias and is a recognised limitation of the MINAP data set.48 Data are uploaded using a
secure online system. Each patient record must contain, as a minimum, the date and time of hospital
admission, the hospital code, the patient’s hospital number and the admission diagnosis. MINAP has
developed a handbook that includes definitions of data points to standardise data collection, which is
available on the MINAP website.49
For some data points, there is a real-time data validation check. For example, the system will query the
serum cholesterol entry (field 2.15) if it is outside the range 2.5–25 mmol/l. In addition, MINAP performs
an annual data validation assessment in which hospitals re-enter data for 20 randomly selected patients
with a diagnosis of NSTEMI. The agreement between the original and re-entered data is recorded and
reported to the hospital.
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Process of obtaining data from the Myocardial Ischaemia National
Audit Project
The primary purpose of MINAP is that of a national audit, but research is recognised as an important
ancillary purpose. MINAP has developed an approval purpose for researchers who wish to obtain data for
this purpose. Previously, researchers have used the data set to describe the epidemiology of myocardial
ischaemia patients and to answer important research questions in this patient group, including the impact
of pre-hospital ECGs on outcome and treatment in ACS, the association between hospital volume and PCI
performance, and an international hospital comparison of treatment and outcome in patients that have an
acute myocardial infarction (AMI).51–53 However, this study is one of the first times that MINAP data have
been used for a research question that specifically focuses on OHCA.
In order to demonstrate the feasibility of this project and to secure funding, MINAP provided our team
with a random sample of 84,194 cases, of which 1431 (1.7%) were identified as cardiac arrest. Following
on from the funding award and project commencement, we were informed by MINAP that we would
need to submit only a revision to our original data application, rather than a new application for data.
Despite this preparatory work, we experienced significant delays in receiving data and unfortunately we
had to return to MINAP on several occasions as the data items that we had requested were not provided.
This process is summarised in Table 1. The key challenge that we experienced was the release of incomplete
data sets, as well as a lack of clarity regarding timelines, processes and the combination of data items that
could be released.
These delays meant that the team were required to request two no-cost extensions from the funder.
Inclusion/exclusion criteria and case identification process
Patient events in the MINAP data set were eligible for inclusion in this study if:
1. they were an adult (aged ≥ 18 years)
2. they had sustained an OHCA attributable to ACS and
3. initial resuscitation attempts were successful, leading to admission to hospital.
TABLE 1 Summary timeline of project MINAP data releases
Date Process
1 March 2014 Project start date
19 June 2014 Application amendment submitted to MINAP
12 September 2014 MINAP advised research team that application would need to be reviewed by the HQIP before it
could be released
10 October 2014 Research team advised that HQIP would review application at meeting on 14 October 2014
27 November 2014 MINAP advised research team that HQIP had approved data release
12 December 2014 Data extract released (number of key data items not included)
17 December 2014 Further data extract released (some key data items still missing)
23 April 2015 Further data extract released
10 June 2015 MINAP promised full case review to explore reasons for delays and incomplete data releases
23 June 2015 Further data extract released (uncleaned extract with cleaning instructions provided two days later)
27 November 2015 Final data extract released
HQIP, Healthcare Quality Improvement Partnership.
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Patient events were excluded if they were:
1. second or subsequent cardiac arrests, or
2. in-hospital cardiac arrest only.
We identified eligible cases using a seven-stage process, which first identified eligible cases and then
excluded cases in accordance with the predefined eligibility criteria. Details of the process are included in
Table 2. As ACS can be difficult to diagnose immediately post OHCA, we made the assumption that all
patients included in the MINAP data set had been assumed to have ACS at the point of admission.
Data were not imputed before case identification, and, thus, we did not include cases if data required for
determining eligibility were missing.
Outcome measures
The primary study outcome was all-cause in-hospital mortality. This was mainly identified through data
field 4.04, ‘death in hospital.’ If field 4.04 was missing, alternative fields were used, such as field 3.16,
‘outcome of arrest,’ field 4.16, ‘discharge destination’, and ONS data.
The secondary outcomes were neurological outcome at hospital discharge and time to all-cause mortality.
TABLE 2 Case identification process
Stage Process Process to identify cases
1 Identify all cases of cardiac arrest Any one of:
l field 3.10 (delay before treatment) – response of cardiac arrest
l field 3.13 (cardiac arrest date/time) – any response
l field 3.14 (cardiac arrest location) – response of before ambulance
arrival, after ambulance arrival, A&E, CCU, medical ward,
elsewhere in hospital, catheter lab
l field 3.15 (arrest presenting rhythm) – any response
l field 3.16 (outcome of arrest) – any response
2 Identify all cases of OHCA Case eligible if field 3.14 (cardiac arrest location) contained response
of ‘before ambulance arrival’ or ‘after ambulance arrival’
If field 3.14 is not completed, then case eligible if date/time in field
3.13 (cardiac arrest date/time) preceded date/time in field 3.06
(date/time arrival at hospital)
3 Identify adult cases of OHCA Age derived from field 1.06 (date of birth)
Case eligible if age was ≥ 18 years
4 Identify first case of OHCA Cases were excluded if 3.13 (cardiac arrest date/time – first arrest only)
was missing
5 Exclude all cases with no ROSC or
where resuscitation was not attempted
Cases were excluded if 3.16 (outcome of arrest) was recorded as no
return of circulation or resuscitation not attempted
6 Exclude duplicate records Cases were excluded if they were duplicated in the data set (e.g. same
case entered twice, transfer to another hospital leading to record
duplication). This process used anonymised patient identifiers (e.g.
anonymised NHS number) and probabilistic matching (e.g. matching
cases based on age, sex, admission hospital, admission time)
7 Exclude records where primary outcome
was missing
Cases were excluded if the primary outcome (hospital survival) was
missing
A&E, accident and emergency; CCU, cardiac care unit.
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9
For neurological outcome at hospital discharge, we dichotomised patients as either survival to hospital
discharge with good neurological outcome or death/poor neurological outcome at hospital discharge.
Neurological outcome was based on field 3.16 (outcome of arrest). Where field 3.16 was missing, we used
the primary outcome data to determine if the patient was dead at hospital discharge. Field 3.16 categorises
patient status at discharge as being either with or without neurological deficit, but there are no clear and
objective criteria on which to make this assessment detailed in the MINAP data set. Thus, this measure of
neurological recovery may not be as useful as either the cerebral performance category or modified Rankin
score, which are usually used in cardiac arrest studies.54
For time to all-cause mortality, we limited the analysis to patients who were discharged alive from hospital.
MINAP linked the data set to ONS data to provide survival days from the date of the cardiac arrest event
and mortality status at this time point (alive or dead). Where these data were unavailable and the patient
survived to hospital discharge, we used the days to discharge as the survival time and identified these
patients as censored (alive) at that point. This applied mainly to patients in later years, when data had not
yet been linked with ONS data.
Modifiable and non-modifiable variables
We categorised variables into five groups to facilitate data management and analysis. These groups were
demographic variables, medical history variables, presenting characteristics of the OHCA variables, care
pathway variables and discharge care variables. Full details of MINAP variables and categories, and how they
were used in the analysis, are included in Appendix 1. Within each group, we recategorised variables where it
was clinically meaningful to do so, particularly where the number of patients in a particular group was small.
In order to prevent the release of data that may enable identification of individual patients, MINAP
provided only the month and year of patient admission. For time fields, the time of hospital admission was
categorised as time point zero and other time fields were then described as a number of minutes, hours or
days prior to or following time point zero.
Demographic variables
This group included age, sex, ethnicity and the deprivation score. Ethnicity was recategorised, as detailed
in Table 3.
The Index of Multiple Deprivation (IMD) is a score of deprivation supplied by the ONS based on postcode
data.55 Geographical areas with an approximate population of 1500 are scored based on seven domains
(income, employment, education, health, crime, barriers to housing and services, and living environment).
In our analysis, we used the absolute score (rather than rank), so a higher score indicates increased deprivation.
Medical history variables
This group included smoking status, diabetes mellitus status, hypercholesterolaemia, heart failure,
cerebrovascular disease, previous AMI, asthma or chronic obstructive pulmonary disease (COPD), chronic
renal failure, peripheral vascular disease, previous angina pectoris, previous PCI, previous coronary artery
bypass graft (CABG) and hypertension. Diabetes status and smoking status were recategorised as shown in
Table 3. Most definitions are based on documented history of the disease. For all variables, a response of
unknown was categorised as missing.
Presenting characteristics of out-of-hospital cardiac arrest variables
This group included time point of cardiac arrest (before or after ambulance arrival), cardiac arrest rhythm,
serum glucose (mmol/l), creatinine (µmol/l), left ventricular ejection fraction (LVEF), haemoglobin (g/dl),
serum cholesterol (mmol/l), admission diagnosis, systolic blood pressure at admission, ECG that determined
treatment, time of day of admission (day/night), Killip class, mini-GRACE (Global Registry of Acute
Coronary Events) score and year of admission. The variable ECG that determined treatment was
recategorised, as shown in Table 3.
METHODS
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TABLE 3 Recategorisation of categorical data points
Field Original responses Recategorised responses
Baseline demographics
Ethnicity (field 1.13) White White
Black Black
Asian Asian
Mixed Other
Other Other
Medical history
Smoking status (field 2.16) Current smoker Ever smoked
Ex-smoker Ever smoked
Never smoked Never smoked
Non-smoker – smoking history unknown Never smoked
Diabetes status (field 2.17) Not diabetic Not diabetic
Diabetes (dietary control) Diabetic
Diabetes (oral medicine) Diabetic
Diabetes (insulin) Diabetic
Insulin plus oral medication Diabetic
Presenting characteristics of OHCA
ECG that determined
treatment (field 2.03)
ST segment elevation ST segment elevation or LBBB
LBBB ST segment elevation or LBBB
ST segment depression ST segment depression or T-wave
changes only
T-wave changes only ST segment depression or T-wave
changes only
Other acute abnormality Other acute abnormality or no acute
changes
No acute changes Other acute abnormality or no acute
changes
Care pathway
Time point of aspirin
administration (field 2.04)
Already on aspirin/antiplatelet drug Already on aspirin/antiplatelet drug
Aspirin/antiplatelet drug given out of
hospital
Aspirin/antiplatelet drug given pre
hospital
Aspirin/antiplatelet drug given after
arrival in hospital
Aspirin/antiplatelet drug given in hospital
Aspirin/antiplatelet contraindicated Not given
Not given Not given
Admitting consultant
(field 2.22)
Cardiologist Cardiologist
Other general physician Other consultant
Other Other consultant
continued
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TABLE 3 Recategorisation of categorical data points (continued )
Field Original responses Recategorised responses
Place where ECG
performed (field 2.23)
Ambulance Pre hospital
Other health-care facility Pre hospital
In hospital In hospital
Admission ward (field 3.17) CCU CCU
Intensive therapy unit Intensive therapy unit
Died in A&E Died in emergency department
Cardiac ward (non-CCU) Cardiac ward (non-CCU)
Acute admissions unit General medical ward or other
General medical ward General medical ward or other
Stepdown ward General medical ward or other
Discharge care
Discharge diagnosis
(field 4.02)
MI (ST elevation) ACS
ACS (troponin positive)/NSTEMI ACS
ACS (troponin negative) ACS
Threatened MI ACS
MI (unconfirmed) ACS
Chest pain of uncertain cause Other
Other diagnosis Other
Takotsubo cardiomyopathy Other
PCI-related MI Other
Echocardiography
(field 4.11)
Yes Yes or planned
Planned after discharge Yes or planned
No No
Not indicated No
Coronary angiography
(field 4.13)
Protocol-driven investigation performed
in this hospital
Protocol driven
Protocol-driven investigation performed
at another hospital
Protocol driven
Symptom-driven investigation performed
in this hospital
Symptom driven
Symptom-driven investigation performed
at another hospital
Symptom driven
Not applicable None
Patient refused None
Not performed None
Coronary intervention
(field 4.14)
PCI PCI
PCI planned after discharge PCI
CABG CABG
CABG planned after discharge CABG
Not applicable None
Patient refused None
Not performed or arranged None
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For admission diagnosis, we combined two fields (2.01, initial diagnosis, and 2.36, site of infarct) to create
a single field to describe both the initial diagnosis and, where appropriate, the site of the infarct. To create
the new field, we recategorised ACS, chest pain cause and other initial diagnosis in field 2.01 as a single
category of other diagnosis. For participants who were recorded in field 2.01 as having a definite myocardial
infarction (MI), we broke down these participants by infarct site from 2.36. The revised field had three
categories: definite MI – anterior infarction; definite MI – other infarction site; and other initial diagnosis.
Time of hospital arrival (field 3.06) was used to classify whether the patient was admitted during the day
(admission time 08.00–19.59 hours) or at night (20:00–07:59 hours). There is little consistency as to the
cut-offs to be used when categorising night and day in studies of OHCA, MI and temporal variability.
Some studies dichotomise as night and day, albeit with variability in time cut-off points, whereas some
studies add an additional category for evening admissions, and other studies include an additional
category for the weekend.56–64 On this basis, we took the pragmatic decision to categorise as discussed
above, which is consistent with a previous OHCA study and similar to the method used in a previous
MI study.56,62 We were unable to analyse the impact of a weekend effect on survival in this study as,
despite recent interest in this issue in the UK, NICOR was unable to release these data on the basis that,
in combination with other variables, it might enable the identification of individual patients.65–67
Laboratory values (glucose, cholesterol, creatinine, haemoglobin) are the first recorded value following
hospital admission, and these are recorded within the first 24 hours of admission. Systolic blood pressure
and heart rate are the first values recorded when the patient is in a stable cardiac rhythm (e.g. sinus rhythm).
Before June 2013, haemoglobin levels in the MINAP data set were reported as g/dl. In June 2013, the unit
of measurement was changed to g/l. An analysis of data suggested that different hospitals were using both
sets of units during 2013. To ensure consistency, we divided all values from 2014 and 2015 by 10 so that
we could report them as g/dl. For 2013, values above 30 were considered to have been reported as g/l,
so were also divided by 10.
The GRACE score is a validated score to predict outcome following acute coronary score, derived from
key patient presenting characteristics.68,69 As not all data points may be available in the MINAP data set,
a mini-GRACE score has been derived, which has been reported and used by the National Institute for
Health and Care Excellence (NICE).70,71 The score has been tested and validated using the MINAP data
set.71 It is derived from eight data points in the MINAP data set, as described in Table 4.
TABLE 3 Recategorisation of categorical data points (continued )
Field Original responses Recategorised responses
Discharge drugsa Yes Yes
No No
Contraindicated No
Patient declined treatment No
Not applicable No
Not indicated No
A&E, accident and emergency; CABG, coronary artery bypass graft; CCU, cardiac care unit; LBBB, left bundle branch block;
MI, myocardial infarction.
a Applies to beta-blocker (field 4.05), angiotensin-converting enzyme inhibitor (field 4.06), statin (field 4.07), aspirin
(field 4.08), thienopyridine inhibitor (field 4.27) and ticagelor (field 4.31).
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TABLE 4 Derivation of the mini-GRACE score
Variable Derivation Category Score
Cardiac arrest All patients in study data
set
Cardiac arrest – yes (required for
patients to be eligible for the study)
30
Age (years) Date of birth (field 1.06)
supplied as age
< 30 0
30–39 1.7 × (age – 30)
40–49 17+ [1.6 × (age – 40)]
50–59 33+ [1.7 × (age – 50)]
60–69 50+ [1.7 × (age – 60)]
70–79 67+ [1.6 × (age – 70)]
80–89 83+ [1.7 × (age – 80)]
≥ 90 100
Loop diuretic Loop diuretic (field 3.34) Yes 20
No 0
ECG – ST-segment
deviation
ECG determining
treatment (field 2.03)
ST segment elevation 17
ST segment depression 17
No acute changes 0
LBBB 0
T-wave changes only 0
Other acute abnormality 0
Cardiac enzymes
elevated
Cardiac markers raised
(field 2.14)
Yes 13
No 0
Creatinine level
(µmol/l)
Creatinine (field 2.34) < 200 5
≥ 200 20
Pulse rate (b.p.m.) Heart rate (field 2.21) < 50 0
50–59 0.3 × (heart rate – 50)
60–69 3+ [0.3 × (heart rate – 60)]
70–79 6+ [0.3 × (heart rate – 70)]
80–89 9+ [0.3 × (heart rate – 80)]
90–99 12+ [0.3 × (heart rate – 90)]
100–109 15+ [0.3 × (heart rate – 100)]
110–149 18+ [0.3 × (heart rate – 110)]
150–199 30+ [0.3 × (heart rate – 150)]
≥ 200 46
SBP (mmHg) SBP (field 2.20) < 80 58
80–99 58 – [0.5 × (SBP – 80)]
100–109 48 – [0.5 × (SBP – 100)]
110–119 43 – [0.4 × (SBP – 110)]
120–129 39 – [0.5 × (SBP – 120)]
130–139 34 – [0.5 × (SBP – 130)]
140–149 29 – [0.5 × (SBP – 140)]
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Care pathway variables
This variable group included hospital volume (OHCA cases per year), hospital pPCI capability, EMS response
time, EMS travel distance, admitting consultant, cardiological care during admission, admission ward, time
point of aspirin administration, place where first 12-lead ECG performed, in-hospital administration of
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, in-hospital use of loop diuretic,
reperfusion treatment and timing, assessment at non-interventional hospital, assessment at intervention
centre, intended reperfusion procedure, procedure performed, reason for no angiography, reason for no
intervention and reason treatment not given.
The following variables were recategorised, as shown in Table 3: time point of aspirin administration,
admitting consultant, place first 12-lead ECG performed and admission ward.
For hospital-level data (distance to hospital, volume and PCI centre), we categorised patients by the hospital
to which they were first admitted. We were supplied with both a hospital code and hospital location
using northings–eastings data. Initial data review suggested that some hospitals may have been assigned
more than one code, so the northings–eastings were used to identify individual hospital locations.
Northings–eastings were not available for eight hospitals (91 patients), so the MINAP hospital codes were
used to categorise these patients.
Distance to hospital was calculated using the Euclidian distance between the participant’s home
address (northings–eastings data to the nearest km) and the hospital to which they were first admitted
(northings–eastings data to the nearest kilometre). MINAP does not collect data on event location, so
we made the assumption that the cardiac arrest event occurred at the patient’s home. This assumption
is supported by UK and international data that show that most cardiac arrests happen at the patient’s
home.5,24 For example, English data show that, where location is recorded, 83.2% of OHCA events occur
in the home.5 However, on the basis that some participants would not have had a cardiac arrest at home
(e.g. they had it at work or in a public place), we considered how to identify cases where there was clear
evidence that the patient had the cardiac arrest outside the home, so that we could classify these data as
missing. Our initial plan to create an upper limit proved to be problematic as the distance was likely to be
significantly greater in rural areas than urban areas. Therefore, for each case, we calculated the distance
between the home address and nearest hospital. When the distance between the participant’s home
address and the hospital they were admitted to was large (> 95th centile) compared with the distance
between the participant’s home address and nearest hospital, we concluded that the cardiac arrest did not
happen at the participant’s home, so we recorded these data as missing.
For hospital volume, we calculated the number of OHCA cases per year at each hospital and categorised
volume as low (1–10 cases), medium (11–24 cases) or high (25–82 cases). Patients were then allocated to
a category based on the initial hospital in which they were treated.
Primary percutaneous coronary intervention centres were defined as a hospital that performed at least
100 pPCI procedures per year, based on the British Cardiovascular Intervention Society recommendation
TABLE 4 Derivation of the mini-GRACE score (continued )
Variable Derivation Category Score
150–159 24 – [0.5 × (SBP – 150)]
160–179 19 – [0.45 × (SBP – 160)]
180–199 10 – [0.5 × (SBP – 180)]
≥ 200 0
b.p.m., beats per minute; LBBB, left bundle branch block; SBP, systolic blood pressure.
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for interventional centres.72 We calculated the number of pPCIs each hospital did per year using the entire
MINAP data set, using MINAP field 3.39 (initial reperfusion therapy). If a patient was treated in a hospital
in a year that it was designated as a pPCI centre, then the patient was categorised as being treated in a
pPCI centre.
Emergency medical service response time was defined as the time (in minutes) from the call for help
(MINAP field 3.02) to arrival of ambulance (field 3.04) or, if this field was missing, to the arrival of a first
responder (field 3.03).
In the MINAP data set, reperfusion treatment data are collected in four key fields, namely initial reperfusion
therapy (field 3.39), additional reperfusion therapy (field 3.40), thrombolytic drug (field 3.36) and date/time of
reperfusion therapy (field 3.09). In our analysis, we considered only the initial reperfusion treatment, which
was classified as either pPCI or thrombolysis. If field 3.39 was missing but the participant was recorded as
having received a thrombolytic drug (field 3.36) then they were classified as having received thrombolysis.
For each reperfusion therapy, we classified the timing as either early, late or not recorded. We classified early
pPCI as a pPCI started within 90 minutes of hospital arrival, and early thrombolysis as administration of a
thrombolytic with 60 minutes of the call for help. Timings outside these windows were considered late.
Current NICE and European Society of Cardiology guidelines do not specifically state a timeframe within which
thrombolysis and pPCI should be performed, except that the chosen therapy should be delivered as soon as
possible and thrombolysis should be considered if pPCI cannot be commenced within 120 minutes.73,74 As
such, our threshold for early thrombolysis was based on the standard described in the Department of Health’s
National Service Framework for Coronary Heart Disease.75 Our threshold for early PCI was based on the
European Society Guidelines, which describe a period from first medical contact to PCI of up to 90 minutes as
an appropriate target.73
Discharge care variables
Discharge care variables included discharge diagnosis, echocardiography, coronary angiography, coronary
intervention, provision of cardiology follow-up, cardiac rehabilitation, discharge drugs (beta-blocker,
angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, statin, aspirin, thienopyridine
inhibitor, ticagrelor), provision of smoking cessation advice and provision of dietary advice.
Discharge diagnosis, echocardiography, coronary angiography, coronary intervention and discharge drugs
were recategorised as detailed in Table 3.
For echocardiography, coronary angiography and coronary intervention, we acknowledged that these
interventions may occur before or following discharge and that when undertaken prior to discharge they
may inform in-hospital treatment. However, we considered them to be best categorised in this domain.
In addition, for antiplatelet drugs (aspirin, thienopyridine inhibitor, ticagrelor) we created three categories:
no antiplatelet therapy on discharge, monotherapy on discharge or dual antiplatelet therapy on discharge. The
category of no antiplatelet therapy was used when a patient received none of the three drugs on discharge.
Monotherapy was used when a patient received any one of the three drug groups. Dual antiplatelet therapy
was used if the patient was prescribed aspirin plus either a thienopyridine inhibitor or ticagrelor.
Missingness and imputation
The MINAP data are incomplete because, for some patients, there are missing observations for the
outcomes and/or variables.76 There are a number of potential reasons for missingness, including:
l omission during data input
l data field introduced during data collection period, but data may have been available prior to that
point [e.g. serum glucose (field 2.28) was introduced as a data field in 2005]
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l data field introduced during data collection period and treatment/data would not be available prior to
that date (e.g. the drug ticagrelor was first licensed in the UK in 2010)
l the patient died before intervention was appropriate (e.g. discharge drugs are not applicable if patient
died during admission)
l data field not relevant given delivery of other care [e.g. why was no angiography performed? (field 3.51)
is not relevant if angiography was performed].
In view of this missingness, a complete-case analysis would lead to discarding a high proportion of data
and create a high risk of bias. To reduce this risk of bias, we used data imputation strategies to minimise
data missingness.
Classifying data as missing
To ensure that data were valid, we classified some available data as missing, and these were then imputed.
For some continuous variables, we applied upper and lower cut-off values to some continuous variables
beyond which data were considered implausible, and thus were classed as missing. For each variable, we
carefully considered the MINAP data definition, as well as the balance between when a variable became
implausible rather than just unlikely. This was based on clinical judgement and review of the data
distribution. The cut-off points that were used are detailed in Table 5.
For categorical variables, data recorded as unknown or not applicable in individual fields were categorised
as missing.
Imputation strategy
Data imputation was undertaken following case identification. No outcomes were imputed.
Our imputation strategy was based on the approach described by Cattle et al.,76 in relation to the MINAP
data set. The imputation method for specific data points is described in Table 6.
Default imputation was used for some variables. For the remaining variables, multiple imputation by chained
equations (MICE) was used.77 This involves fitting a model for each variable included in the imputation model.
For binary variables, a logistic regression was fitted, where the binary variable for which missing values were
being imputed was the outcome variable and the other variables in the imputation model are used as
predictor variables. For categorical variables with more than two categories, polytomous regression, which
generalises binary logistic regression to allow more than two categories in the variable for which missing
TABLE 5 Cut-off points used for baseline continuous variables
Variable Unit of measurement
Cut-off point
Lower Upper
EMS response time minutes < 0 > 180
Cholesterol mmol/l ≤ 0 > 30
SBP mmHg < 50 > 230
Heart rate b.p.m. < 25 > 180
Glucose mmol/l < 1 > 60
Creatinine µmol/l ≤ 0 –
Haemoglobin g/dl < 5 > 30
Reperfusion treatment time – < 0 minutes > 72 hours
IMD score – ≤ 0 –
b.p.m., beats per minute; SBP, systolic blood pressure.
DOI: 10.3310/hsdr06140 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 14
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Couper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
TABLE 6 Imputation strategy used
Variable Modelling strategy
Demographic
Age No missingness
Sex Binary logistic regression
Ethnicity Polytomous regression
IMD score PMM
Medical history
Smoking status Binary logistic regression
Diabetes status Binary logistic regression
Hypercholesterolaemia Default imputation – missing responses
categorised as no
Heart failure Default imputation – missing responses
categorised as no
Cerebrovascular disease Default imputation – missing responses
categorised as no
Previous AMI Default imputation – missing responses
categorised as no
Asthma or COPD Default imputation – missing responses
categorised as no
Chronic renal failure Default imputation – missing responses
categorised as no
Peripheral vascular disease Default imputation – missing responses
categorised as no
Previous angina Default imputation – missing responses
categorised as no
Previous PCI Default imputation – missing responses
categorised as no
Previous CABG Default imputation – missing responses
categorised as no
Hypertension Default imputation – missing responses
categorised as no
Presenting characteristics of OHCA
Time point of cardiac arrest Binary logistic regression
Cardiac arrest rhythm Polytomous regression
Serum glucose (mmol/l) PMM
Creatinine PMM
LVEF Polytomous regression
Haemoglobin (g/dl) PMM
Serum cholesterol (mmol/l) PMM
Admission diagnosis Polytomous regression
SBP at admission (mmHg) PMM
ECG that determined treatment Polytomous regression
Heart rate at admission PMM
Time of the day of admission (day/night) No missingness
Year of admission No missingness
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values are being imputed was used. For continuous variables, predictive mean matching (PMM)
was used to impute missing values. PMM involves fitting a linear model with the imputed value being an
observed (non-missing) value sampled from the values closest to the value suggested by the linear model.
The models for different variables are fitted in a chain. To achieve true target distributions, several iterations
(each iteration consists of one chain of models for all imputed variables) are required.
For the fields that relate to thienopyridine inhibitors at discharge, we were not supplied with data before
2009. We therefore default imputed for the period before 2009, and incorporated two year slopes
(2003–8 and 2009–15) in our adjusted analysis.
The MICE package in the R statistical program (The R Foundation for Statistical Computing, Vienna, Austria)
(R is a language and environment for statistical computing) was used to perform the multiple imputation.77
TABLE 6 Imputation strategy used (continued )
Variable Modelling strategy
Care pathway
Hospital volume (OHCA cases per year) No missingness
Hospital pPCI capability No missingness
EMS response time PMM
EMS travel distance PMM
Admitting consultant Binary logistic regression
Cardiological care during admission Binary logistic regression
Admission ward Polytomous regression
Time point of aspirin administration Polytomous regression
Place where ECG performed Polytomous regression
Angiotensin-converting enzyme inhibitor (in-hospital use) Default imputation – missing responses
categorised as no
Loop diuretic (in-hospital use) Default imputation – missing responses
categorised as no
Reperfusion treatment and timing Default imputation – missing responses
categorised as no
Discharge care
Discharge diagnosis Binary logistic regression
Echocardiography Binary logistic regression
Coronary angiography Polytomous regression
Coronary intervention Polytomous regression
Followed up by cardiologist Polytomous regression
Cardiac rehabilitation Polytomous regression
Discharged on beta-blocker Binary logistic regression
Discharged on angiotensin-converting enzyme inhibitor Binary logistic regression
Discharged on statin Binary logistic regression
Discharged on aspirin Binary logistic regression
Discharged on thienopyridine inhibitor or ticagrelor Year 2003–8: default imputation – missing
responses categorised as no
Year 2009–15: polytomous regression
PMM, predictive mean matching; SBP, systolic blood pressure.
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Default imputation was first performed for the appropriate predictor variables (such as medical history
predictor variables). Subsequently, we used the resulting data set as the ‘complete-cases’ data set to
impute 25 data sets with 30 iterations. Convergence was assessed by checking whether or not the
imputation chains mixed well for all variables.
Statistical approach
Data were analysed by the study statistician (PK). The initial data processing, as described above, and
descriptive analyses for complete cases were performed using SPPS statistics, version 22 (IBM SPSS Statistics,
Armonk, NY, USA). The R statistical program was used for multiple imputation, descriptive analysis after
multiple imputation, fitting models for in-hospital mortality and neurological outcome [using the gamm4
package (Simon Wood and Fabian Scheipl, 2016. gamm4: Generalised Additive Mixed Models using ‘mgcv’
and ‘lme4’. R package version 0.2–4. https://CRAN.R-project.org/package=gamm4)], and time to all-cause
mortality [using coxme package (Terry M Therneau, 2015. coxme: Mixed Effects Cox Models. R package
version 2.2–5. https://CRAN.R-project.org/package=coxme)].
Categorical predictor variables are reported as the number of patients in each category and the
corresponding percentages. For continuous predictor variables, mean and median are reported to describe
typical values and dispersion is described using standard deviation (SD), range and interquartile range (IQR).
In-hospital mortality and neurological outcome analyses
Unadjusted analysis of in-hospital mortality
The primary outcome of in-hospital mortality was analysed using univariate random effects (RE) logistic
regression models for each predictor variable. The RE term for the hospital allowed for similarity of
in-hospital mortality rates within a hospital and variability between hospitals to be modelled to account
for the multilevel nature of the data and to distinguish between hospital- and patient-level factors. For
each predictor variable, unadjusted odds ratios (ORs) were obtained from the univariate model using both
the pre-imputation and the imputed data sets. For each variable, we report the OR and 95% confidence
intervals (CIs), as well as the p-values, which test the null hypothesis that the OR is equal to 1. ORs with
a value greater than one indicate increased in-hospital mortality rate and a value less than 1 indicates
reduced in-hospital mortality.
For analysis after multiple imputation, a RE logistic regression model was fitted to obtain the estimate for
the log of the OR [loge(OR)] and the standard error (SE) for each imputed data set. Estimates from each of
the 25 imputed data sets were combined using Rubin’s rules78 to get an estimate for loge(OR) and SE of all
imputed data sets. These were used to calculate the corresponding 95% CI and the p-value. Results are
presented as OR and 95% CI by taking the exponent of the estimate for loge(OR) and confidence limits of
the CI on loge(OR) scale.
The model fit for each model was assessed using the adjusted R2 and the Akaike information criterion
(AIC). For the pre-imputation analysis, the different number of complete cases for each different predictor
variable means that only adjusted R2 was used to compare model fit. For the analysis of imputed data sets,
the median (from separate analyses of the 25 imputed data sets) adjusted R2 and AICs are used.
The RE estimate was used to assess if a predictor variable explains the variability of in-hospital mortality
across hospitals. A variable that predicts in-hospital mortality and explains substantial variability, and that
has a large imbalance across hospitals, would have a large R2-value and small RE estimate. Using the RE
and the latent formulation, the intraclass correlation (ICC) was obtained using the following formula:79
ICC =
RE
RE + (π2/3)
. (1)
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Relationship for continuous predictor variables and in-hospital mortality
Before fitting the models for continuous variables, the form of the relationships between the primary outcome
and the continuous predictor variables were explored. For each continuous predictor variable, patients were
grouped using deciles and the proportion of in-hospital mortality, and the log of the ratio of proportion
of those who died in hospital to the proportion of those who survived to hospital discharge (the logit) was
calculated. We then plotted the mid-point values in the deciles against the logits. If this relationship was
approximately linear, a linear term was used. If this relationship was approximately convex (or concave), linear
and quadratic terms were included in the model. If the linear relationship seemed linear but with different
slopes for two different intervals, two linear parameters for the different intervals were included in the model.
Adjusted analysis of in-hospital mortality
A multivariate RE (multilevel) logistic regression model was used to predict in-hospital mortality. We
included as many clinically relevant predictor variables in the model as possible, while avoiding including
two predictor variables that led to biased OR estimates due to multicollinearity as a result of the two
predictors being highly correlated. Modifiable variables were added after adding non-modifiable predictor
variables to enable us to assess how the prediction improves when modifiable variables are added to a
model that includes non-modifiable predictor variables only. The model included an adjustment for year of
admission. We used two slopes in the model (2003–8 and 2009–15) to reflect missingness of thienopyridine
inhibitor data and the point that pPCI became the most frequently used emergent reperfusion treatment in
the MINAP data set.48 Appendix 1 shows details of which variables were included in the model.
We added groups of variables to the model in the following order: demographic variables, medical history
variables, presenting characteristics of OHCA variables, and care pathway variables. In each group, the first
predictor variable added to the model was the one, based on unadjusted results, that explained the most
variability in the data. Generally, predictor variables were added into the model by balancing the variability
explained by the model (quantified by the adjusted R2 and the AIC) and the variability across hospitals
explained in the model (quantified by RE estimate). Variables were retained in the model even if the
OR estimates were not statistically significant. As variables were added in the model, the change in OR
estimates, the adjusted R2, AIC and RE estimates were noted to allow assessment of multicollinearity and
model fits. The only reasons that a variable was not included in the model were if there was evidence of
multicollinearity or the OR estimate was clearly confounded by an unmeasured confounding variable. It
was concluded that there was a multicollinearity problem if combined OR estimates changed markedly and
graphical data representations (e.g. bar graphs, box plots) showed a high degree of correlation. R2-values
were used to quantify the amount of variability in in-hospital mortality across patients explained by the
predictor variables. RE and ICC estimates for the null and the adjusted model were compared to quantify
the amount of variability in in-hospital mortality across hospitals explained by the model.
Adjusted analysis of the neurological outcome
Neurological outcome was analysed as a binary outcome, with the two categories being (1) discharged
with good neurological outcome and (2) discharged with poor neurological outcome or died in hospital.
We used the same approach as was used for the primary outcome. Therefore, only one adjusted model,
corresponding to the final adjusted model fitted for the primary outcome, was fitted for this outcome.
Appendix 1 shows details of which variables were included in the model for this analysis.
Analysis of time to all-cause mortality
Proportional hazards Cox regression RE models were used to analyse time to all-cause mortality for each
predictor variable. Unadjusted hazard ratios (HRs) were obtained for a model using both the pre-imputation
and the imputed data sets. For each variable, we report the HR and 95% CIs, as well as the p-values, which
tests the null hypothesis that the HR is equal to 1. A HR greater than one indicates a higher hazard rate of
death and a HR less than 1 indicates lower hazard rate of death.
For analysis after multiple imputation, results were combined using Rubin’s rules,78 as for the analysis for
in-hospital mortality, except that HR and log(HR) are used in place of OR and log(OR).
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Appendix 1 shows details of which variables were included in the model for time to all-cause mortality.
Model fits for different models were assessed using the AIC. For the analysis using imputed data sets, the
median (from separate analyses of the 25 imputed data sets) AICs were used. The AIC reported by the
‘coxme’ package is the difference between the AIC of the fitted model and the AIC of the null model,
with a higher AIC value indicating a better fit.
For the adjusted analysis, the final model was developed in a similar way to that described for the
in-hospital mortality.
Sensitivity analyses
We performed sensitivity analyses to assess the robustness of the results to the missing data methods used
and assumptions made.80,81 For the in-hospital mortality and neurological outcome analyses, we conducted
five analyses, namely patients admitted to hospital between 2003 and 2008; patients admitted to hospital
between 2009 and 2015; patients where the ECG determining treatment showed ST elevation or left
bundle branch block (LBBB); patients where the ECG determining treatment showed something other
than ST elevation or LBBB; and a complete-case analysis. When the defining category was missing in the
pre-imputation data set, the case was not included in the sensitivity analysis. The rationale for the cut-off
point for the two time periods was that it was between 2008 and 2009 that the use of PCI became more
frequent than thrombolysis as a reperfusion treatment.48 For the time to all-cause mortality analysis, we
conducted a complete-case analysis. These complete-case analyses included only patients for whom all
relevant data points were available.
Sample size
In preparation for this project, MINAP provided a random sample of 84,194 cases, from which we identified
1431 eligible cardiac arrest events. Of these cases, 345 patients (24%) died in hospital, 847 patients (59%)
survived to leave hospital and the outcome was missing in the remaining 239 (17%) patients.
Therefore, taking the most conservative approach (assuming the sample data set is representative of the
whole data set), we expected to identify approximately 14,310 eligible OHCA cases, of whom 3434
(24% × 14,310) would die in hospital. For logistic regression and Cox regression models, it is recommended
that there are 10 events for each predictor variable, so that 3434 events (in-hospital deaths) will be sufficient
to model the MINAP data to answer our research question.82 Based on these projections, we are able to
reliably detect a rate difference of 4% or more with at least 90% power at a 5% significance level. When
the prevalence of a predictor variable reaches 50%, it will be possible to detect a rate difference of 2% with
a power of approximately 70%.
Patient and public involvement input
The project was supported by two patient and public representatives (BE and JL), who were full members
of the research team. They contributed to finalising the objectives of the research, interpretation of analysis
and reviewing and approving the final version of this report.
Ethics considerations
This study was secondary research that utilised an anonymised data set. In accordance with the policies of
author’s institutions, ethics review was sought from and granted by the University of Warwick Biomedical
Research Ethics Committee.
The Myocardial Ischaemia National Audit Project forms part of NICOR, which is registered as a data controller
under the Data Protection Act 199883 and has permission to collect and store patient-identifiable information
without consent in accordance with section 251 of the National Health Service Act 2006.84
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Chapter 4 Results
Case identification
The data set provided by MINAP comprised 1,127,140 cases that were included in the audit between 2003
and 2015. To this data set, we applied the seven-stage case identification process described in Table 2.
We identified 73,875 cases of cardiac arrest, although the majority of these were in-hospital cardiac arrests
or the location/time was not recorded (n = 50,836). We excluded five cases in which the participant was
aged under 18 years and a further 38 cases in which the age was not recorded. Of the remaining 22,906
cases, 2743 were excluded because it was not described as the participant’s index cardiac arrest event and
1240 cases were excluded because resuscitation was not attempted or there was no ROSC. In step 6,
a further 1241 records were excluded because of evidence of record duplication. Finally, in step 7,
78 cases were excluded because they were missing primary outcome data. The case identification
process is shown in Figure 3.
In total, 17,604 cases were included in the analysis of our primary outcome, which represents 1.6% of the
entire data set.
The analysis of neurological outcome included 15,286 patients. There were 2542 patients for whom field
3.16 was not recorded or the patient was recorded as transferred to another hospital. We reduced this
missingness by cross-referencing against the primary outcome and identifying 222 patients who died before
discharge. As such, neurological outcome data were missing for 2318 (13.2%) patients in the cohort.
The time to all-cause mortality analysis included 12,483 patients. After excluding patients who died before
discharge (n = 5047), there were 810 patients for whom ONS long-term survival data were not available.
We reduced this missingness by using the combination of time to discharge and survival status at discharge.
Data missingness and performance of imputation
Data categorised as missing
As described in the methods, we applied cut-off points to some continuous variables, such that markedly
outlying values were removed and categorised as missing. In total, these cut-off points affected 4707
values across 10 data fields. Often, this was because data had been incorrectly recorded as zero. Full
details are included as Table 7.
Summary of missingness across the study cohort
The missingness in individual data points varied markedly. In our data set, missingness varied between 0%
(age, admission time) and 98.3% (why no angiography), with the missingness for most variables being in
the range 10–20%. Table 8 shows the missingness for all variables across all patients (cohort used for the
hospital mortality/neurological analyses) and the cohort used for the time to all-cause mortality analysis.
For demographic variables, there were only 46 cases with sex missing. The number of cases missing
at least one demographic variable was 4182 (23.8%) as missingness for demographic variables was not
simultaneous, so, for example, cases missing ethnicity do not necessarily have IMD score missing. After
default imputation for medical history variables, the only predictor variables with missing values were
diabetes status (n = 1885, 10.7%) and smoking status (n = 3615, 20.5%). The number of cases missing
at least one demographic variable or diabetes status or smoking status value was 7281 (41.4%).
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In the OHCA presenting characteristics group, location of cardiac arrest was missing for only 67 cases.
Systolic blood pressure and heart rate tended to be missing simultaneously, so the number of cases
missing either of them was 3348 (19.0%), which is close to the individual missing proportions. Similarly,
haemoglobin and creatinine levels tended to be missing simultaneously, with the number of cases missing
either of them being 6173 (35.1%). There are few cases of missing data values for cardiac arrest rhythm
(n = 1104, 6.3%) and ECG that determined treatment (n = 612, 3.5%), but there are large proportions of
missing values for admission diagnosis (n = 3185, 18.1%) and LVEF (n = 9954, 56.5%). Across the OHCA
presenting characteristic variable group, there was at least one missing value in 14,520 (82.5%) cases.
In care pathway variables, EMS response time and EMS distance were not generally missing simultaneously,
with the number of cases missing at least one value for these variables being 6269 (35.6%). The proportions
of missing values for admitting consultant (n = 321, 1.8%) and admission ward (n = 204, 1.2%) were low.
Total cases
(n = 1,127,140)
Cases of OHCA
(n = 22,949)
Cases of cardiac arrest
(n = 73,785)
Adult OHCA cases
(n = 22,906)
Eligible cases
(n = 17,604)
Primary outcome available
(n = 17,604)
First OHCA case
(n = 20,163)
Resuscitation attempted 
and successful 
(n = 18,923)
Unique cases
(n = 17,682)
Exclude cases where no cardiac arrest
(n = 1,053,355)
Exclude non-OHCAs
(n = 50,836)
• In-hospital cardiac arrest, n = 50,536
• Location and time of arrest not stated, n = 300
Exclude those aged < 18 years or with 
age missing
(n = 43)
• Aged < 18 years, n = 5
• Age missing, n = 38
Exclude cases where not first
cardiac arrest
(n = 2743)
Exclude cases where resuscitation not
attempted or no ROSC
(n = 1240)
• No ROSC, n = 1219
• Resuscitation not attempted, n = 21
Exclude multiple entries
(n = 1241)
• Transfer to another hospital, n = 1042
• Duplicate entry in data set, n = 97
• Other, n = 102
Exclude cases where primary outcome missing
(n = 78)
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FIGURE 3 Study case identification diagram. Adapted from Couper et al.,85 with permission from Elsevier. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 7 Summary of data categorised as missing
Variable
Number of cases in which
data were removed Details
EMS response time 36 Upper cut-off point: data from 33 patients removed as
response time > 180 minutes
Lower cut-off point: data from 3 patients removed as
response time < 0 minutes
Cholesterol 447 Upper cut-off point: data from 13 patients removed as
recorded cholesterol > 30 mmol/l
Lower cut-off point: data from 434 patients removed as
recorded cholesterol = 0 mmol/l
SBP (mmHg) 268 Upper cut-off point: data from 36 patients removed as
recorded SBP > 230mmHg
Lower cut-off point: data from 232 patients removed as
recorded SBP < 50 mmHg
Heart rate (b.p.m.) 284 Upper cut-off point: data from 74 patients removed as
recorded heart rate > 180 b.p.m.
Lower cut-off point: data from 210 patients removed as
recorded heart rate < 25 b.p.m.
Glucose (mmol/l) 138 Upper cut-off point: data from 21 patients removed as
recorded glucose > 60 mmol/l
Lower cut-off point: data from 117 patients removed as
recorded glucose < 1 mmol/l
Creatinine (µmol/l) 158 Upper cut-off point: no upper cut-off point
Lower cut-off point: data from 158 patients removed as
recorded creatinine = 0 µmol/l
Haemoglobin (g/dl) 690 Upper cut-off point: data from 425 patients removed as
recorded haemoglobin > 30 g/dl
Lower cut-off point: data from 265 patients removed as
recorded haemoglobin < 5 g/dl
Reperfusion treatment time 20 Upper cut-off point: data from 16 patients removed as
recorded reperfusion treatment time > 72 hours
Lower cut-off point: data from four patients removed as
recorded reperfusion treatment time < 0 hours
IMD score 1048 Upper cut-off point: no upper cut-off point
Lower cut-off point: data from 1048 patients removed as
recorded IMD score of ≤ 0
EMS distance (km) 1618 Upper cut-off point: data from 1618 cases where
distance from home postcode to treating hospital was
over 31 km further than distance from home postcode to
closest hospital
Lower cut-off point: no lower cut-off
b.p.m., beats per minute; SBP, systolic blood pressure
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TABLE 8 Missingness across all data fields
Variable
All patients
(N= 17,604), n (%)
Time to all-cause mortality
analysis (N= 12,483), n (%)
Demographic variables
Age (years) Only patients with age known included
Sex 46 (0.3) 40 (0.3)
Ethnicity 2296 (13.0) 1586 (12.7)
IMD score 2276 (12.9) 1620 (13.0)
Medical history variables
Smoking status 3615 (20.5) 1513 (12.1)
Diabetes status 1885 (10.7) 919 (7.4)
Hypercholesterolaemia 2503 (14.2) 1414 (11.3)
Heart failure 2274 (12.9) 1244 (10.0)
Cerebrovascular disease 2279 (12.9) 1253 (10.0)
Previous AMI 1905 (10.8) 1001 (8.0)
Asthma or COPD 2337 (13.3) 1319 (10.6)
Chronic renal failure 2300 (13.1) 1268 (10.2)
Peripheral vascular disease 2377 (13.5) 1325 (10.6)
Previous angina 2110 (12.0) 1134 (9.1)
Previous PCI 2123 (12.1) 1151 (9.2)
Previous CABG 2058 (11.7) 1120 (9.0)
Hypertension 2019 (11.5) 1063 (8.5)
Presenting characteristics of OHCA variables
Time point of cardiac arrest 67 (0.4) 45 (0.4)
Cardiac arrest rhythm 1104 (6.3) 743 (6.0)
Serum glucose (mmol/l) 5082 (28.9) 3205 (25.7)
Creatinine (µmol/l) 5432 (30.9) 3588 (28.7)
LVEF 9954 (56.5) 6119 (49.0)
Haemoglobin (g/dl) 6019 (34.2) 4032 (32.3)
Serum cholesterol (mmol/l) 8105 (46.0) 4414 (35.4)
Admission diagnosis 3185 (18.1) 2307 (18.5)
SBP at admission (mmHg) 2955 (16.8) 1887 (15.1)
ECG that determined treatment 612 (3.5) 321 (2.6)
Heart rate at admission (b.p.m.) 3304 (17.2) 1948 (15.6)
Time of the day of admission (day/night) 0 (0) 0 (0)
Killip class 11,712 (66.5) 8320 (66.7)
Mini-GRACE score 9040 (51.4) NA
Year of admission 0 (0) 0 (0)
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TABLE 8 Missingness across all data fields (continued )
Variable
All patients
(N= 17,604), n (%)
Time to all-cause mortality
analysis (N= 12,483), n (%)
Care pathway variables
Hospital volume (OHCA cases per year) 0 (0) 0 (0)
Hospital pPCI capability 0 (0) 0 (0)
EMS response time 4179 (23.7) 2837 (22.7)
EMS travel distance 2922 (16.6) 2169 (17.4)
Admitting consultant 321 (1.8) 183 (1.5)
Cardiological care during admission 4424 (25.1) 2937 (23.5)
Admission ward 204 (1.2) 137 (1.1)
Time point of aspirin administration 1503 (8.5) 860 (6.9)
Place where ECG performed 3000 (17.0) 2000 (16.0)
Angiotensin-converting enzyme inhibitor (in-hospital use) 2843 (16.1) 1876 (15.0)
Loop diuretic (in-hospital use) 2968 (16.9) 2006 (16.1)
Reperfusion treatment and timing 2431 (13.8) 1467 (11.8)
Assessment at non-intervention hospital 6392 (36.3) 4569 (36.6)
Assessment at intervention centre 10,616 (60.3) 7156 (57.3)
Intended reperfusion procedure 10,365 (58.9) 6976 (55.9)
Procedure performed 10,506 (59.7) 7100 (56.9)
Reason for no angiography 17,308 (98.3) 12,343 (98.9)
Reason for no intervention 16,585 (94.2) 11,785 (94.4)
Reason treatment not given 3961 (22.5) 3178 (25.5)
Discharge care variables
Discharge diagnosis 285 (1.6) 71 (0.6)
Echocardiography 2516 (14.3) 1273 (10.2)
Coronary angiography 2150 (12.2) 1580 (12.7)
Coronary intervention 3130 (17.8) 2329 (18.7)
Followed up by cardiologist NA 3373 (27.0)
Cardiac rehabilitation NA 1800 (14.4)
Discharged on beta-blocker NA 2662 (21.3)
Discharged on angiotensin-converting enzyme inhibitor NA 2723 (21.8)
Discharged on statin NA 2661 (21.3)
Discharged on aspirin NA 2598 (20.8)
Discharged on thienopyridine inhibitor NA 6558 (52.5)
Discharged on ticagrelor NA 10,977 (87.9)
Discharged on thienopyridine inhibitor or ticagrelor NA 6201 (49.7)
Smoking cessation advice NA 3365 (27.0)
Dietary advice on discharge NA 5506 (44.1)
b.p.m., beats per minute; NA, not applicable, SBP, systolic blood pressure.
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI: 10.3310/hsdr06140 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 14
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Couper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
The proportion of missing data for the other care pathway predictor variables included in the modelling
were between 10% and 20%. Across all cases, the number of cases with a missing value for a care pathway
predictor variable was 10,152 (57.7%).
Across all variable groups, the number of cases with at least one missing value was 16,163 (91.8%).
Performance of the imputation
Multiple imputation chains for all variables mixed well, suggesting that convergence was achieved
(see Figures 11–14 in Appendix 2).
Overview of cohort
Our cohort of 17,604 patients who had an OHCA attributable to ACS, and who survived to hospital
admission, was collected over a 12-year period between January 2003 and June 2015. Overall, the number
of cases recorded per year increased over the course of the study, with a peak of 2129 cases in 2012
(Figure 4). This was principally driven by an increase in STEMI cases, but the actual proportion of STEMI
cases was relatively consistent over time (68–78% of cases per year were STEMI cases).
Patient cases were collected from 239 hospitals. The median number of cases reported per hospital over
the study period was 46 (IQR 21–92; range 1–517).
In our patient cohort, most patients survived to hospital discharge (n = 12,557, 71.3%), but there was
variability in survival by hospital. Figure 5 shows hospital mortality across the 94 hospitals that contributed
at least 60 patient cases; the survival rate ranged from 34% to 89% (median 71.4%, IQR 60.7–76.9%).
For discharge with good neurological outcome, 9041 (59.1%) of the 15,286 analysed patients survived
to hospital discharge with good neurological outcome. As shown in Figure 6, there was evidence of
variability between the 94 hospitals that contributed at least 60 patients (range 13–84%; median 58.9%,
IQR 44.2–66.8%).
Of the 12,483 patients who survived to hospital who were included in the time to all-cause mortality
analysis, 1926 (15.4%) died during the follow-up period. The mean survival time was 84.3 months
(95% CI 83.5 to 85.1 months).
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FIGURE 4 Number of cases per year for complete years (2003–14) with breakdown by diagnosis. Adapted from
Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 5 Variability in hospital survival across the 94 hospitals with at least 60 cases. Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 6 Variability in hospital survival with good neurological outcome across the 94 hospitals with at least 60 cases.
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Patient characteristics
Table 9 shows the characteristics of patients included in the in-hospital mortality analysis for both the
pre-imputation and the imputed data sets.
Comparison of the two data sets shows that reported characteristics across them are similar where logistic
regression, polytomous regression or PMM was used to impute missing values. However, as expected,
the percentages are different where default imputation was used (e.g. medical history variables).
In this section, we summarise key characteristics based on the pre-imputation data set.
Patient demographics
In our patient cohort, most patients were male (n = 13,188, 75.1%) and of white ethnicity (n = 14,343,
93.7%) and the mean age was 65.3 years (SD 13.2 years). The mean IMD score, where a higher score
indicates increased deprivation, was 22.3 (SD 15.9; range 0.59–85.6).
Past medical history
Most patients were current or former smokers (n = 8883, 63.5%). The most common comorbidities were
hypertension (n = 6389, 41.0%), hypercholesterolaemia (n = 3906, 25.9%), previous AMI (n = 3092,
19.7%), angina pectoris (n = 2758, 17.8%), diabetes mellitus (n = 2158, 13.7%) and asthma/COPD
(n = 1814, 11.9%). The incidence of other comorbidities (cerebrovascular disease, heart failure, peripheral
vascular disease and chronic renal failure) was < 10% for each disease. A minority of patients had
previously received a PCI (n = 1061, 6.9%) or CABG (n = 790, 5.1%). Most patients (n = 10,729, 60.9%)
had at least one comorbidity.
Presenting characteristics of out-of-hospital cardiac arrest
Most cardiac arrest events occurred before ambulance arrival (n = 10,533, 60.1%), with a presenting
rhythm of ventricular fibrillation (VF) or ventricular tachycardia (VT) (n = 14,778, 89.6%). For the
non-shockable presenting rhythms, the breakdown between asystole (n = 885, 5.4%) and pulseless
electrical activity (PEA) (n = 837, 5.1%) was similar. Most patients were admitted to the hospital during
daytime hours (08.00–19.59 hours) (n = 11,741, 66.7%).
The most common admission diagnosis was definite MI (anterior infarction, n = 3897, 27.0%; other
infarction site, n = 3639, 25.2%). ST-segment elevation/LBBB was the most common ECG finding
(n = 12,220, 71.9%).
The mean admission systolic blood pressure and heart rate were 125.7 mmHg (SD 29.2 mmHg) and
89.2 beats per minute (SD 24.8 beats per minute), respectively.
Care pathway
The median for EMS response time was 8 minutes (IQR 5–14 minutes). The median distance between the
patient’s home address and the hospital to which they were first admitted was 8.1 km (IQR 3.9–15.8 km).
The patient distribution between low-volume (≤ 10 OHCA cases per year), medium-volume (11–24 OHCA
cases per year) and high-volume (25–82 OHCA cases per year) hospitals was 45.4% (n = 7984), 37.0%
(n = 6516) and 17.6% (n = 3104), respectively. The first hospital in which most patients (n = 9804, 55.7%)
were treated was classified as a PCI centre if the centre performed at least 100 pPCIs in the year that
patient was admitted.
Most patients were admitted under a consultant cardiologist (n = 10,680, 61.8%) and received cardiological
care during admission (n = 11,960, 90.7%). Just over half of patients were admitted to the cardiac care unit
(CCU) (also referred to as the coronary care unit) (n = 8872, 51.0%) and approximately one-third of patients
were admitted to the intensive care unit (n = 6154, 35.4%). Patients typically received aspirin or were
already on aspirin (n = 14,126, 87.7%) and received a pre-hospital ECG (n = 11,053, 75.7%).
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TABLE 9 Overview of participant characteristics for in-hospital mortality cohort (pre-imputation and imputed
data sets)
Variable Pre imputationa
After imputation
(N= 17,604)
Demographic variables, n (%)
Age (years)
Range 20–114 20–114
Mean (SD) 65.3 (13.15) 65.3 (13.15)
Median (IQR) 65.7 (56–75) 65.7 (56–75)
Sex
Female 4370 (24.9) 4385 (24.9)
Ethnicity
White 14,343 (93.7) 15,916 (90.4)
Asian 531 (3.5) 797 (4.5)
Black 131 (0.9) 416 (2.4)
Other 303 (2.0) 475 (2.7)
IMD score
Range 0.59–85.59 0.59–85.59
Mean (SD) 22.31 (15.91) 22.17 (15.87)
Median (IQR) 17.8 (10.3–30.9) 17.6 (10.2–30.7)
Medical history variables, n (%)
Smoking status
Ever smoked 8883 (63.5) 10,941 (62.1)
Never smoked 5106 (36.5) 6663 (37.8)
Diabetes status
Diabetic 2158 (13.7) 2428 (13.8)
Not diabetic 13,561 (86.3) 15,176 (86.2)
Hypercholesterolaemia
Yes 3906 (25.9) 3906 (22.2)
Heart failure
Yes 760 (5.0) 760 (4.3)
Cerebrovascular disease
Yes 1071 (7.0) 1071 (6.1)
Previous AMI
Yes 3092 (19.7) 3092 (17.6)
Asthma or COPD
Yes 1814 (11.9) 1814 (10.3)
Chronic renal failure
Yes 555 (3.6) 555 (3.2)
Peripheral vascular disease
Yes 587 (3.9) 587 (3.3)
Previous angina
Yes 2758 (17.8) 2758 (15.7)
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TABLE 9 Overview of participant characteristics for in-hospital mortality cohort (pre-imputation and imputed
data sets) (continued )
Variable Pre imputationa
After imputation
(N= 17,604)
Previous PCI
Yes 1061 (6.9) 1061 (6.0)
Previous CABG
Yes 790 (5.1) 790 (4.5)
Hypertension
Yes 6389 (41.0) 6389 (36.3)
Presenting characteristics of OHCA variables, n (%)
Time point of cardiac arrest
Before ambulance arrival 10,533 (60.1) 10,571 (60.0)
After ambulance arrival 7004 (39.9) 7033 (40.0)
Cardiac arrest rhythm
Asystole 885 (5.4) 963 (5.5)
PEA 837 (5.1) 912 (5.2)
VF/VT 14,778 (89.6) 15,729 (89.3)
Serum glucose (mmol/l)
Range 1–59 1–59
Mean (SD) 10.94 (5.00) 10.97 (5.07)
Median (IQR) 10.0 (7.3–13.2) 10.0 (7.3–13.3)
Creatinine (µmol/l)
Range 1–1512 1–1512
Mean (SD) 108.12 (55.72) 109.66 (57.01)
Median (IQR) 99 (81–121) 100 (81–123)
LVEF
Good 2783 (36.4) 5712 (32.4)
Moderate 3131 (40.9) 6260 (35.6)
Poor 1736 (22.7) 5632 (32.0)
Haemoglobin (g/dl)
Range 5–23.50 5–23.50
Mean (SD) 13.57 (2.03) 13.55 (2.06)
Median (IQR) 13.9 (12.2–15.0) 13.9 (12.2–15.0)
Serum cholesterol (mmol/l)
Range 1–30 1–30
Mean (SD) 4.80 (1.51) 4.65 (1.53)
Median (IQR) 4.7 (3.8–5.6) 4.5 (3.6–5.5)
Admission diagnosis
Definite MI – anterior infarction 3897 (27.0) 5045 (28.7)
Definite MI – other infarction site 3639 (25.2) 5652 (32.1)
Other initial diagnosis 6883 (47.7) 6907 (39.2)
continued
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TABLE 9 Overview of participant characteristics for in-hospital mortality cohort (pre-imputation and imputed
data sets) (continued )
Variable Pre imputationa
After imputation
(N= 17,604)
SBP at admission (mmHg)
Range 50–230 50–230
Mean (SD) 125.69 (29.17) 125.39 (29.40)
Median (IQR) 124 (107–143) 124 (106–143)
ECG that determined treatment
ST segment elevation or LBBB 12,220 (71.9) 12,472 (70.8)
ST segment depression or T-wave changes only 2325 (13.7) 2508 (14.2)
Other acute abnormality or no acute changes 2447 (14.4) 2624 (14.9)
Heart rate at admission (b.p.m.)
Range 25–180 25–180
Mean (SD) 89.22 (24.79) 89.15 (25.00)
Median (IQR) 86 (72–104) 86 (72–104)
Time of the day of admission (day/night)
08.00 to < 20.00 hours 11,741 (66.7%) 11,741 (66.7%)
Killip class Not imputed
Basal crepitations and/or elevated venous pressure 796 (13.5)
Pulmonary oedema 317 (5.4)
Cardiogenic shock 1029 (17.5)
No evidence of heart failure 3612 (61.3)
Not applicable 138 (2.3)
Mini-GRACE score Not imputed
Range 69–275
Mean (SD) 173 (28.37)
Median (IQR) 172 (153–193)
Care pathway variables, n (%)
Hospital volume (OHCA cases per year)
1 to 10 cases 7984 (45.4) 7984 (45.4)
11 to 24 cases 6516 (37.0) 6516 (37.0)
25 to 82 cases 3104 (17.6) 3104 (17.6)
Hospital pPCI capability
pPCI capable 7800 (44.3) 7800 (44.3)
pPCI incapable 9804 (55.7) 9804 (55.7)
EMS response time (minutes)
Range 0–180 0–180
Mean (SD) 11.53 (11.82) 11.62 (12.42)
Median (IQR) 8.00 (5–14) 8.00 (5–14)
EMS travel distance (km)
Range 0–242 0–242
Mean (SD) 11.24 (10.08) 11.46 (10.23)
Median (IQR) 8.07 (3.86–15.82) 8.28 (3.94–16.24)
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TABLE 9 Overview of participant characteristics for in-hospital mortality cohort (pre-imputation and imputed
data sets) (continued )
Variable Pre imputationa
After imputation
(N= 17,604)
Admitting consultant
Cardiologist 10,680 (61.8) 10,825 (61.5)
Other consultant 6603 (37.5) 6779 (38.5)
Cardiological care during admission
Yes 11,960 (90.7) 14,034 (79.7)
Admission ward
CCU 8872 (51.0) 8966 (50.9)
Cardiac ward – non CCU 500 (2.9) 502 (2.9)
Intensive therapy unit 6154 (35.4) 6225 (35.4)
General medical ward or other 1534 (8.8) 1565 (8.9)
Died in ED 340 (1.9) 346 (2.0)
Time point of aspirin administration, n (%)
Already on aspirin/antiplatelet drug 2636 (16.4) 2865 (16.3)
Aspirin/antiplatelet given pre hospital 5324 (33.1) 5681 (32.3)
Aspirin/antiplatelet given in-hospital 6166 (38.3) 6759 (38.4)
Not given 1975 (12.3) 2299 (13.1)
Place where ECG performed
Ambulance 11,053 (75.7) 12,206 (69.3)
In hospital 3551 (24.3) 5398 (30.7)
Angiotensin-converting enzyme inhibitor (in-hospital use), n (%)
Yes 5333 (36.1) 5333 (30.3)
Loop diuretic (in-hospital use)
Yes 4486 (30.7) 4486 (25.5)
Reperfusion treatment and timing
None 5633 (37.1) 8064 (45.8)
Thrombolysis (performed early) 1080 (7.1) 1080 (6.1)
Thrombolysis (performed late) 1930 (12.7) 1930 (11.0)
Thrombolysis (time missing) 370 (2.4) 370 (2.1)
pPCI (performed early) 4424 (29.2) 4424 (25.1)
pPCI (performed late) 1063 (7.0) 1063 (6.0)
pPCI (time missing) 673 (4.4) 673 (3.8)
Assessment at non-intervention hospital Not imputed
No contact with non-interventional hospital 8928 (79.6)
Patient remains in ambulance 34 (0.3)
ED 1870 (16.7)
Acute assessment unit 34 (0.3)
continued
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TABLE 9 Overview of participant characteristics for in-hospital mortality cohort (pre-imputation and imputed
data sets) (continued )
Variable Pre imputationa
After imputation
(N= 17,604)
CCU/cardiac facility 170 (1.5)
Self-referral 27 (0.2)
Already in hospital 93 (0.8)
Other 56 (0.5)
Assessment at intervention centre Not imputed
Assessed in ED 2158 (30.9)
Acute assessment unit 51 (0.7)
CCU/cardiac facility 1064 (15.2)
Catheter laboratory 3683 (52.7)
Already in hospital 32 (0.5)
Intended reperfusion procedure Not imputed
None 649 (9.0)
Primary PCI 5939 (82.0)
Rescue PCI 153 (2.1)
Thrombolytic treatment 105 (1.5)
Other coronary intervention 393 (5.4)
Procedure performed Not imputed
No angiography 522 (7.4)
Angiography but no PCI 1017 (14.3)
Angiography and PCI 5559 (78.3)
Reason for no angiography Not imputed
Diagnosis not ACS 35 (11.8)
Patient refused 11 (3.7)
Complication before angiography could be performed 22 (7.4)
Angiography inappropriate because of comorbidity 171 (57.8)
Technical failure 3 (1.0)
Laboratory unavailable 8 (2.7)
Other 46 (15.5)
Reason for no intervention Not imputed
Complication before PCI could be performed 37 (3.6)
Patient refused 5 (0.5)
PCI felt to be inappropriate 213 (20.9)
Angiographically normal coronaries/mild
disease/infarct-related vessel unclear
342 (33.6)
Surgical disease 264 (25.9)
Technical failure 40 (3.9)
Other 118 (11.6)
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Reperfusion treatment (pPCI or thrombolysis) was delivered to 62.8% (n = 9540) of patients. Of these
9540 patients, the majority received pPCI (pPCI, n = 6160, 64.6%; thrombolysis, n = 3380, 35.4%).
Figures 7–9 show the percentage of patients receiving reperfusion treatment by year for all patients
(see Figure 7), STEMI patients (see Figure 8) and patients who did not have a STEMI (see Figure 9). All figures
show an increase in use of reperfusion over time, although this increase is notably higher in the STEMI group
than in the group of patients who did not have a STEMI. In all groups, there is a move away from the use of
thrombolysis to pPCI over the study period. The point at which the use of pPCI overtakes thrombolysis use is
around 2008–9, such that by the end of the study period very few patients received thrombolysis.
TABLE 9 Overview of participant characteristics for in-hospital mortality cohort (pre-imputation and imputed
data sets) (continued )
Variable Pre imputationa
After imputation
(N= 17,604)
Reason treatment not given Not imputed
None 6650 (48.7)
Ineligible ECG 4078 (29.9)
Too late 118 (0.9)
Risk of haemorrhage 391 (2.9)
Uncontrolled hypertension 9 (0.1)
Administrative failure 13 (0.1)
Elective decision 1078 (7.9)
Patient refused treatment 8 (0.1)
Other 1049 (7.7)
Unknown 249 (1.8)
Discharge care variables, n (%)
Discharge diagnosis
ACS 16,476 (95.1) 16,756 (95.2)
Other 843 (4.9) 848 (4.8)
Echocardiography
No 3948 (26.2) 5069 (28.2)
Yes or planned after discharge 11,140 (73.8) 12,535 (71.2)
Coronary angiography
Protocol-driven investigation 3974 (25.7) 4422 (25.1)
Symptom-driven investigation 3378 (21.9) 3883 (22.1)
Not performed 8102 (52.4) 9299 (52.8)
Coronary intervention
PCI 4364 (30.3) 5069 (31.5)
CABG 464 (3.2) 591 (3.4)
Not performed or arranged 9591 (66.5) 11,473 (65.2)
b.p.m., beats per minute; CCU, cardiac care unit; PEA, pulseless electrical activity; SBP, systolic blood pressure;
VF, ventricular fibrillation; VT, ventricular tachycardia.
a The N for each group is equal to 17,604 minus the number of missing cases (see Table 7).
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 7 Percentage of patients receiving reperfusion treatment by year (all patients). Adapted from Couper et al.,85
with permission from Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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FIGURE 8 Percentage of patients receiving reperfusion treatment by year (patients presenting with STEMI).
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Discharge care variables
In most patients, the discharge diagnosis was ACS (n = 16,476, 95.1%). The majority of patients
underwent echocardiography during their hospital stay, or this was planned to take place after discharge
(n = 11,140, 73.8%).
Primary outcome: hospital mortality
Unadjusted analysis
Unadjusted ORs for in-hospital mortality in relation to variables in the imputed data set are presented in
Table 10. For categorical predictor, the column, Patients, n (%), describes the number and percentage of
patients in that category who died in hospital.
Demographic variables
Demographic variables associated with increased in-hospital mortality include female sex, increased age,
and increased deprivation measured by the IMD score. Ethnicity was not associated with hospital mortality.
Demographic variables did not explain much variability in the data set, with age having the highest R2,
at 6%.
Medical history variables
All medical history variables were associated with mortality, except hypertension and previous PCI. Being a
smoker and having hypercholesterolaemia were associated with reduced mortality. All other conditions
(diabetes mellitus, heart failure, cerebrovascular disease, previous AMI, asthma or COPD, chronic renal
failure, peripheral vascular disease, previous angina pectoris and previous CABG) were associated with
increased mortality. Medical history variables explained little variability in the data set, with the maximum
R2 being 1.7% for diabetes status.
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FIGURE 9 Percentage of patients receiving reperfusion treatment by year (patients not presenting with STEMI).
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 10 Unadjusted ORs for in-hospital mortality
Variable Patients, n (%) OR (95% CI), p-valuea RE estimate (R2, AIC)
Null model 0.433 (0.000, 20242)
Demographic variables
Age (years) NA 1.043 (1.040 to 1.046), < 0.001 0.411 (0.060, 19332)
Sex 0.434 (0.013, 20046)
Male 3403 (25.7) 0.577 (0.535 to 0.622), < 0.001
Female 1644 (37.5) –
Ethnicity 0.435 (0.000, 20245)
Asian 235 (29.5) 1.109 (0.918 to 1.339), 0.283
Black 142 (34.1) 1.022 (0.705 to 1.482), 0.909
Other 146 (30.7) 1.129 (0.874 to 1.457), 0.353
White 4524 (28.4) –
IMD score NA 1.005 (1.002 to 1.007), < 0.001 0.431 (0.001, 20228)
Medical history variables
Smoking status 0.431 (0.013, 20055)
Ever smoked 2704 (24.7) 0.610 (0.564 to 0.661), < 0.001
Never smoked 2343 (35.2) –
Diabetes status 0.430 (0.017, 20015)
Diabetic 1042 (42.9) 2.063 (1.869 to 2.278), < 0.001
Not diabetic 4005 (26.4) –
Hypercholesterolaemia 0.421 (0.007, 20149)
Yes 846 (21.7) 0.648 (0.594 to 0.708), < 0.001
No 4201 (30.7) –
Heart failure 0.425 (0.009, 20138)
Yes 372 (48.9) 2.271 (1.948 to 2.648), < 0.001
No 4675 (27.8) –
Cerebrovascular disease 0.426 (0.006, 20160)
Yes 461 (43.0) 1.878 (1.647 to 2.142), < 0.001
No 4586 (27.7) –
Previous AMI 0.431 (0.002, 20216)
Yes 1039 (33.6) 1.267 (1.161 to 1.381), < 0.001
No 4008 (27.6) –
Asthma or COPD 0.430 (0.002, 20213)
Yes 643 (35.4) 1.362 (1.224 to 1.516), < 0.001
No 4404 (27.9) –
Chronic renal failure 0.429 (0.007, 20161)
Yes 274 (49.4) 2.322 (1.942 to 2.774), < 0.001
No 4773 (28.0) –
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TABLE 10 Unadjusted ORs for in-hospital mortality (continued )
Variable Patients, n (%) OR (95% CI), p-valuea RE estimate (R2, AIC)
Peripheral vascular disease 0.433 (0.003, 20204)
Yes 241 (41.1) 1.791 (1.503 to 2.135), < 0.001
No 4806 (28.2) –
Previous angina 0.430 (0.002, 20223)
Yes 927 (33.6) 1.245 (1.136 to 1.364), < 0.001
No 4120 (27.8) –
Previous PCI 0.431 (0.000, 20242)
Yes 269 (25.4) 0.893 (0.771 to 1.035), 0.134
No 4778 (28.9) –
Previous CABG 0.432 (0.001, 20238)
Yes 272 (34.4) 1.225 (1.047 to 1.433), 0.011
No 4775 (28.4) –
Hypertension 0.433 (0.000, 20244)
Yes 1835 (28.7) 0.998 (0.930 to 1.072), 0.963
No 3212 (28.6) –
Presenting characteristics of OHCA variables
Time point of cardiac arrest 0.368 (0.063, 19294)
After ambulance arrival 1034 (14.7) 0.302 (0.279 to 0.327), < 0.001
Before ambulance arrival 4013 (38.0) –
Cardiac arrest rhythm 0.368 (0.104, 18894)
PEA 647 (70.9) 1.024 (0.825 to 1.27), 0.830
VF/VT 3715 (23.6) 0.139 (0.119 to 0.162), < 0.001
Asystole 685 (71.1) –
Serum glucose (mmol/l) NA 1.132 (1.120 to 1.144), < 0.001 0.423 (0.083, 18993)
Creatinine (µmol/l) NA 1.011 (1.009 to 1.013), < 0.001 0.414 (0.070, 19353)
LVEF, n (%) 0.475 (0.078, 18947)
Good 891 (15.6) 0.197 (0.150 to 0.260), < 0.001
Moderate 1490 (23.8) 0.334 (0.264 to 0.422), < 0.001
Poor 2666 (47.3) –
Haemoglobin (g/dl) NA 0.795 (0.772 to 0.820), < 0.001 0.440 (0.045, 19525)
Serum cholesterol (mmol/l) NA 0.776 (0.737 to 0.817), < 0.001 0.431 (0.029, 19861)
Admission diagnosis 0.378 (0.019, 20089)
Other diagnosis 259 (36.6) 1.717 (1.555 to 1.894), < 0.001
Definite MI (other infarction site) 1401 (24.8) 1.142 (1.015 to 1.284), 0.027
Definite MI (anterior infarction) 1117 (22.1) –
SBP at admission (mmHg) NA – 0.451 (0.043, 19519)
Linear termb –50.47 (–55.54 to –45.4), < 0.001
Quadratic termb 34.32 (29.57 to 39.07), < 0.001
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TABLE 10 Unadjusted ORs for in-hospital mortality (continued )
Variable Patients, n (%) OR (95% CI), p-valuea RE estimate (R2, AIC)
ECG that determined treatment 0.415 (0.005, 20214)
ST segment elevation or LBBB 3290 (26.4) 0.936 (0.845 to 1.037), 0.206
Other acute abnormality or no acute
changes
950 (36.2) 1.239 (1.092 to 1.406), 0.001
ST segment depression/T-wave
changes only
807 (32.2) –
Heart rate at admission (b.p.m.) NA 1.003 (1.002 to 1.005), < 0.001 0.428 (0.002, 20225)
Time of the day of admission (day/night) 0.434 (0.000, 20242)
20.00 to < 08.00 hours 1648 (28.1) 0.942 (0.876 to 1.012), 0.104
08.00 to < 20.00 hours 3399 (28.9)
Year NA – 0.465 (–0.002, 20177)
Slope (2003–8) 0.955 (0.922 to 0.988), 0.009
Slope (2009–15) 1.073 (1.046 to 1.100), < 0.001
Care pathway variables
Hospital volume (OHCA cases per year) 0.414 (0.006, 20241)
0 to 10 cases 2422 (30.3) 1.510 (0.987 to 2.311), 0.058
11 to 24 cases 1990 (30.5) 1.766 (1.109 to 2.810), 0.017
25 to 82 cases 635 (20.5) –
Hospital pPCI capability 0.418 (0.003, 20242)
pPCI capable 1858 (23.8) 0.911 (0.811 to 1.023), 0.115
pPCI incapable 3189 (32.5) –
EMS response time (minutes) NA 0.991 (0.987 to 0.995), < 0.001 0.427 (0.003, 20217)
EMS travel distance (km) NA 0.977 (0.973 to 0.981), < 0.001 0.420 (0.011, 20113)
Admitting consultant 0.352 (0.056, 19595)
Cardiologist 2188 (20.2) 0.323 (0.296 to 0.353), < 0.001
Other consultant 2859 (42.2) –
Cardiological care during admission 0.332 (0.073, 19388)
Yes 3035 (21.6) 0.275 (0.176 to 0.431), < 0.001
No 2012 (56.4) –
Admission ward 0.272 (0.178, 17490)
Intensive therapy unit 2776 (44.6) 3.405 (2.478 to 4.678), < 0.001
CCU 1095 (12.2) 0.587 (0.426 to 0.809), 0.001
Died in ED 345 (99.7) Not estimable
General medical ward or other 753 (48.1) 4.050 (2.908 to 5.640), < 0.001
Cardiac ward – non-CCU 78 (15.5) –
Time point of aspirin administration 0.332 (0.140, 18257)
Already on aspirin/antiplatelet drug 992 (34.6) 0.244 (0.214 to 0.278), < 0.001
Aspirin/antiplatelet given out of
hospital
679 (12.0) 0.067 (0.058 to 0.076), < 0.001
Aspirin/antiplatelet given in hospital 1845 (27.3) 0.176 (0.157 to 0.198), < 0.001
Not given 1531 (66.6) –
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TABLE 10 Unadjusted ORs for in-hospital mortality (continued )
Variable Patients, n (%) OR (95% CI), p-valuea RE estimate (R2, AIC)
Place where ECG performed 0.413 (0.014, 20096)
In hospital 1623 (37.5) 1.696 (1.466 to 1.963), < 0.001
Ambulance 3424 (25.8) –
Angiotensin-converting enzyme inhibitor (in-hospital use) 0.522 (0.086, 18340)
Yes 454 (8.5) 0.114 (0.101 to 0.127), < 0.001
No 4593 (37.4) –
Loop diuretic (in-hospital use) 0.440 (0.001, 20221)
Yes 1196 (26.7) 0.821 (0.757 to 0.890), < 0.001
No 3851 (29.4) –
Reperfusion treatment and timing 0.363 (0.042, 19719)
Thrombolysis (performed early) 161 (14.9) 0.297 (0.248 to 0.356), < 0.001
Thrombolysis (performed late) 448 (23.2) 0.502 (0.445 to 0.567), < 0.001
Thrombolysis (time missing) 116 (31.4) 0.814 (0.643 to 1.030), 0.086
pPCI (performed early) 755 (17.1) 0.418 (0.376 to 0.465), < 0.001
pPCI (performed late) 365 (34.3) 1.048 (0.905 to 1.213), 0.532
pPCI (time missing) 154 (22.9) 0.586 (0.478 to 0.718), < 0.001
None 3048 (37.8) –
Discharge care variables
Discharge diagnosis 0.432 (0.001, 20239)
ACS 4752 (28.4) 0.824 (0.692 to 0.981), 0.029
Other 295 (34.8) –
Echocardiography 0.489 (0.139, 17925)
Yes or planned 2258 (18.0) 0.139 (0.127 to 0.153), < 0.001
No 2789 (55.0) –
Coronary angiography 0.529 (0.123, 17550)
Protocol driven 510 (11.5) 0.093 (0.081 to 0.107), < 0.001
Symptom driven 449 (11.6) 0.096 (0.084 to 0.111), < 0.001
None 4088 (44.0) –
Coronary intervention 0.442 (0.074, 18710)
PCI 717 (12.9) 0.177 (0.157 to 0.198), < 0.001
CABG 12 (2.0) 0.024 (0.010 to 0.056), < 0.001
None 4318 (37.6) –
b.p.m., beats per minute; NA, not applicable; SBP, systolic blood pressure.
a Values describe OR (95% CI), p-value, unless stated otherwise.
b Estimates on the logarithmic scale.
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Presenting characteristics for out-of-hospital cardiac arrest
Cardiac arrest following ambulance arrival and an initial cardiac arrest rhythm of VF/VT were both associated
with reduced mortality. Increased heart rate, glucose and creatinine were associated with increased mortality.
In contrast, increased haemoglobin and cholesterol were associated with reduced mortality. In comparison
with ST segment depression/T-wave changes, an ECG with evidence of ST-segment elevation/LBBB was not
associated with mortality, but an ECG showing no acute changes or other abnormality was associated with
increased mortality. The time of admission was not associated with mortality.
Some presenting characteristics of OHCA variables explain significant variability in the data, including
cardiac arrest rhythm (R2 = 10.4%) and glucose (R2 = 8.3%)
Care pathway variables
All care pathway variables were associated with an effect on mortality, except hospital PCI capability.
Administration of aspirin, pre-hospital ECG, admission under a cardiologist, cardiological care during
admission and reperfusion therapy were associated with reduced mortality. Both increased EMS response
time and transfer distance (patient home to hospital) were associated with reduced mortality. Compared
with patients treated in the highest volume hospitals, patients treated in mid-volume hospitals (11–24 cases
per year) had increased mortality.
Some care pathway predictor variables also explain substantial variability in the data, including admission
ward (R2 = 17.8%) and time point of aspirin administration (R2 = 14.0%).
Discharge care variables
Echocardiography, coronary angiography and coronary intervention delivery were all associated with
reduced mortality. Echocardiography (R2 = 13.9%) and coronary angiography (R2 = 12.3%) explained
substantial data variability.
Adjusted analysis
The adjusted model for in-hospital mortality is shown in tabular form in Table 11 and as a caterpillar plot
in Figure 10. The model consists of 37 predictor variables and explains 36.1% (R2 = 0.361) of the variability
in in-hospital mortality across patients. The RE estimate (0.215) and ICC (0.061) are lower than those for the
null model, such that the predictor variables explain some variability in in-hospital mortality across hospitals.
TABLE 11 Adjusted analysis for hospital mortality
Variable
Primary analysis; analysis after imputation,a
OR (95% CI), p-value (n= 17,604)
Demographic variables
Age (years) 1.046 (1.042 to 1.051), < 0.001
Sex
Male 0.877 (0.786 to 0.979), 0.019
Femaleb
Ethnicity
Asian 1.022 (0.804 to 1.299), 0.860
Black 0.939 (0.602 to 1.464), 0.780
Other 0.991 (0.723 to 1.358), 0.956
Whiteb
IMD score 1.005 (1.002 to 1.008), 0.003
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TABLE 11 Adjusted analysis for hospital mortality (continued )
Variable
Primary analysis; analysis after imputation,a
OR (95% CI), p-value (n= 17,604)
Medical history variables
Smoking status
Ever smoked 0.903 (0.812 to 1.004), 0.059
Never smokedb
Diabetes status
Diabetic 1.125 (0.981 to 1.290), 0.092
Not diabeticb
Hypercholesterolaemia
Yes 0.692 (0.615 to 0.779), < 0.001
Nob
Heart failure
Yes 1.318 (1.074 to 1.618), 0.008
Nob
Cerebrovascular disease
Yes 1.299 (1.097 to 1.537), 0.002
Nob
Previous AMI
Yes 1.028 (0.900 to 1.173), 0.685
Nob
Asthma or COPD
Yes 1.247 (1.087 to 1.431), 0.002
Nob
Chronic renal failure
Yes 1.065 (0.841 to 1.350), 0.601
Nob
Peripheral vascular disease
Yes 1.517 (1.208 to 1.904), < 0.001
Nob
Previous angina
Yes 1.011 (0.885 to 1.156), 0.867
Nob
Previous PCI
Yes 1.025 (0.840 to 1.251), 0.806
Nob
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TABLE 11 Adjusted analysis for hospital mortality (continued )
Variable
Primary analysis; analysis after imputation,a
OR (95% CI), p-value (n= 17,604)
Previous CABG
Yes 0.996 (0.811 to 1.222), 0.966
Nob
Hypertension
Yes 0.865 (0.784 to 0.955), 0.004
Nob
Presenting characteristics variables
Time point of cardiac arrest
After ambulance arrival 0.492 (0.441 to 0.548), < 0.001
Before ambulance arrivalb
Cardiac arrest rhythm
PEA 0.847 (0.658 to 1.088), 0.194
VF/VT 0.217 (0.180 to 0.262), < 0.001
Asystoleb
Serum glucose (mmol/l) 1.109 (1.096 to 1.122), < 0.001
Haemoglobin (g/dl) 0.912 (0.878 to 0.946), < 0.001
Serum cholesterol (mmol/l) 0.956 (0.906 to 1.010), 0.108
Admission diagnosis
Other diagnosis 0.876 (0.750 to 1.024), 0.097
Definite MI – other infarct site 1.022 (0.890 to 1.173), 0.762
Definite MI – anterior infarctb
SBP at admission (mmHg)
Linear termc –42.15 (–48.35 to –35.96), < 0.001
Quadratic termc 17.68 (11.79 to 23.57), < 0.001
ECG that determined treatment
ST segment elevation or LBBB 1.592 (1.364 to 1.858), < 0.001
ST segment depression or T-wave changes only 0.907 (0.775 to 1.062), 0.227
Other acute abnormality or no acute changesb
Heart rate at admission (b.p.m.) 1.005 (1.004 to 1.007), < 0.001
Time of the day of admission (day/night)
20.00 to < 08.00 hours 1.091 (0.994 to 1.196), 0.066
08.00 to < 20.00b hours
Year
Slope (2003–8) 0.947 (0.895 to 1.002), 0.057
Slope (2009–15) 1.044 (1.009 to 1.079), 0.012
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
TABLE 11 Adjusted analysis for hospital mortality (continued )
Variable
Primary analysis; analysis after imputation,a
OR (95% CI), p-value (n= 17,604)
Care pathway variables
Hospital volume (OHCA cases per year)
0–10 cases 1.033 (0.723 to 1.474), 0.860
11–24 cases 1.259 (0.877 to 1.808), 0.211
25–82 casesb
Hospital pPCI capability
pPCI capable 1.262 (1.043 to 1.527), 0.017
pPCI incapableb
EMS response time (minutes) 0.999 (0.995 to 1.004), 0.776
EMS travel distance (km) 0.994 (0.989 to 0.999), 0.024
Admitting consultant
Cardiologist 0.725 (0.641 to 0.822), < 0.001
Other consultantb
Admission ward
Intensive therapy unit 3.741 (3.331 to 4.202), < 0.001
Died in ED Not estimable
General ward or other 3.452 (2.941 to 4.051), < 0.001
Cardiac ward – non-CCU 1.212 (0.841 to 1.748), 0.302
CCUb
Place where ECG performed
In hospital 1.125 (0.970 to 1.304), 0.120
Pre hospitalb
Reperfusion treatment and timing
Thrombolysis (performed early) 0.672 (0.523 to 0.863), 0.002
Thrombolysis (performed late) 0.860 (0.723 to 1.023), 0.088
Thrombolysis (time missing) 0.954 (0.702 to 1.298), 0.766
pPCI (performed early) 0.704 (0.600 to 0.826), < 0.001
pPCI (performed late) 0.941 (0.773 to 1.145), 0.542
pPCI (time missing) 0.690 (0.532 to 0.893), 0.005
Noneb
RE estimate (adjusted R2, AIC) 0.215d (0.361,d 14134d)
b.p.m., beats per minute; SBP, systolic blood pressure.
a Values describe OR (95% CI), p-value, unless stated otherwise.
b Reference category.
c Estimates on the logarithmic scale.
d Median from 25 data sets.
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 10 Caterpillar plot for OR of in-hospital mortality (adjusted analysis). NA, not applicable.
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Demographic variables
As in the unadjusted model, female sex, increased age and increased deprivation measured by the
IMD score were associated with increased mortality. As before, ethnicity was not associated with hospital
mortality. A model that contains only demographic variables explains 6.8% of variability in the data.
Medical history variables
In the adjusted model, hypercholesterolaemia continued to be associated with reduced mortality.
In addition, hypertension was associated with reduced mortality. Heart failure, cerebrovascular disease,
asthma or COPD and peripheral vascular disease were associated with increased mortality. Diabetes
mellitus, smoking status, previous AMI, chronic renal failure, previous angina pectoris, previous PCI and
previous CABG were not associated with mortality.
Presenting characteristics for out-of-hospital cardiac arrest variables
The adjusted analysis showed an association between cardiac arrest following ambulance arrival and an
initial cardiac arrest rhythm of VF/VT and reduced mortality.
The admission diagnosis was not associated with mortality, but an ECG showing ST-segment elevation or
LBBB, compared with no acute changes, was associated with increased mortality. Increased heart rate and
glucose levels were also associated with increased mortality. Increased haemoglobin levels were associated
with reduced mortality. Cholesterol levels and time of day were not associated with mortality.
In relation to the year slopes, mortality did not change in the period 2003–8, but there was evidence of
increased mortality for each year between 2009 and 2015.
Care pathway variables
Emergency medical service response time, hospital volume and the location where ECG was performed were
not associated with survival. Although admission to a pPCI centre seemed to be associated with increased
mortality, early pPCI and pPCI where time was missing were associated with reduced mortality. Similarly, early
thrombolysis was associated with reduced mortality. Neither late pPCI nor late thrombolysis influenced survival.
Each additional kilometre travelled to hospital appeared to be associated with a small decrease in mortality.
Admission under a cardiologist was associated with reduced mortality. The admission ward was associated
with mortality, such that, compared with patients admitted to a CCU, those admitted to the intensive
therapy unit or general ward tended to have higher mortality.
Sensitivity analyses
Our sensitivity analyses of the primary outcome included a complete-case analysis, 2003–8 data,
2009–15 data, STEMI patients and patients who did not present with a STEMI. These analyses are
included in Table 12.
Across these analyses, results tended to be more variable and CIs wider because of the smaller sample size.
Nevertheless, the directions of effects are broadly similar to primary analysis results where the effect was
statistically significant. However, there are noteworthy differences across the data sets. In the complete
case and 2009–15 analyses, PEA as the presenting rhythm is associated with a statistically significant
reduction in mortality compared with asystole. In the complete-case cohort, the ORs for most reperfusion
treatments change direction and indicate harm. This association is statistically significant for thrombolysis
(late) and thrombolysis (time missing).
In the cases that did not present with a STEMI, admission during the night (between 20.00 and 07.59 hours)
was associated with increased mortality. For the year slope between 2003 and 2008, each year was
associated with a reduction in mortality. For hospital PCI capability, the direction of OR changed, suggesting
benefit to admission to a PCI centre in this patient group, although this did not reach statistical significance.
Importantly in this subgroup, there was no evidence of reduced mortality with the use of a reperfusion
treatment.
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TABLE 12 Sensitivity analysis for hospital mortality
Variable
OR (95% CI), p-valuea
Complete-case
analysis
(n= 2284)
2003–8 data;
analysis after
imputation
(n= 6075)
2009–15 data;
analysis after
imputation
(n= 11,529)
STEMI patients;
analysis after
imputation
(n= 12,220)b
Other (not
STEMI) patients;
analysis after
imputation
(n= 4772)b
Demographic variables
Age (years) 1.047 (1.028 to
1.065), < 0.001
1.048 (1.041 to
1.056), < 0.001
1.046 (1.041 to
1.051), < 0.001
1.048 (1.043 to
1.054), < 0.001
1.048 (1.040 to
1.056), < 0.001
Sex
Male 0.843 (0.554 to
1.284), 0.427
0.733 (0.597 to
0.900), 0.003
0.961 (0.844 to
1.094), 0.545
0.921 (0.806 to
1.052), 0.226
0.758 (0.621 to
0.925), 0.006
Femalec
Ethnicity
Asian 0.870 (0.330 to
2.292), 0.778
0.931 (0.535 to
1.619), 0.799
1.004 (0.762 to
1.323), 0.977
0.961 (0.725 to
1.275), 0.783
1.167 (0.702 to
1.939), 0.551
Black Not estimable 1.370 (0.481 to
3.905), 0.556
0.860 (0.528 to
1.399), 0.542
0.833 (0.509 to
1.364), 0.468
1.059 (0.511 to
2.198), 0.877
Other 0.769 (0.085 to
6.956), 0.815
1.056 (0.617 to
1.808), 0.843
0.918 (0.612 to
1.376), 0.677
1.023 (0.726 to
1.440), 0.898
0.871 (0.417 to
1.819), 0.713
Whitec
IMD score 1.005 (0.994 to
1.017), 0.368
1.006 (1.000 to
1.012), 0.039
1.004 (1.001 to
1.008), 0.026
1.002 (0.998 to
1.006), 0.323
1.010 (1.004 to
1.016), 0.002
Medical history variables
Smoking status
Ever smoked 0.927 (0.629 to
1.367), 0.703
0.886 (0.725 to
1.083), 0.239
0.906 (0.798 to
1.030), 0.130
0.875 (0.765 to
1.000), 0.050
1.009 (0.830 to
1.226), 0.927
Never smokedc
Diabetes
Diabetic 1.446 (0.848 to
2.465), 0.176
1.041 (0.792 to
1.367), 0.773
1.180 (0.999 to
1.394), 0.052
1.162 (0.976 to
1.384), 0.091
1.123 (0.890 to
1.416), 0.329
Not diabeticc
Hypercholesterolaemia
Yes 0.754 (0.485 to
1.172), 0.210
0.679 (0.539 to
0.855), 0.001
0.684 (0.594 to
0.787), < 0.001
0.669 (0.577 to
0.776), < 0.001
0.684 (0.551 to
0.850), 0.001
Noc
Heart failure
Yes 1.248 (0.552 to
2.820), 0.594
1.235 (0.877 to
1.739), 0.227
1.383 (1.062 to
1.801), 0.016
1.584 (1.178 to
2.128), 0.002
1.192 (0.874 to
1.624), 0.267
Noc
Cerebrovascular disease
Yes 1.364 (0.686 to
2.713), 0.376
1.571 (1.166 to
2.116), 0.003
1.176 (0.958 to
1.445), 0.122
1.075 (0.858 to
1.348), 0.529
1.703 (1.294 to
2.241), < 0.001
Noc
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TABLE 12 Sensitivity analysis for hospital mortality (continued )
Variable
OR (95% CI), p-valuea
Complete-case
analysis
(n= 2284)
2003–8 data;
analysis after
imputation
(n= 6075)
2009–15 data;
analysis after
imputation
(n= 11,529)
STEMI patients;
analysis after
imputation
(n= 12,220)b
Other (not
STEMI) patients;
analysis after
imputation
(n= 4772)b
Previous AMI
Yes 1.012 (0.587 to
1.744), 0.966
0.953 (0.758 to
1.198), 0.678
1.076 (0.912 to
1.269), 0.385
0.997 (0.836 to
1.188), 0.971
1.118 (0.899 to
1.39), 0.327
Noc
Asthma or COPD
Yes 0.988 (0.556 to
1.757), 0.968
1.364 (1.064 to
1.750), 0.014
1.202 (1.017 to
1.421), 0.031
1.228 (1.030 to
1.463), 0.022
1.246 (0.975 to
1.591), 0.079
Noc
Chronic renal failure
Yes 1.399 (0.568 to
3.450), 0.465
0.772 (0.487 to
1.223), 0.270
1.168 (0.879 to
1.551), 0.285
0.864 (0.613 to
1.219), 0.406
1.390 (0.969 to
1.995), 0.073
Noc
Peripheral vascular disease
Yes 2.199 (0.961 to
5.034), 0.062
1.444 (0.953 to
2.188), 0.083
1.622 (1.231 to
2.139), 0.001
1.723 (1.286 to
2.309), < 0.001
1.338 (0.903 to
1.981), 0.146
Noc
Previous angina
Yes 1.383 (0.824 to
2.322), 0.219
0.968 (0.769 to
1.218), 0.780
1.021 (0.864 to
1.207), 0.805
1.037 (0.869 to
1.239), 0.684
0.926 (0.743 to
1.154), 0.494
Noc
Previous PCI
Yes 1.307 (0.661 to
2.584), 0.441
1.042 (0.680 to
1.596), 0.850
1.011 (0.803 to
1.272), 0.928
1.051 (0.815 to
1.356), 0.700
0.923 (0.652 to
1.305), 0.649
Noc
Previous CABG
Yes 0.752 (0.348 to
1.629), 0.471
1.458 (0.976 to
2.178), 0.066
0.862 (0.677 to
1.098), 0.229
1.189 (0.894 to
1.583), 0.235
0.830 (0.607 to
1.135), 0.244
Noc
Hypertension
Yes 0.930 (0.624 to
1.385), 0.791
0.857 (0.717 to
1.024), 0.089
0.866 (0.768 to
0.976), 0.019
0.849 (0.752 to
0.960), 0.009
0.866 (0.723 to
1.038), 0.120
Noc
Presenting characteristics variables
Time point of cardiac arrest
After ambulance
arrival
0.467 (0.298 to
0.732), 0.001
0.486 (0.402 to
0.587), < 0.001
0.499 (0.436 to
0.571), < 0.001
0.483 (0.425 to
0.548), < 0.001
0.424 (0.331 to
0.544), < 0.001
Before ambulance
arrivalc
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TABLE 12 Sensitivity analysis for hospital mortality (continued )
Variable
OR (95% CI), p-valuea
Complete-case
analysis
(n= 2284)
2003–8 data;
analysis after
imputation
(n= 6075)
2009–15 data;
analysis after
imputation
(n= 11,529)
STEMI patients;
analysis after
imputation
(n= 12,220)b
Other (not
STEMI) patients;
analysis after
imputation
(n= 4772)b
Cardiac arrest rhythm
PEA 0.137 (0.05 to
0.375), < 0.001
1.128 (0.720 to
1.769), 0.599
0.727 (0.532 to
0.994), 0.045
0.730 (0.507 to
1.051), 0.091
0.846 (0.573 to
1.248), 0.399
VF/VT 0.090 (0.047 to
0.174), < 0.001
0.240 (0.173 to
0.332), < 0.001
0.202 (0.159 to
0.256), < 0.001
0.189 (0.145 to
0.247), < 0.001
0.231 (0.172 to
0.310), < 0.001
Asystolec
Serum glucose
(mmol/l)
1.125 (1.083 to
1.167), < 0.001
1.103 (1.077 to
1.130), < 0.001
1.113 (1.100 to
1.127), < 0.001
1.113 (1.097 to
1.130), < 0.001
1.103 (1.081 to
1.126), < 0.001
Haemoglobin (g/dl) 0.835 (0.758 to
0.920), < 0.001
0.900 (0.825 to
0.982), 0.017
0.919 (0.890 to
0.948), < 0.001
0.920 (0.884 to
0.958), < 0.001
0.892 (0.842 to
0.945), < 0.001
Serum cholesterol
(mmol/l)
0.846 (0.721 to
0.992), 0.039
0.970 (0.898 to
1.049), 0.445
0.952 (0.889 to
1.020), 0.160
0.953 (0.892 to
1.017), 0.150
0.980 (0.910 to
1.056), 0.595
Admission diagnosis
Other diagnosis 1.144 (0.604 to
2.167), 0.679
1.063 (0.763 to
1.479), 0.719
0.797 (0.661 to
0.960), 0.017
1.005 (0.850 to
1.188), 0.956
0.586 (0.329 to
1.043), 0.069
Definite MI –
other infarct site
0.988 (0.616 to
1.586), 0.961
1.165 (0.791 to
1.717), 0.440
0.988 (0.858 to
1.137), 0.864
1.029 (0.898 to
1.179), 0.679
1.192 (0.603 to
2.358), 0.614
Definite MI –
anterior infarctc
SBP at admission (mmHg)
Linear termd –7.43 (–15.57
to 0.70), 0.073
–26.62 (–33.3
to –19.9),
< 0.001
–33.18 (–39.1
to –27.2),
< 0.001
–33.76 (–40.3 to
–27.3), < 0.001
–23.45 (–29.6 to
–17.3), < 0.001
Quadratic termd 8.14 (0.87 to
15.41), 0.028
9.16 (2.96 to
15.36), 0.004
15.18 (9.41 to
20.95), < 0.001
16.96 (11.00 to
22.92), < 0.001
6.42 (0.46 to
12.38), 0.035
ECG that determined treatment
ST segment
elevation or LBBB
1.473 (0.758 to
2.861), 0.253
1.644 (1.266 to
2.135), < 0.001
1.555 (1.283 to
1.884), < 0.001
Only ‘ST segment
elevation or
LBBB’ patients
included in the
analysis
These data were
not included
ST segment
depression or
T-wave changes
only
0.532 (0.268 to
1.058), 0.072
0.890 (0.682 to
1.163), 0.394
0.904 (0.743 to
1.099), 0.311
0.859 (0.728 to
1.014), 0.073
Other acute abnormality or no acute changesc
Heart rate at
admission (b.p.m.)
1.013 (1.006 to
1.020), < 0.001
1.008 (1.005 to
1.012), < 0.001
1.003 (1.001 to
1.006), 0.003
1.006 (1.004 to
1.008), < 0.001
1.005 (1.002 to
1.008), 0.004
Time of day of admission (day/night)
20.00 to
< 08.00 hours
1.116 (0.764 to
1.629), 0.570
1.120 (0.946 to
1.326), 0.188
1.082 (0.968 to
1.210), 0.164
1.037 (0.926 to
1.163), 0.528
1.203 (1.010 to
1.433), 0.038
08.00 to
< 20.00c hours
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TABLE 12 Sensitivity analysis for hospital mortality (continued )
Variable
OR (95% CI), p-valuea
Complete-case
analysis
(n= 2284)
2003–8 data;
analysis after
imputation
(n= 6075)
2009–15 data;
analysis after
imputation
(n= 11,529)
STEMI patients;
analysis after
imputation
(n= 12,220)b
Other (not
STEMI) patients;
analysis after
imputation
(n= 4772)b
Year
Slope (2003–8) 0.616 (0.264 to
1.437), 0.262
0.946 (0.891 to
1.004), 0.068
These data
were excluded
0.996 (0.931 to
1.066), 0.916
0.885 (0.810 to
0.968), 0.008
Slope (2009–15) 1.003 (0.873 to
1.152), 0.966
These data
were excluded
1.038 (1.004 to
1.074), 0.029
1.038 (0.998 to
1.081), 0.065
1.016 (0.953 to
1.082), 0.632
Care pathway variables
Hospital volume (OHCA cases)
0–10 cases 1.726 (0.663 to
4.494), 0.263
0.972 (0.516 to
1.831), 0.931
1.126 (0.771 to
1.643), 0.539
1.229 (0.904 to
1.670), 0.189
0.688 (0.386 to
1.229), 0.207
11–24 cases 2.302 (0.972 to
5.456), 0.058
1.168 (0.607 to
2.247), 0.642
1.276 (0.897 to
1.816), 0.175
1.242 (0.926 to
1.667), 0.148
0.948 (0.534 to
1.681), 0.854
25–82 casesc
Hospital pPCI capability
pPCI capable 1.001 (0.515 to
1.948), 0.998
1.156 (0.702 to
1.902), 0.569
1.403 (1.101 to
1.789), 0.006
1.584 (1.261 to
1.989), < 0.001
0.849 (0.605 to
1.190), 0.342
pPCI incapablec
EMS response time
(minutes)
1.015 (1.000 to
1.031), 0.058
0.998 (0.988 to
1.008), 0.703
1.000 (0.994 to
1.005), 0.861
1.000 (0.995 to
1.005), 0.996
0.997 (0.987 to
1.007), 0.589
EMS travel distance
(km)
0.988 (0.967 to
1.011), 0.301
0.999 (0.989 to
1.009), 0.810
0.992 (0.986 to
0.998), 0.009
0.992 (0.986 to
0.998), 0.012
0.997 (0.987 to
1.008), 0.612
Admitting consultant
Cardiologist 0.676 (0.418 to
1.094), 0.111
0.739 (0.604 to
0.904), 0.003
0.694 (0.590 to
0.816), < 0.001
0.794 (0.680 to
0.927), 0.003
0.615 (0.494 to
0.766), < 0.001
Other consultantc
Admission ward
Intensive therapy
unit
3.833 (2.374 to
6.188), < 0.001
4.632 (3.744 to
5.732), < 0.001
3.461 (3.009 to
3.982), < 0.001
3.267 (2.852 to
3.742), < 0.001
5.239 (4.107 to
6.685), < 0.001
Died in ED Not estimable Not estimable Not estimable Not estimable Not estimable
General ward or
other
5.554 (2.882 to
10.70), < 0.001
3.461 (2.670 to
4.487), < 0.001
3.601 (2.910 to
4.457), < 0.001
3.549 (2.884 to
4.368), < 0.001
3.575 (2.642 to
4.838), < 0.001
Cardiac ward –
non-CCU
4.952 (1.432 to
17.13), 0.012
2.012 (0.925 to
4.374), 0.078
1.127 (0.748 to
1.699), 0.567
1.148 (0.728 to
1.810), 0.552
1.588 (0.861 to
2.929), 0.138
CCUc
Place where ECG performed
In hospital 1.127 (0.717 to
1.771), 0.604
1.257 (0.931 to
1.697), 0.136
1.049 (0.909 to
1.211), 0.513
1.127 (0.956 to
1.329), 0.154
1.088 (0.878 to
1.348), 0.439
Pre hospitalc
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Secondary outcome: neurological outcome at discharge
Adjusted analysis
The adjusted analysis for neurological outcome at discharge is presented in Table 13. The results of the
analysis are similar to those reported for the primary outcome (in-hospital mortality), although there are a
few important differences.
In the baseline demographic category, sex was found not to be predictive of neurological outcome.
In the care pathway category, the location where the ECG was performed did influence outcome, such
that in-hospital ECG was associated with a poorer outcome. In contrast to the primary outcome analysis,
there was no evidence of an association between transfer distance or admission to a pPCI centre and
neurological outcome. Finally, in this analysis there was a statistically significant association between late
thrombolysis and improved neurological outcome.
Sensitivity analyses
In sensitivity analyses, there was a similar pattern to that observed in the primary outcome sensitivity
analyses in that the reduced sample sizes led to greater variability in results and wider CIs (Table 14).
However, the results in the sensitivity analyses were broadly similar to those reported in the analysis of the
whole cohort.
TABLE 12 Sensitivity analysis for hospital mortality (continued )
Variable
OR (95% CI), p-valuea
Complete-case
analysis
(n= 2284)
2003–8 data;
analysis after
imputation
(n= 6075)
2009–15 data;
analysis after
imputation
(n= 11,529)
STEMI patients;
analysis after
imputation
(n= 12,220)b
Other (not
STEMI) patients;
analysis after
imputation
(n= 4772)b
Reperfusion treatment and timing
Thrombolysis
(performed early)
1.199 (0.396 to
3.631), 0.749
0.676 (0.488 to
0.936), 0.180
0.791 (0.502 to
1.248), 0.314
0.714 (0.550 to
0.926), 0.011
0.501 (0.121 to
2.071), 0.340
Thrombolysis
(performed late)
2.114 (1.035 to
4.318), 0.040
0.849 (0.666 to
1.083), 0.188
0.920 (0.706 to
1.199), 0.536
0.893 (0.741 to
1.075), 0.231
0.939 (0.480 to
1.837), 0.854
Thrombolysis
(time missing)
28.03 (3.038 to
258.6), 0.003
0.833 (0.537 to
1.292), 0.414
0.995 (0.620 to
1.597), 0.982
0.940 (0.672 to
1.315), 0.717
1.248 (0.500 to
3.117), 0.635
pPCI (performed
early)
1.176 (0.598 to
2.312), 0.639
0.449 (0.208 to
0.968), 0.041
0.685 (0.576 to
0.815), < 0.001
0.618 (0.518 to
0.737), < 0.001
0.802 (0.430 to
1.498), 0.490
pPCI (performed
late)
0.811 (0.377 to
1.743), 0.592
1.924 (0.969 to
3.819), 0.062
0.894 (0.724 to
1.103), 0.294
0.836 (0.675 to
1.035), 0.100
0.967 (0.479 to
1.952), 0.926
pPCI (time missing) 1.149 (0.341 to
3.875), 0.822
0.506 (0.117 to
2.183), 0.361
0.661 (0.504 to
0.867), 0.003
0.610 (0.463 to
0.802), < 0.001
1.496 (0.593 to
3.773), 0.393
Nonec
RE estimate
(adjusted R2, AIC)
0.192
(0.296, 1042)
0.311e
(0.399,e 4608e)
0.192e
(0.346,e 9539e)
0.118e
(0.354,e 9471e)
0.378e
(0.365,e 4133e)
b.p.m., beats per minute; SBP, systolic blood pressure.
a Values describe OR (95% CI), p-value, unless stated otherwise.
b Data for 612 patients missing prior to imputation for ECG that determined treatment, so not included in analysis.
c Reference category.
d Estimates on the logarithmic scale.
e Median from 25 data sets.
Adapted from Couper et al.,85 with permission from Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 13 Adjusted analysis for neurological outcome
Variable Analysis after imputation, OR (95% CI), p-value (n= 15,286)
Demographic variables
Age (years) 1.030 (1.026 to 1.034), < 0.001
Sex
Male 0.955 (0.860 to 1.061), 0.391
Femalea
Ethnicity
Asian 1.138 (0.904 to 1.433), 0.271
Black 1.054 (0.697 to 1.594), 0.804
Other 1.009 (0.757 to 1.345), 0.952
Whitea
IMD score 1.003 (1.000 to 1.007), 0.032
Medical history variables
Smoking status
Ever smoked 0.941 (0.843 to 1.051), 0.281
Never smokeda
Diabetes status
Diabetic 1.003 (0.875 to 1.150), 0.964
Not diabetica
Hypercholesterolaemia
Yes 0.714 (0.638 to 0.800), < 0.001
Noa
Heart failure
Yes 1.358 (1.096 to 1.682), 0.005
Noa
Cerebrovascular disease
Yes 1.227 (1.034 to 1.456), 0.019
Noa
Previous AMI
Yes 1.005 (0.881 to 1.147), 0.940
Noa
Asthma or COPD
Yes 1.171 (1.022 to 1.342), 0.023
Noa
Chronic renal failure
Yes 1.031 (0.806 to 1.319), 0.807
Noa
Peripheral vascular disease
Yes 1.560 (1.240 to 1.961), < 0.001
Noa
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TABLE 13 Adjusted analysis for neurological outcome (continued )
Variable Analysis after imputation, OR (95% CI), p-value (n= 15,286)
Previous angina
Yes 0.932 (0.816 to 1.065), 0.303
Noa
Previous PCI
Yes 0.986 (0.811 to 1.199), 0.888
Noa
Previous CABG
Yes 1.027 (0.833 to 1.265), 0.806
Noa
Hypertension
Yes 0.820 (0.745 to 0.903), < 0.001
Noa
Presenting characteristics variables
Time point of cardiac arrest
After ambulance arrival 0.428 (0.387 to 0.473), < 0.001
Before ambulance arrivala
Cardiac arrest rhythm
PEA 0.842 (0.629 to 1.125), 0.244
VF/VT 0.263 (0.212 to 0.324), < 0.001
Asystolea
Serum glucose (mmol/l) 1.092 (1.080 to 1.104), < 0.001
Haemoglobin (g/dl) 0.930 (0.904 to 0.957), < 0.001
Serum cholesterol (mmol/l) 0.961 (0.920 to 1.004), 0.077
Admission diagnosis
Other diagnosis 0.880 (0.756 to 1.023), 0.097
Definite MI – other infarct site 1.020 (0.896 to 1.161), 0.769
Definite MI – anterior infarcta
SBP at admission (mmHg)
Linear termb –34.37 (–40.31 to –28.43), < 0.001
Quadratic termb 16.27 (10.73 to 21.80), < 0.001
ECG that determined treatment
ST segment elevation or LBBB 1.528 (1.310 to 1.782), < 0.001
ST segment depression T-wave changes only 0.966 (0.828 to 1.128), 0.662
Other acute abnormality or no acute changesa
Heart rate (b.p.m.) 1.004 (1.002 to 1.006), < 0.001
Time of the day of admission (day/night)
20.00 to < 08.00 hours 1.020 (0.933 to 1.115), 0.662
08.00 to < 20.00a hours
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TABLE 13 Adjusted analysis for neurological outcome (continued )
Variable Analysis after imputation, OR (95% CI), p-value (n= 15,286)
Year
Slope (2003–8) 0.985 (0.936 to 1.037), 0.575
Slope (2009–15) 1.054 (1.020 to 1.089), 0.002
Care pathway variables
Hospital volume (OHCA cases per year)
0–10 cases 0.942 (0.671 to 1.323), 0.731
11–24 cases 1.113 (0.788 to 1.574), 0.543
25–82 casesa
Hospital pPCI capability
pPCI capable 1.030 (0.859 to 1.235), 0.748
pPCI incapablea
EMS response time (minutes) 1.000 (0.996 to 1.004), 0.900
EMS travel distance (km) 0.996 (0.991 to 1.001), 0.122
Admitting consultant
Cardiologist 0.743 (0.658 to 0.838), < 0.001
Other consultanta
Admission ward
Intensive therapy unit 3.797 (3.399 to 4.241), < 0.001
Died in ED Not estimable
General ward or other 2.992 (2.541 to 3.522), < 0.001
Cardiac ward – non-CCU 1.092 (0.781 to 1.526), 0.607
CCUa
Place where ECG performed
In hospital 1.164 (1.024 to 1.324), 0.020
Pre hospitala
Reperfusion treatment and timing
Thrombolysis (performed early) 0.661 (0.528 to 0.826), < 0.001
Thrombolysis (performed late) 0.811 (0.686 to 0.959), 0.014
Thrombolysis (time missing) 0.899 (0.663 to 1.220), 0.495
pPCI (performed early) 0.678 (0.582 to 0.791), < 0.001
pPCI (performed late) 0.912 (0.752 to 1.107), 0.352
pPCI (time missing) 0.830 (0.644 to 1.070), 0.151
Nonea
RE estimate (adjusted R2, AIC) 0.206c (0.352,c 14455c)
b.p.m., beats per minute; SBP, systolic blood pressure.
a Reference category.
b Estimates on the logarithmic scale.
c Median from 25 data sets.
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TABLE 14 Sensitivity analyses for neurological outcome
Variable
OR (95% CI), p-value
Complete-case
analysis
(n= 2109)
2003–8 data;
analysis after
imputation
(n= 5292)
2009–15 data;
analysis after
imputation
(n= 9994)
STEMI patients;
analysis after
imputation
(n= 10,701)a
Other (not
STEMI) patients;
analysis after
imputation
(n= 4045)a
Demographic variables
Age (years) 1.017 (1.004 to
1.031), 0.010
1.025 (1.018 to
1.031), < 0.001
1.034 (1.029 to
1.039), < 0.001
1.033 (1.028 to
1.038), < 0.001
1.028 (1.020 to
1.035), < 0.001
Sex
Male 1.200 (0.845 to
1.706), 0.308
0.807 (0.675 to
0.965), 0.019
1.054 (0.924 to
1.202), 0.433
0.986 (0.866 to
1.122), 0.829
0.897 (0.734 to
1.096), 0.287
Femaleb
Ethnicity
Asian 2.295 (1.137 to
4.632), 0.020
0.960 (0.595 to
1.551), 0.868
1.159 (0.882 to
1.525), 0.289
1.133 (0.858 to
1.495), 0.379
1.259 (0.764 to
2.073), 0.366
Black 2.361 (0.387 to
14.41), 0.352
1.026 (0.356 to
2.958), 0.962
1.044 (0.666 to
1.637), 0.850
1.065 (0.649 to
1.749), 0.803
1.003 (0.499 to
2.015), 0.993
Other 2.084 (0.625 to
6.951), 0.232
0.973 (0.595 to
1.591), 0.912
0.951 (0.655 to
1.381), 0.792
1.008 (0.729 to
1.393), 0.964
0.991 (0.508 to
1.936), 0.980
Whiteb
IMD score 1.005 (0.996 to
1.015), 0.262
1.004 (0.999 to
1.009), 0.149
1.004 (1.000 to
1.008), 0.050
1.004 (1.000 to
1.008), 0.069
1.003 (0.997 to
1.009), 0.383
Medical history variables
Smoking status
Ever smoked 1.134 (0.833 to
1.544), 0.423
1.002 (0.832 to
1.205), 0.987
0.904 (0.793 to
1.030), 0.129
0.942 (0.824 to
1.077), 0.383
0.960 (0.792 to
1.163), 0.675
Never smokedb
Diabetes status
Diabetic 0.804 (0.508 to
1.272), 0.351
0.883 (0.691 to
1.128), 0.319
1.067 (0.900 to
1.265), 0.458
1.035 (0.869 to
1.231), 0.701
0.978 (0.775 to
1.233), 0.851
Not diabeticb
Hypercholesterolaemia
Yes 0.766 (0.541 to
1.084), 0.133
0.753 (0.612 to
0.926), 0.007
0.674 (0.588 to
0.774), < 0.001
0.672 (0.584 to
0.773), < 0.001
0.772 (0.627 to
0.952), 0.015
Nob
Heart failure
Yes 1.167 (0.559 to
2.438), 0.681
1.261 (0.899 to
1.769), 0.179
1.422 (1.069 to
1.892), 0.016
1.619 (1.186 to
2.210), 0.002
1.271 (0.923 to
1.748), 0.141
Nob
Cerebrovascular disease
Yes 1.036 (0.569 to
1.886), 0.909
1.417 (1.058 to
1.898), 0.019
1.141 (0.921 to
1.412), 0.227
1.190 (0.947 to
1.494), 0.135
1.317 (0.997 to
1.740), 0.053
Nob
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TABLE 14 Sensitivity analyses for neurological outcome (continued )
Variable
OR (95% CI), p-value
Complete-case
analysis
(n= 2109)
2003–8 data;
analysis after
imputation
(n= 5292)
2009–15 data;
analysis after
imputation
(n= 9994)
STEMI patients;
analysis after
imputation
(n= 10,701)a
Other (not
STEMI) patients;
analysis after
imputation
(n= 4045)a
Previous AMI
Yes 0.967 (0.618 to
1.513), 0.883
0.898 (0.724 to
1.115), 0.331
1.070 (0.904 to
1.267), 0.433
0.947 (0.794 to
1.129), 0.544
1.062 (0.857 to
1.316), 0.583
Nob
Asthma or COPD
Yes 1.240 (0.792 to
1.940), 0.347
1.311 (1.035 to
1.662), 0.025
1.119 (0.946 to
1.325), 0.190
1.106 (0.933 to
1.312), 0.246
1.320 (1.031 to
1.690), 0.028
Nob
Chronic renal failure
Yes 1.950 (0.851 to
4.469), 0.115
0.720 (0.458 to
1.132), 0.155
1.155 (0.851 to
1.567), 0.354
0.857 (0.603 to
1.218), 0.389
1.239 (0.850 to
1.806), 0.265
Nob
Peripheral vascular disease
Yes 1.745 (0.800 to
3.808), 0.162
1.442 (0.972 to
2.140), 0.069
1.672 (1.255 to
2.228), < 0.001
1.663 (1.241 to
2.226), 0.001
1.477 (0.991 to
2.201), 0.056
Nob
Previous angina
Yes 1.196 (0.782 to
1.828), 0.409
0.968 (0.777 to
1.205), 0.771
0.905 (0.763 to
1.073), 0.251
0.920 (0.770 to
1.098), 0.356
0.941 (0.757 to
1.169), 0.582
Nob
Previous PCI
Yes 1.060 (0.597 to
1.885), 0.842
0.958 (0.642 to
1.430), 0.834
0.981 (0.778 to
1.237), 0.874
1.065 (0.828 to
1.369), 0.624
0.848 (0.605 to
1.189), 0.338
Nob
Previous CABG
Yes 0.789 (0.404 to
1.542), 0.488
1.311 (0.881 to
1.950), 0.182
0.923 (0.718 to
1.186), 0.530
1.151 (0.856 to
1.549), 0.352
0.934 (0.685 to
1.275), 0.668
Nob
Hypertension
Yes 0.936 (0.684 to
1.280), 0.678
0.765 (0.649 to
0.901), 0.001
0.852 (0.756 to
0.961), 0.009
0.823 (0.731 to
0.925), 0.001
0.799 (0.668 to
0.954), 0.013
Nob
Presenting characteristics variables
Time point of cardiac arrest
After ambulance
arrival
0.625 (0.443 to
0.883), 0.008
0.423 (0.358 to
0.499), < 0.001
0.426 (0.375 to
0.484), < 0.001
0.413 (0.367 to
0.464), < 0.001
0.459 (0.367 to
0.573), < 0.001
Nob
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TABLE 14 Sensitivity analyses for neurological outcome (continued )
Variable
OR (95% CI), p-value
Complete-case
analysis
(n= 2109)
2003–8 data;
analysis after
imputation
(n= 5292)
2009–15 data;
analysis after
imputation
(n= 9994)
STEMI patients;
analysis after
imputation
(n= 10,701)a
Other (not
STEMI) patients;
analysis after
imputation
(n= 4045)a
Cardiac arrest rhythm
PEA 0.267 (0.103 to
0.691), 0.006
1.046 (0.638 to
1.716), 0.858
0.707 (0.488 to
1.023), 0.066
0.730 (0.484 to
1.103), 0.135
0.851 (0.546 to
1.326), 0.476
VF/VT 0.154 (0.081 to
0.294), < 0.001
0.301 (0.212 to
0.427), < 0.001
0.230 (0.175 to
0.303), < 0.001
0.230 (0.170 to
0.310), < 0.001
0.279 (0.201 to
0.388), < 0.001
Asystoleb
Serum glucose
(mmol/l)
1.104 (1.069 to
1.140), < 0.001
1.073 (1.052 to
1.095), < 0.001
1.104 (1.090 to
1.118), < 0.001
1.097 (1.083 to
1.112), < 0.001
1.080 (1.059 to
1.101), < 0.001
Haemoglobin (g/dl) 0.938 (0.867 to
1.014), 0.109
0.929 (0.878 to
0.983), 0.010
0.935 (0.907 to
0.964), < 0.001
0.929 (0.898 to
0.961), < 0.001
0.935 (0.887 to
0.984), 0.011
Serum cholesterol
(mmol/l)
0.884 (0.784 to
0.997), 0.045
0.955 (0.898 to
1.016), 0.145
0.965 (0.908 to
1.026), 0.257
0.961 (0.911 to
1.014), 0.145
0.976 (0.914 to
1.043), 0.475
Admission diagnosis
Other diagnosis 0.696 (0.415 to
1.167), 0.170
1.098 (0.832 to
1.448), 0.509
0.795 (0.659 to
0.959), 0.017
1.024 (0.865 to
1.211), 0.786
0.464 (0.265 to
0.814), 0.007
Definite MI –
other infarct site
0.649 (0.451 to
0.933), 0.019
1.168 (0.867 to
1.574), 0.308
0.971 (0.848 to
1.113), 0.672
1.024 (0.893 to
1.174), 0.735
0.870 (0.453 to
1.670), 0.675
Definite MI –
anterior infarctb
SBP at admission (mmHg)
Linear termc –9.88 (–16.36
to -3.41), 0.003
–22.11 (–28.2 to
–16.0), < 0.001
–26.35 (–32.2 to
–20.5), < 0.001
–27.12 (–33.3 to
–21.0), < 0.001
–19.67 (–25.2 to
–14.1), < 0.001
Quadratic termc 2.73 (–3.33 to
8.79), 0.378
7.63 (1.80 to
13.46), 0.010
14.79 (9.24 to
20.34), < 0.001
15.37 (9.85 to
20.88), < 0.001
6.24 (0.53 to
11.95), 0.032
ECG that determined treatment
ST segment
elevation or LBBB
1.348 (0.768 to
2.368), 0.298
1.379 (1.078 to
1.763), 0.010
1.653 (1.357 to
2.014), < 0.001
Only ‘ST segment
elevation or
LBBB’ patients
included in the
analysis
These data
were excluded
ST segment
depression
T-wave changes
only
1.171 (0.678 to
2.024), 0.572
0.836 (0.650 to
1.077), 0.165
1.067 (0.875 to
1.301), 0.524
0.928 (0.788 to
1.092), 0.368
Other acute
abnormality or no
acute changesb
Heart rate at
admission (b.p.m.)
1.007 (1.001 to
1.013), 0.017
1.006 (1.003 to
1.009), < 0.001
1.002 (1.000 to
1.005), 0.049
1.005 (1.002 to
1.007), < 0.001
1.003 (1.000 to
1.007), 0.048
Time of day of admission (day/night)
20.00 to
< 08.00 hours
1.011 (0.750 to
1.362), 0.944
1.033 (0.884 to
1.206), 0.686
1.020 (0.913 to
1.140), 0.721
0.989 (0.887 to
1.104), 0.846
1.082 (0.911 to
1.284), 0.369
08.00 to
< 20.00b hours
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TABLE 14 Sensitivity analyses for neurological outcome (continued )
Variable
OR (95% CI), p-value
Complete-case
analysis
(n= 2109)
2003–8 data;
analysis after
imputation
(n= 5292)
2009–15 data;
analysis after
imputation
(n= 9994)
STEMI patients;
analysis after
imputation
(n= 10,701)a
Other (not
STEMI) patients;
analysis after
imputation
(n= 4045)a
Year
Slope (2003–8) 0.983 (0.512 to
1.889), 0.960
0.987 (0.936 to
1.040), 0618
These data
were excluded
1.008 (0.947 to
1.072), 0.807
0.970 (0.892 to
1.055), 0.479
Slope (2009–15) 0.948 (0.850 to
1.056), 0.331
These data
were excluded
1.050 (1.015 to
1.086), 0.004
1.046 (1.006 to
1.088), 0.023
1.041 (0.978 to
1.109), 0.205
Care pathway variables
Hospital volume (OHCA cases per year)
0–10 cases 1.176 (0.596 to
2.319), 0.640
1.115 (0.653 to
1.904), 0.690
0.874 (0.586 to
1.302), 0.507
1.128 (0.812 to
1.569), 0.473
0.597 (0.347
1.027), 0.062
11–24 cases 1.335 (0.735 to
2.424), 0.342
1.155 (0.663 to
2.011), 0.611
1.131 (0.776 to
1.648), 0.523
1.097 (0.793 to
1.516), 0.576
0.945 (0.553
1.614), 0.835
25–82 casesb
Hospital pPCI capability
pPCI capable 0.678 (0.402 to
1.142), 0.144
0.896 (0.579 to
1.386), 0.620
1.037 (0.811 to
1.327), 0.771
1.307 (1.047 to
1.631), 0.018
0.617 (0.448
0.850), 0.003
pPCI incapableb
EMS response time
(minutes)
1.006 (0.992 to
1.019), 0.420
0.999 (0.990 to
1.008), 0.857
1.000 (0.996 to
1.005), 0.918
1.002 (0.997 to
1.006), 0.501
0.997 (0.987
1.007), 0.513
EMS travel distance
(km)
1.006 (0.990 to
1.022), 0.479
0.998 (0.988 to
1.008), 0.668
0.995 (0.989 to
1.001), 0.103
0.994 (0.989 to
1.000), 0.066
0.997 (0.987
1.008), 0.605
Admitting consultant
Cardiologist 0.899 (0.613 to
1.319), 0.588
0.718 (0.601 to
0.858), < 0.001
0.758 (0.644 to
0.892), 0.001
0.777 (0.668 to
0.903), 0.001
0.671 (0.547
0.823), < 0.001
Other consultantb
Admission ward
Intensive therapy
unit
3.153 (2.179 to
4.562), < 0.001
3.899 (3.228 to
4.711), < 0.001
3.815 (3.330 to
4.370), < 0.001
3.560 (3.130 to
4.050), < 0.001
4.255 (3.426
5.284), < 0.001
Died in ED Not estimable Not estimable Not estimable Not estimable Not estimable
General ward or
other
2.857 (1.640 to
4.976), < 0.001
2.482 (1.947 to
3.166), < 0.001
3.704 (2.959 to
4.636), < 0.001
3.096 (2.511 to
3.818), < 0.001
2.729 (2.047
3.640), < 0.001
Cardiac ward –
non-CCU
1.654 (0.592 to
4.624), 0.337
2.042 (1.073 to
3.885), 0.030
0.944 (0.634 to
1.403), 0.774
1.114 (0.722 to
1.720), 0.625
1.165 (0.667
2.036), 0.591
CCUb
Place where ECG performed
In hospital 1.475 (1.019 to
2.135), 0.040
1.201 (0.951 to
1.517), 0.124
1.135 (0.980 to
1.314), 0.090
1.154 (0.986 to
1.351), 0.074
1.128 (0.927
1.374), 0.229
Pre hospitalb
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There were a few results of note. In relation to admission to a PCI centre, this, counterintuitively, was
associated with worse outcome for STEMI patients but improved outcome for other cases. Furthermore,
reperfusion treatment was found to be of no benefit in the cohort of patients who did not have a STEMI.
Secondary outcome: time to all-cause mortality
Overview of cohort
The analysis of time to all-cause mortality included the 12,483 patients who survived to hospital discharge
for whom data were available on outcome.
The characteristics of this cohort are included in Table 15 for both the pre-imputation and the imputed
data sets. As was the case for the in-hospital mortality patient cohort, the pre-imputation and imputed
data sets for the time to all-cause mortality patient cohorts are similar. Furthermore, the imputed data sets
for both hospital mortality and time to all-cause mortality cohorts are broadly similar (Tables 9 and 15).
The key, albeit small, differences between cohorts typically relate to variables that were associated with hospital
mortality. For example, patients in the time to all-cause mortality cohort tended to be slightly younger [mean
age 65.3 (SD 13.2) years vs. 63.3 (SD 12.8) years], were more likely to be male (75.1% v 78.2% patients),
less likely to have a comorbidity (e.g. heart failure, 5.0% vs. 3.5% of patients), more likely to have a cardiac
arrest after ambulance arrival (39.9% vs. 47.7% of patients), initial rhythm was more likely to be VF/VT
(89.6% vs. 95.9% of patients) and were more likely to have received reperfusion treatment (62.9% vs.
68.4% of patients).
TABLE 14 Sensitivity analyses for neurological outcome (continued )
Variable
OR (95% CI), p-value
Complete-case
analysis
(n= 2109)
2003–8 data;
analysis after
imputation
(n= 5292)
2009–15 data;
analysis after
imputation
(n= 9994)
STEMI patients;
analysis after
imputation
(n= 10,701)a
Other (not
STEMI) patients;
analysis after
imputation
(n= 4045)a
Reperfusion treatment and timing
Thrombolysis
(performed early)
0.867 (0.410 to
1.831), 0.708
0.677 (0.513 to
0.892), 0.006
0.656 (0.420 to
1.025), 0.064
0.735 (0.580 to
0.930), 0.010
0.363 (0.094
1.398), 0.141
Thrombolysis
(performed late)
0.562 (0.307 to
1.028), 0.062
0.793 (0.635 to
0.990), 0.041
0.870 (0.662 to
1.142), 0.315
0.852 (0.711 to
1.022), 0.084
0.948 (0.495
1.818), 0.873
Thrombolysis
(time missing)
10.695 (1.46 to
78.41), 0.020
0.882 (0.594 to
1.311), 0.535
0.901 (0.539 to
1.504), 0.690
0.888 (0.634 to
1.243), 0.488
0.997 (0.411
2.418), 0.996
pPCI (performed
early)
0.670 (0.400 to
1.123), 0.129
0.586 (0.323 to
1.065), 0.079
0.658 (0.553 to
0.782), < 0.001
0.623 (0.523 to
0.741), < 0.001
0.707 (0.392
1.274), 0.249
pPCI (performed
late)
0.567 (0.305 to
1.055), 0.073
1.806 (0.956 to
3.413), 0.068
0.853 (0.690 to
1.053), 0.138
0.837 (0.678 to
1.033), 0.097
0.581 (0.296
1.144), 0.116
pPCI (time missing) 2.156 (0.758 to
6.132), 0.150
0.315 (0.069 to
1.439), 0.136
0.802 (0.611 to
1.052), 0.111
0.746 (0.567 to
0.982), 0.037
1.843 (0.744
4.564), 0.187
Noneb
RE estimate
(Adjusted R2, AIC)
0.138
(0.256 to 1505)
0.217d
(0.358d to 5064d)
0.232d
(0.351,d 9421d)
0.159d
(0.352,d 9892d)
0.339d
(0.319,d 4135d)
b.p.m., beats per minute; SBP, systolic blood pressure.
a Excludes cases where ECG that determined treatment field was missing in pre-imputation data set.
b Reference category.
c Estimates on the logarithmic scale.
d Median from 25 data sets.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets)
Variable Pre-imputationa Imputed data set (N= 12,483)
Demographic variables, n (%)
Age (years)
Range 20–114 20–114
Mean (SD) 63.3 (12.82) 63.3 (12.82)
Median (IQR) 63.3 (54–73) 63.3 (54–73)
Sex
Female 2715 (21.8) 2721 (21.8)
Ethnicity
White 10,234 (93.9) 11,340 (90.8)
Asian 361 (3.3) 541 (4.3)
Black 93 (0.9) 273 (2.2)
Other 187 (1.7) 329 (2.6)
IMD score
Range 0.72–85.59 0.72–85.59
Mean (SD) 21.98 (15.80) 22.00 (15.76)
Median (IQR) 17.4 (10.1–30.3) 17.5 (10.1–30.2)
Medical history variables, n (%)
Smoking status
Ever smoked 7244 (66.0) 8157 (65.3)
Never smoked 3726 (34.0) 4326 (34.7)
Diabetes status
Diabetic 1266 (10.9) 1385 (11.1)
Not diabetic 10,298 (89.1) 11,098 (88.9)
Hypercholesterolaemia
Yes 3055 (27.6) 3055 (24.5)
Heart failure
Yes 388 (3.5) 388 (3.1)
Cerebrovascular disease
Yes 610 (5.4) 610 (4.9)
Previous AMI
Yes 2048 (17.8) 2048 (16.4)
Asthma or COPD
Yes 1170 (10.5) 1170 (9.4)
Chronic renal failure
Yes 281 (2.5) 281 (2.3)
Peripheral vascular disease
Yes 346 (3.1) 346 (2.8)
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TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets) (continued )
Variable Pre-imputationa Imputed data set (N= 12,483)
Previous angina
Yes 1827 (16.1) 1827 (14.6)
Previous PCI
Yes 791 (7.0) 791 (6.3)
Previous CABG
Yes 517 (4.5) 517 (4.1)
Hypertension
Yes 4551 (39.9) 4551 (36.5)
Presenting characteristics of OHCA variables, n (%)
Time point of cardiac arrest
Before ambulance arrival 6503 (52.3) 6528 (52.3)
After ambulance arrival 5935 (47.7) 5955 (47.7)
Cardiac arrest rhythm
Asystole 249 (2.1) 276 (2.2)
PEA 237 (2.0) 259 (2.1)
VF/VT 11,254 (95.9) 11,948 (95.7)
Serum glucose (mmol/l)
Range 1–48.5 1–59
Mean (SD) 10.07 (4.20) 10.07 (4.30)
Median (IQR) 9.1 (7.0–12.0) 9.1 (7.0–12.0)
Creatinine (μmol/l)
Range 1–1219 1–1219
Mean (SD) 99.35 (42.10) 101.98 (44.93)
Median (IQR) 94 (78–112) 95 (78–115)
LVEF
Good 2534 (39.8) 5140 (41.2)
Moderate 2692 (42.3) 4927 (39.5)
Poor 1138 (17.9) 2416 (19.4)
Haemoglobin (g/dl)
Range 5–21.60 5–21.60
Mean (SD) 13.81 (1.92) 13.70 (1.98)
Median (IQR) 14.0 (12.7–15.0) 14.0 (12.5–15.0)
Serum cholesterol (mmol/l)
Range 1–18 1–20.50
Mean (SD) 4.87 (1.39) 4.79 (1.45)
Median (IQR) 4.8 (3.9–5.7) 4.7 (3.8–5.7)
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TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets) (continued )
Variable Pre-imputationa Imputed data set (N= 12,483)
Admission diagnosis
Definite MI – anterior infarction 3087 (30.3) 4023 (32.2)
Definite MI – other infarction site 2766 (27.2) 4122 (33.0)
Other initial diagnosis 4323 (42.5) 4338 (34.8)
SBP at admission (mmHg)
Range 50–230 50–230
Mean (SD) 128.51 (27.57) 128.61 (27.90)
Median (IQR) 127 (110–145) 127 (110–145)
ECG that determined treatment
ST segment elevation or LBBB 9000 (74.0) 9137 (73.2)
ST segment depression or T-wave changes only 1587 (13.0) 1677 (13.4)
Other acute abnormality or no acute changes 1575 (13.0) 1669 (13.4)
Heart rate at admission (b.p.m.)
Range 25–180 25–180
Mean (SD) 88.34 (23.77) 88.42 (23.96)
Median (IQR) 85 (72–101) 85 (72–102)
Time of the day of admission (day/night)
08.00 to < 20.00 hours 8290 (66.4) 8290 (66.4)
Killip class Not imputed
Basal crepitations and/or elevated venous pressure 590 (14.2)
Pulmonary oedema 217 (5.2)
Cardiogenic shock 443 (10.6)
No evidence of heart failure 2913 (70.0)
Not applicable 0 (0)
Care pathway variables, n (%)
Hospital volume (OHCA cases per year)
1–10 cases 5507 (44.1) 5507 (44.1)
11–24 cases 4509 (36.1) 4509 (36.1)
25–82 cases 2467 (19.8) 2467 (19.8)
Hospital pPCI capability
pPCI capable 5937 (47.6) 5937 (47.6)
pPCI incapable 6546 (52.4) 6546 (52.4)
EMS response time (minutes)
Range 0–180 0–180
Mean (SD) 11.99 (12.44) 11.86 (12.41)
Median (IQR) 9.00 (5–14) 8.00 (5–14)
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TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets) (continued )
Variable Pre-imputationa Imputed data set (N= 12,483)
EMS travel distance (km)
Range 0–242 0–242
Mean (SD) 11.90 (10.50) 12.29 (10.80)
Median (IQR) 8.78 (4.22–16.79) 9.27 (4.34–17.42)
Admitting consultant
Cardiologist 8506 (69.2) 8615 (69.0)
Other consultant 3794 (30.8) 3868 (31.0)
Cardiological care during admission
Yes 9243 (96.8) 10,597 (84.9)
Admission ward
CCU 7742 (62.7) 7803 (62.5)
Cardiac ward – non-CCU 422 (3.4) 425 (3.4)
Intensive therapy unit 3393 (27.5) 3437 (27.5)
General medical ward or other 789 (6.4) 817 (6.5)
Died in ED 0 (0) 1 (0)
Time point of aspirin administration
Already on aspirin/antiplatelet drug 1744 (15.0) 1867 (15.0)
Aspirin/antiplatelet given pre-hospital 4706 (40.5) 5016 (40.2)
Aspirin/antiplatelet given in-hospital 4512 (38.8) 4857 (38.9)
Not given 661 (5.7) 743 (6.0)
Place where ECG performed
Pre hospital 8166 (77.9) 9084 (72.8)
In hospital 2317 (22.1) 3399 (27.2)
Thienopyridine inhibitor (in-hospital use)
Yes 849 (12.1)
Angiotensin-converting enzyme inhibitor (in-hospital use)
Yes 4876 (46.0) 4876 (39.1)
Loop diuretic (in-hospital use)
Yes 3286 (31.4) 3286 (26.3)
Reperfusion treatment and timing
None 3482 (31.6) 4929 (39.6)
Thrombolysis (performed early) 919 (8.3) 919 (7.4)
Thrombolysis (performed late) 1479 (13.4) 1479 (11.8)
Thrombolysis (time missing) 254 (2.3) 254 (2.0)
pPCI (performed early) 3665 (33.3) 3665 (29.4)
pPCI (performed late) 698 (6.3) 698 (5.6)
pPCI (time missing) 519 (4.7) 519 (4.2)
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TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets) (continued )
Variable Pre-imputationa Imputed data set (N= 12,483)
Assessment at non-intervention hospital Not imputed
No contact with non-interventional hospital 6117 (77.3)
Patient remains in ambulance 25 (0.3)
ED 1433 (18.1)
Acute assessment unit 25 (0.3)
CCU/cardiac facility 157 (2.0)
Self-referral 27 (0.3)
Already in hospital 83 (1.0)
Other 47 (0.6)
Assessment at intervention centre Not imputed
Assessed in ED 1447 (27.2)
Acute assessment unit 28 (0.5)
CCU/cardiac facility 932 (17.5)
Catheter laboratory 2902 (54.5)
Already in hospital 18 (0.3)
Intended reperfusion procedure Not imputed
None 412 (7.5)
Primary PCI 4558 (82.8)
Rescue PCI 123 (2.2)
Thrombolytic treatment 83 (1.5)
Other coronary intervention 331 (6.0)
Procedure performed Not imputed
No angiography 217 (4.0)
Angiography but no PCI 705 (13.1)
Angiography and PCI 4461 (82.9)
Reason for no angiography Not imputed
Diagnosis not ACS 21 (15.0)
Patient refused 9 (6.4)
Complication before angiography could be performed 14 (10.0)
Angiography inappropriate because of comorbidity 52 (37.1)
Technical failure 2 (1.4)
Laboratory unavailable 7 (5.0)
Other 35 (25.0)
Reason for no intervention Not imputed
Complication before PCI could be performed 15 (2.1)
Patient refused 5 (0.7)
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TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets) (continued )
Variable Pre-imputationa Imputed data set (N= 12,483)
PCI felt to be inappropriate 112 (16.0)
Angiographically normal coronaries/mild
disease/infarct related vessel unclear
255 (36.5)
Surgical disease 209 (29.9)
Technical failure 24 (3.4)
Other 78 (11.2)
Reason treatment not given Not imputed
None 5115 (55.0)
Ineligible ECG 2629 (28.3)
Too late 69 (0.7)
Risk of haemorrhage 224 (2.4)
Uncontrolled hypertension 3 (0.03)
Administrative failure 8 (0.1)
Elective decision 456 (4.9)
Patient refused treatment 6 (0.1)
Other 610 (6.6)
Unknown 185 (2.0)
Discharge care variables, n (%)
Discharge diagnosis
ACS 11,865 (95.6) 11,935 (95.6)
Other 547 (4.4) 548 (4.4)
Echocardiography
No 1866 (16.6) 2237 (17.9)
Yes or planned after discharge 9344 (83.4) 10,246 (82.1)
Coronary angiography
Protocol driven investigation 3502 (32.1) 3921 (31.4)
Symptom driven investigation 2959 (27.1) 3440 (27.6)
Not performed 4442 (40.7) 5122 (41.0)
Coronary intervention
PCI 3734 (36.8) 4758 (38.1)
CABG 456 (4.5) 595 (4.8)
Not performed or arranged 5964 (58.7) 7130 (57.1)
Followed up by cardiologist
No cardiology follow up 612 (6.7) 1771 (14.2)
Cardiologist 8498 (93.3) 10,712 (85.8)
Cardiac rehabilitation
No 1000 (9.4) 1456 (11.7)
Yes 9683 (90.6) 11,027 (88.3)
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In relation to discharge variables, most patients were discharged on the following drugs: a statin
(n = 9339, 95.1%), angiotensin-converting-enzyme (ACE) inhibitor (n = 8898, 91.2%), antiplatelet therapy
(dual therapy, n = 5652, 59.3%; monotherapy, n = 3576, 37.5%) and beta-blocker (n = 8844, 90.1%).
In addition, patients were usually followed up by a cardiologist (n = 8498, 93.3%) and received cardiac
rehabilitation (n = 9683, 90.6%).
Unadjusted analysis
The unadjusted analysis of time to all-cause mortality is included in Table 16.
Among demographic variables, both increased age and female sex were associated with worse outcome.
Ethnicity was not associated with outcome. In contrast to other outcomes, although there was a trend to
worse outcome as deprivation increased, this did not reach statistical significance in this analysis.
For medical history variables, most medical conditions (previous AMI, heart failure, chronic renal failure,
previous angina pectoris, diabetes mellitus, cerebrovascular disease, hypertension, asthma or COPD,
peripheral vascular disease, previous CABG and previous PCI) were associated with an increased mortality.
For smoking status, the ever smoked category was associated with reduced mortality. Hypercholesterolaemia
was not associated with mortality.
TABLE 15 Overview of participant characteristics for time to all-cause mortality cohort (pre-imputation and
imputed data sets) (continued )
Variable Pre-imputationa Imputed data set (N= 12,483)
Discharged on beta-blocker
No 977 (9.9) 3639 (29.2)
Yes 8844 (90.1) 8844 (70.8)
Discharged on angiotensin-converting enzyme inhibitor
No 862 (8.8) 3585 (28.7)
Yes 8898 (91.2) 8898 (71.3)
Discharged on statin
No 483 (4.9) 3144 (25.2)
Yes 9339 (95.1) 9339 (74.8)
Discharged on antiplatelet
Dual antiplatelet 5652 (59.3) 5929 (47.5)
Single antiplatelet 3576 (37.5) 4338 (34.7)
No antiplatelet 307 (3.2) 2216 (17.8)
Smoking cessation advice Not imputed
Non-smoker 6522 (71.5)
No 179 (2.0)
Yes 2417 (26.5)
Dietary advice on discharge Not imputed
No 556 (8.0)
Not applicable 583 (8.3)
Yes 5838 (83.7)
b.p.m., beats per minute; SBP, systolic blood pressure.
a Sample size = 12,483 minus missing data.
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TABLE 16 Unadjusted analysis for time to all-cause mortality
Variable
Imputed data set
HR (95% CI), p-value RE estimate (AIC)
Demographic variables
Age (years) 1.075 (1.070 to 1.079), < 0.001 0.040 (1364)
Sex 0.068 (63)
Male 0.744 (0.672 to 0.823), < 0.001
Female
Ethnicity 0.067 (32)
Asian 0.797 (0.583 to 1.092), 0.158
Black 1.017 (0.654 to 1.582), 0.940
Other 0.883 (0.629 to 1.239), 0.471
White
IMD score 1.003 (1.000 to 1.006), 0.086 0.069 (35)
Medical history variables
Smoking status 0.067 (70)
Ever smoked 0.742 (0.672 to 0.819), < 0.001
Never smoked
Diabetes status 0.067 (135)
Diabetic 1.909 (1.692 to 2.154), < 0.001
Not diabetic
Hypercholesterolaemia 0.069 (32)
Yes 0.998 (0.897 to 1.110), 0.969
No
Heart failure 0.064 (238)
Yes 3.861 (3.304 to 4.512), < 0.001
No
Cerebrovascular disease 0.065 (116)
Yes 2.224 (1.908 to 2.593), < 0.001
No
Previous AMI 0.059 (300)
Yes 2.405 (2.180 to 2.654), < 0.001
No
Asthma or COPD 0.067 (78)
Yes 1.623 (1.423 to 1.852), < 0.001
No
Chronic renal failure 0.068 (192)
Yes 4.107 (3.421 to 4.929), < 0.001
No
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TABLE 16 Unadjusted analysis for time to all-cause mortality (continued )
Variable
Imputed data set
HR (95% CI), p-value RE estimate (AIC)
Peripheral vascular disease 0.069 (73)
Yes 2.105 (1.717 to 2.582), < 0.001
No
Previous angina 0.061 (176)
Yes 1.978 (1.781 to 2.197), < 0.001
No
Previous PCI 0.071 (43)
Yes 1.361 (1.148 to 1.613), < 0.001
No
Previous CABG 0.065 (66)
Yes 1.797 (1.499 to 2.153), < 0.001
No
Hypertension 0.069 (81)
Yes 1.390 (1.269 to 1.522), < 0.001
No
Presenting characteristics of OCHA variables
Time point of cardiac arrest 0.066 (57)
After ambulance arrival 0.791 (0.722 to 0.867), < 0.001
Before ambulance arrival
Cardiac arrest rhythm 0.065 (115)
PEA 1.193 (0.850 to 1.675), 0.308
VF/VT 0.472 (0.371 to 0.600), < 0.001
Asystole
Serum glucose (mmol/l) 1.031 (1.017 to 1.046), < 0.001 0.067 (66)
Creatinine (μmol/l) 1.004 (1.002 to 1.005), < 0.001 0.074 (162)
Haemoglobin (g/dl) 0.823 (0.797 to 0.851), < 0.001 0.076 (350)
Serum cholesterol (mmol/l) 0.760 (0.727 to 0.794), < 0.001 0.073 (273)
Admission diagnosis 0.030 (264)
Other diagnosis 2.373 (2.070 to 2.720), < 0.001
Definite MI (other infarction site) 1.362 (1.147 to 1.616), < 0.001
Definite MI (anterior infarction)
SBP at admission (mmHg) 0.998 (0.996 to 1.000), 0.035 0.071 (38)
ECG that determined treatment 0.043 (148)
ST segment elevation or LBBB 0.615 (0.544 to 0.694), < 0.001
Other acute abnormality or no acute changes 1.102 (0.948 to 1.280), 0.205
ST segment depression or T-wave changes only
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TABLE 16 Unadjusted analysis for time to all-cause mortality (continued )
Variable
Imputed data set
HR (95% CI), p-value RE estimate (AIC)
Heart rate at admission (b.p.m.) 1.001 (0.999 to 1.003), 0.322 0.069 (33)
Time of the day of admission 0.070 (38)
20.00 to < 08.00 hours 0.884 (0.803 to 0.974), 0.012
08.00 to < 20.00 hours
Year 0.987 (0.973 to 1.002), 0.087 0.063 (34)
Care pathway variables
Hospital volume (OHCA cases per year) 0.051 (42)
0–10 cases 1.330 (1.090 to 1.623), 0.005
11–24 cases 1.081 (0.872 to 1.341), 0.476
25–82 cases
Hospital pPCI capability 0.032 (65)
pPCI capable 0.703 (0.629 to 0.785), < 0.001
pPCI incapable
EMS response time (minutes) 0.999 (0.995 to 1.004), 0.784 0.069 (32)
EMS travel distance (km) 0.992 (0.987 to 0.997), 0.003 0.062 (43)
Admitting consultant 0.049 (57)
Cardiologist 0.765 (0.692 to 0.845), < 0.001
Other consultant
Admission ward 0.071 (97)
Intensive therapy unit 1.050 (0.943 to 1.170), 0.373
General medical ward or other 1.917 (1.647 to 2.232), < 0.001
Cardiac ward – non CCU 1.590 (1.188 to 2.127), 0.002
CCU
Place where ECG performed 0.062 (51)
In hospital 1.282 (1.125 to 1.460), < 0.001
Pre hospital
Reperfusion treatment and timing 0.028 (269)
Thrombolysis (performed early) 0.393 (0.320 to 0.481), < 0.001
Thrombolysis (performed late) 0.553 (0.479 to 0.639), < 0.001
Thrombolysis (time missing) 0.604 (0.438 to 0.832), 0.002
pPCI (performed early) 0.455 (0.399 to 0.519), < 0.001
pPCI (performed late) 0.451 (0.348 to 0.585), < 0.001
pPCI (time missing) 0.828 (0.635 to 1.079), 0.161
None
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TABLE 16 Unadjusted analysis for time to all-cause mortality (continued )
Variable
Imputed data set
HR (95% CI), p-value RE estimate (AIC)
Discharge variables
Discharge diagnosis 0.069 (52)
ACS 0.627 (0.517 to 0.761), < 0.001
Other diagnosis
Echocardiography 0.065 (54)
Done or planned 0.763 (0.679 to 0.857), < 0.001
No
Coronary angiography 0.088 (222)
Protocol driven 0.542 (0.478 to 0.614), < 0.001
Symptom driven 0.475 (0.411 to 0.549), < 0.001
None
Followed up by cardiologist 0.046 (192)
Yes 0.493 (0.430 to 0.567), < 0.001
No
Cardiac rehabilitation 0.071 (256)
Yes 0.401 (0.350 to 0.461), < 0.001
No
Discharged on beta-blocker 0.047 (187)
Yes 0.545 (0.496 to 0.598), < 0.001
No
Discharged on angiotensin-converting enzyme inhibitor 0.050 (182)
Yes 0.547 (0.498 to 0.601), < 0.001
No
Discharged on statin 0.054 (124)
Yes 0.609 (0.553 to 0.672), < 0.001
No
Discharged on aspirin 0.050 (116)
Yes 0.618 (0.559 to 0.682), < 0.001
No
Discharged on thienopyridine inhibitor or ticagrelor 0.042 (89)
Yes 0.674 (0.605 to 0.752), < 0.001
No
Antiplatelet therapy on discharge 0.034 (148)
Dual antiplatelet 0.497 (0.435 to 0.568), < 0.001
Single antiplatelet 0.780 (0.691 to 0.882), < 0.001
No antiplatelet
b.p.m., beats per minute; SBP, systolic blood pressure.
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For presenting characteristics, most results were similar to the unadjusted in-hospital mortality with factors
such as cardiac arrest following ambulance arrival, initial rhythm of VF/VT, and increased haemoglobin
levels associated with improved survival. There was an association between admission between 20.00 and
07.59 and improved outcome.
For care pathway variables, results were again similar to the unadjusted in-hospital mortality analysis.
Factors such as reperfusion therapy (both pPCI and thrombolysis) and admission under a cardiologist were
associated with reduced mortality. However, in this cohort, patient admission to very low volume hospitals
was associated with worse outcome, while admission to a PCI centre was associated with improved outcome.
Importantly, the need to be admitted to an intensive care unit did not influence long-term outcome.
Discharge interventions such as drugs (antiplatelet therapy, statins, ACE inhibitor, beta-blockers) were all
associated with improved outcome. Similarly, follow-up by a cardiologist and cardiac rehabilitation were
associated with improved outcome.
Adjusted analysis
The results for the adjusted analysis are included as Table 17.
For demographic variables, increased age and deprivation were predictive of increased mortality, but
ethnicity and sex were not associated with mortality.
In the adjusted model, only four medical history variables (previous AMI, heart failure, diabetes mellitus,
and asthma or COPD) were associated with worse outcome. In addition, the effect estimate for smoking
status changed direction in this model so the ever smoked category became associated with increased
mortality. The remaining medical conditions were not associated with outcome.
In the presenting characteristics of OHCA variable section, laboratory values (haemoglobin, cholesterol,
glucose, creatinine) were associated with the outcome, although the effect size was small. There was a
trend towards improved outcome when the arrest occurred after ambulance arrival, although this did not
reach statistical significance. In this model, time of day of admission was not associated with outcome.
The year slope suggested worse outcome over time.
None of the care pathway variables was associated with time to all-cause mortality. Although, generally,
the effect estimate direction was the same as in previous models, the estimate was closer to one and the
result was not statistically significant.
The discharge care variables that do not predict hazard of death are echocardiography, discharge diagnosis,
antiplatelet prescription and statin prescription. The provision of coronary angiography, cardiology follow-up and
cardiac rehabilitation were associated with reduced the risk of mortality. Similarly, discharge on beta-blocker or
ACE inhibitor were associated with improved outcome.
Sensitivity analyses
We undertook a complete-case analysis of 1381 (11.1% of cohort) patients with complete data (Table 17).
The results were broadly similar to the adjusted analysis of the imputed data set, although some effects
switched direction and/or became non-significant. For example, in the imputed data set, the HR for previous
AMI was 1.394 (95% CI 1.2 to 1.6), but the HR was 0.850 (95% CI 0.5 to 1.5) in the complete-case analysis.
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TABLE 17 Adjusted analysis for time to all-cause mortality
Predictor variable
HR (95% CI), p-value
Primary analysis: analysis
after imputation (n= 12,483)
Complete-case analysis
(n= 1381)
Demographic variables
Age (years) 1.061 (1.055 to 1.066), < 0.001 1.080 (1.059 to 1.102), < 0.001
Sex
Male 1.062 (0.942 to 1.197), 0.328 1.373 (0.841 to 2.243), 0.205
Femalea
Ethnicity
Asian 0.999 (0.722 to 1.381), 0.994 0.875 (0.307 to 2.495), 0.802
Black 0.888 (0.562 to 1.403), 0.610 1.064 (0.137 to 8.284), 0.953
Other 0.875 (0.613 to 1.250), 0.464 1.742 (0.388 to 7.816), 0.469
Whitea
IMD score 1.007 (1.003 to 1.010), < 0.001 1.012 (1.000 to 1.024), 0.053
Medical history variables
Smoking status
Ever smoked 1.122 (1.006 to 1.251), 0.039 1.435 (0.958 to 2.149), 0.080
Never smokeda
Diabetes status
Diabetic 1.163 (1.008 to 1.342), 0.038 1.394 (0.822 to 2.362), 0.217
Not diabetica
Heart failure
Yes 1.428 (1.196 to 1.705), < 0.001 2.926 (1.373 to 6.238), 0.005
Noa
Cerebrovascular disease
Yes 1.132 (0.963 to 1.331), 0.132 1.750 (1.017 to 3.009), 0.043
Noa
Previous AMI
Yes 1.394 (1.232 to 1.576), < 0.001 0.850 (0.497 to 1.453), 0.553
Noa
Asthma or COPD
Yes 1.266 (1.102 to 1.454), 0.001 1.366 (0.805 to 2.319), 0.248
Noa
Chronic renal failure
Yes 1.163 (0.922 to 1.467), 0.204 1.298 (0.534 to 3.156), 0.565
Noa
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TABLE 17 Adjusted analysis for time to all-cause mortality (continued )
Predictor variable
HR (95% CI), p-value
Primary analysis: analysis
after imputation (n= 12,483)
Complete-case analysis
(n= 1381)
Peripheral vascular disease
Yes 1.163 (0.937 to 1.443), 0.171 1.149 (0.474 to 2.786), 0.759
Noa
Previous angina
Yes 1.012 (0.892 to 1.147), 0.856 0.980 (0.583 to 1.647), 0.939
No
Previous PCI
Yes 1.034 (0.856 to 1.248), 0.731 1.441 (0.725 to 2.865), 0.298
Noa
Previous CABG
Yes 0.960 (0.788 to 1.169), 0.683 1.152 (0.539 to 2.464), 0.715
Noa
Presenting characteristics of patients and OHCA variables
Time point of cardiac arrest
After ambulance arrival 0.907 (0.815 to 1.010), 0.074 0.849 (0.548 to 1.315), 0.463
Before ambulance arrivala
Cardiac arrest rhythm
PEA 1.099 (0.774 to 1.560), 0.597 0.922 (0.167 to 5.102), 0.926
VF/VT 0.772 (0.598 to 0.998), 0.048 0.821 (0.226 to 2.975), 0.764
Asystolea
Serum glucose (mmol/l) 1.017 (1.003 to 1.032), 0.019 0.991 (0.941 to 1.044), 0.737
Creatinine (μmol/l) 1.001 (1.000 to 1.002), 0.005 1.011 (1.006 to 1.017), < 0.001
Haemoglobin (g/dl) 0.942 (0.908 to 0.977), 0.001 0.862 (0.775 to 0.959), 0.006
Serum cholesterol (mmol/l) 0.925 (0.879 to 0.973), 0.003 0.987 (0.845 to 1.152), 0.866
Admission diagnosis
Other diagnosis 1.300 (1.086 to 1.556), 0.004 1.079 (0.529 to 2.197), 0.835
Definite MI – other infarct site 1.167 (0.977 to 1.395), 0.089 0.909 (0.571 to 1.447), 0.688
Definite MI – anterior infarcta
SBP at admission (mmHg) 0.997 (0.995 to 0.999), 0.007 0.997 (0.991 to 1.004), 0.451
ECG determining treatment
ST segment elevation or LBBB 1.039 (0.888 to 1.216), 0.635 1.234 (0.634 to 2.401), 0.536
ST segment depression or T-wave changes only 0.992 (0.852 to 1.155), 0.919 0.775 (0.382 to 1.574), 0.481
Other acute abnormality or No acute changesa
Heart rate at admission (b.p.m.) 1.004 (1.002 to 1.006), < 0.001 1.005 (0.997 to 1.013), 0.200
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TABLE 17 Adjusted analysis for time to all-cause mortality (continued )
Predictor variable
HR (95% CI), p-value
Primary analysis: analysis
after imputation (n= 12,483)
Complete-case analysis
(n= 1381)
Time of day of admission (day/night)
20.00 to < 08.00 hours 1.016 (0.919 to 1.123), 0.761 1.416 (0.967 to 2.072), 0.074
08.00 to < 20.00a hours
Year 1.045 (1.019 to 1.071), 0.001 1.036 (0.902 to 1.190), 0.618
Care pathway variables
Hospital volume (OHCA cases per year)
0–10 cases 0.998 (0.800 to 1.247), 0.989 1.125 (0.548 to 2.312), 0.748
1–24 cases 1.067 (0.863 to 1.318), 0.550 0.970 (0.538 to 1.748), 0.918
25–82 casesa
Hospital pPCI capability
pPCI capable 0.919 (0.762 to 1.108), 0.375 0.834 (0.442 to 1.572), 0.574
pPCI incapablea
EMS response time (minutes) 1.001 (0.997 to 1.005), 0.653 0.998 (0.979 to 1.018), 0.867
EMS travel distance (km) 1.000 (0.994 to 1.006), 0.985 0.995 (0.975 to 1.014), 0.585
Admitting consultant
Cardiologist 1.120 (0.992 to 1.266), 0.068 0.866 (0.505 to 1.486), 0.602
Other consultanta
Admission ward
Intensive therapy unit 1.022 (0.897 to 1.166), 0.741 0.840 (0.477 to 1.477), 0.544
General ward or other 1.212 (1.026 to 1.431), 0.024 1.302 (0.541 to 3.133), 0.557
Cardiac ward – non-CCU 1.192 (0.896 to 1.585), 0.229 1.107 (0.344 to 3.566), 0.864
CCUa
Place where ECG performed
In hospital 0.912 (0.799 to 1.042), 0.175 1.198 (0.679 to 2.114), 0.533
Pre hospitala
Reperfusion treatment and timing
Thrombolysis (performed early) 0.895 (0.703 to 1.140), 0.371 0.434 (0.130 to 1.448), 0.175
Thrombolysis (performed late) 0.925 (0.773 to 1.108), 0.399 0.685 (0.316 to 1.484), 0.337
Thrombolysis (time missing) 1.025 (0.733 to 1.434), 0.833 b
pPCI (performed early) 0.972 (0.798 to 1.185), 0.782 0.936 (0.480 to 1.826), 0.846
pPCI (performed late) 0.833 (0.621 to 1.118), 0.224 0.502 (0.162 to 1.556), 0.233
pPCI (time missing) 1.171 (0.873 to 1.571), 0.293 3.278 (1.089 to 9.865), 0.035
Nonea
continued
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TABLE 17 Adjusted analysis for time to all-cause mortality (continued )
Predictor variable
HR (95% CI), p-value
Primary analysis: analysis
after imputation (n= 12,483)
Complete-case analysis
(n= 1381)
Discharge care variables
Discharge diagnosis
ACS 1.168 (0.942 to 1.447), 0.156 1.604 (0.366 to 7.036), 0.531
Other diagnosisa
Echocardiography
Done or planned 0.973 (0.859 to 1.102), 0.663 1.135 (0.607 to 2.120), 0.692
Noa
Coronary angiography
Protocol driven 0.678 (0.592 to 0.777), < 0.001 0.980 (0.618 to 1.555), 0.931
Symptom driven 0.657 (0.563 to 0.767), < 0.001 1.066 (0.640 to 1.776), 0.806
Nonea
Followed by a cardiologist
Yes 0.704 (0.586 to 0.844), < 0.001 0.374 (0.180 to 0.776), 0.008
Noa
Cardiac rehabilitation
Yes 0.640 (0.541 to 0.757), < 0.001 0.737 (0.340 to 1.597), 0.439
Noa
Discharged on beta-blocker
Yes 0.833 (0.725 to 0.956), 0.010 0.824 (0.460 to 1.474), 0.514
Noa
Discharged on ACE inhibitor
Yes 0.780 (0.677 to 0.899), 0.001 0.673 (0.373 to 1.216), 0.190
Noa
Discharged on statin
Yes 1.004 (0.843 to 1.195), 0.967 0.343 (0.149 to 0.791), 0.012
Noa
Antiplatelet therapy on discharge
Dual antiplatelet 0.823 (0.654 to 1.034), 0.094 1.291 (0.483 to 3.452), 0.610
Single antiplatelet 1.055 (0.887 to 1.253), 0.545 1.268 (0.458 to 3.513), 0.648
No antiplateleta
RE estimate (median AIC) 0.033c (2084)c 0.000 (155)
b.p.m., beats per minute; SBP, systolic blood pressure.
a Reference category.
b The two patients in this category were recategorised to the category ‘Thrombolysis (performed late)’ to enable
model convergence.
c Median from 25 imputed data sets.
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Chapter 5 Discussion
Summary of findings
In this cohort study, we included data from 17,604 patients who had an OHCA secondary to ACS
between 2003 and 2015, and who were included in the MINAP data set. The study showed evidence of
variability in survival between hospitals. Among hospitals with at least 60 cases over the study period,
hospital survival rates ranged from 34% to 89% (overall survival rate was 71.3%). Modelling that adjusted
for patient and treatment characteristics could account for only 36.1% of this variability.
We used an imputed data set to identify modifiable and non-modifiable factors associated with our three
outcomes (in-hospital mortality, neurological outcome and time to all-cause mortality).
For our primary outcome (in-hospital mortality), variables associated with reduced mortality outcome included
male sex, hypercholesterolaemia, hypertension, OHCA after ambulance arrival, increased haemoglobin level,
systolic blood pressure and heart rate, increased distance to hospital, arrest rhythm of VF/VT, reperfusion
treatment and admission under a cardiologist. Factors associated with increased mortality included increased
age, increased deprivation, heart failure, cerebrovascular disease, peripheral vascular disease, asthma/COPD,
increased glucose level, ECG showing ST elevation or LBBB and treatment in a PCI centre. Key factors
unrelated to outcome included ethnicity, admission diagnosis, time of day of admission, hospital volume and
place where ECG was performed. In sensitivity analyses, results were similar to the main analysis. In patients
who had a STEMI, reperfusion treatment was associated with improved outcome, although, paradoxically,
treatment in a pPCI centre was associated with worse outcome. In contrast, for patients who did not have a
STEMI, both reperfusion treatment and treatment in a pPCI centre had no association with outcome.
For neurological outcome, the results of the adjusted analysis were similar to those of our primary outcome
of in-hospital mortality. However, pre-hospital ECG, compared with in-hospital ECG, was associated with
improved outcome. Furthermore, neither treatment in a pPCI centre nor EMS transport distance was
associated with outcome. In sensitivity analyses, treatment in a pPCI centre was associated with worse
outcome for STEMI patients, but improved outcome in other patients. Reperfusion treatment in patients
who did not have a STEMI was not associated with outcome.
The analysis of time to all-cause mortality included only patients who survived to hospital discharge. In this
analysis, demographic variables (age, deprivation) and past medical history (heart failure, cerebrovascular
disease, diabetes mellitus, asthma or COPD, smoking status) were associated with outcome. Some presenting
OHCA characteristic variables were associated with outcome (haemoglobin, glucose, creatinine, diagnosis).
However, none of the care pathway variables was associated with long-term mortality, suggesting that
in-hospital treatment influences hospital survival but not long-term mortality following survival to hospital
discharge. Discharge interventions, such as drug therapy (beta-blocker, ACE inhibitor), cardiology follow-up
and cardiac rehabilitation, did influence outcome, although antiplatelet therapy did not influence the
long-term outcome.
Modifiable factors
The decision as to where to transport a patient following successful resuscitation from OHCA is challenging.
For pre-hospital clinicians, the decision requires careful consideration of the potential benefits to the patient
of access to specialist services and clinical teams at a large centre versus the risk of longer transport times.
In our analysis, we used categorisation as a pPCI centre and hospital volume as markers of large, specialist
centres. In our analysis, neither of these factors was associated with improved outcome and our primary
analysis found that admission to a pPCI centre was associated with worse outcome.
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In other health areas, such as trauma, surgery and critical care, increased patient volume is associated with
improved outcomes at a hospital level.86–89 In MI, there appears to be similar evidence of a relationship
between increased hospital volume and improved patient outcome.90,91 Furthermore, in patients treated
with pPCI, increased hospital PCI volume is also associated with improved survival, although there is no
association in patients treated with thrombolytics.37,38,92 Based on such data, the British Cardiovascular
Intervention Society recommend that hospitals must undertake at least 100 pPCIs per year to function as a
pPCI centre.72
For OHCA, however, there is inconsistency between studies as to the relationship between hospital volume
and its effect on patient outcome.93–98 For example, Schober et al.94 included 2238 OHCA patients admitted
to seven hospitals in Vienna, Austria, and found that the highest volume centre reported the highest
survival rate. In contrast, Cudnik et al.93 analysed data from 4125 patients with OHCA of cardiac origin
admitted to 155 US hospitals, but found no association between volume and patient outcome. Instead of
volume, it may be that for OHCA patients it is the specialist services (e.g. critical care, PCI) that are available
at the treating hospital, rather than its volume, that are most associated with patient outcome.30,34,98–103 For
example, Stub et al.34 scored 111 North American hospitals based on the availability of coronary angiography,
targeted temperature management and use of delayed prognostication, and correlated these performance
measures with 3252 OHCA cases from the Resuscitation Outcomes Consortium. In an adjusted analysis, the
authors reported that the highest performing hospitals reported the highest rates of hospital survival and
survival with good neurological outcome.
This correlates with our finding that, although admission to a pPCI centre may be associated with
increased mortality, the actual delivery of reperfusion treatment appeared to be the most important
modifiable factor associated with improved survival in this patient cohort, particularly when delivered early.
In our patient cohort, over 50% of patients received reperfusion treatment. Both early thrombolysis and
primary PCI seemed to significantly reduce the risk of in-hospital death across all cases, although sensitivity
analyses suggested that this effect was limited to STEMI cases. This supports current recommendations
that resuscitated OHCA patients with a STEMI should be considered for reperfusion.73,74,104 In contrast,
guidelines for OHCA patients who do not have a STEMI recommend that these patients may be considered
for reperfusion once non-cardiac causes for the OHCA have been ruled out.74,104,105 This is seemingly driven
by evidence that these OHCA patients with cardiac arrest resulting from a cardiac cause frequently have an
occluded coronary vessel.16,99,106,107 However, observational studies of the effect of PCI following OHCA in
patients who have not had a STEMI have produced mixed results, with some finding evidence of a survival
benefit while others report that there is no effect on survival.16,107–110
Over the course of our study, we noted that the use of thrombolysis decreased as the use of pPCI increased,
such that overall there was an increase in the use of reperfusion treatment. In 2015, three-quarters of
patients presenting with a STEMI in the context of OHCA received pPCI. In contrast, less than 15% of
patients who did not present with a STEMI received pPCI. This is consistent with data from across the MINAP
data set and correlates with data showing that pPCI is the preferred reperfusion strategy in STEMI.48,111,112
Following successful resuscitation, the management of OHCA patients may be complex owing to post-cardiac-
arrest syndrome.21 This is evidenced in an observational study of 248 post-cardiac-arrest patients transferred
by a critical care transfer team in which a critical clinical event occurred in 23% of patients and 6% suffered a
rearrest.113 There is therefore a possible risk associated with prolonged transportation. Counterintuitively, our
primary outcome analysis suggested that for each kilometre travelled, mortality reduced (OR of death 0.994,
95% CI 0.989–0.999). The explanation for this finding is unclear, particularly as it contrasts with a previous
observational study of 10,315 critically ill patients transported by English Ambulance Services between
1997 and 2001, which found that each additional 10 km travelled was associated with an absolute increase
in mortality of 1%.114 Importantly, however, this study excluded OHCA patients. International data from
OHCA patients suggests that there is no association (benefit or harm) between distance or time travelled and
patient outcome.115–117
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There are a number of possible explanations for this unexpected finding. The first is that the analysis was
based on the assumption that cardiac arrests included in the analysis occurred in the home. We chose
this approach, as MINAP records only the patient’s home postcode rather than the location of the cardiac
arrest. This approach seemed reasonable as other studies show that most cardiac arrests occur in the
home, although we are unable to test this in our population.5,24 Interestingly, the median transport
distance reported in this study was only slightly longer than that reported in the study by Nicholl et al.114
(median 5 km vs. 8 km). Second, this may be a type I statistical error, particularly given the small effect
size and the associated 95% CI, which was close to 1. Notably, our reported point estimate was similar
to the point estimates reported in other studies.115,116 A third explanation is that this is a true effect due to
patients being transferred longer distances to specialist centres for treatment, which were associated with
improved outcome, but the effect was confounded by other variables. In Cudnik et al.’s115 observational
study of 7540 patients who had suffered an OHCA resulting from a cardiac cause, there was evidence
of an association between being transferred to the nearest hospital, rather than a more distant hospital,
and increased mortality.115
In this study, the use of pre-hospital ECG was not associated with improved survival in the analysis of the
primary outcome, but was associated with improved neurological survival in our secondary analysis. The
use of pre-hospital ECG is recommended by international guidelines to triage the patient to a specialist
centre for pPCI in the event that the ECG shows a STEMI.73,104 A previous study demonstrated how the use
of pre-hospital ECG was associated with increased timeliness of pPCI and reduced mortality.51
Synthesising these data surrounding pPCI centre, reperfusion treatment, hospital volume, pre-hospital ECG
and EMS transport distance is challenging. However, it would seem reasonable to suggest patients in this
cohort should receive a pre-hospital ECG following ROSC in order to triage them to appropriate care. If
there is an indication for reperfusion treatment, then it would be reasonable to transfer the patient to a
specialist centre to receive this treatment. If there is uncertainty as to the cause of the cardiac arrest and
the patient’s ECG does not show ST elevation, then the patient may be transferred to the nearest hospital
with appropriate facilities to meet the patient’s care needs (e.g. critical care, cardiology services), which
may also be beneficial for relatives. Several clinical trials are planned or in progress to address the role of
pPCI among patients with NSTEMI, which should help to reduce uncertainty about how best to manage
this patient group (e.g. Patterson et al.42).
In patients who survived to leave hospital, discharge interventions were strongly associated with long-term
mortality, such as discharge on a beta-blocker and ACE inhibitor and referral to coronary rehabilitation.
These interventions are recommended in current guidelines.73,105 In contrast, antiplatelet therapy and
statins on discharge were not associated with long-term mortality in our study. The reason for this finding
is unclear as there is good evidence that they are effective in reducing long-term mortality following
MI.118,119 This may be partly explained by a selection bias, as patients with a better long-term prognosis,
as indicated by blood pressure and renal function, may be more likely to be prescribed beta-blockers and
ACE inhibitors, whereas prescription of antiplatelets and statins may be less influenced by these factors.
We also acknowledge that our antiplatelet analysis may have been affected by the non-availability of
pre-2009 thienopyridine inhibitor data. Furthermore, a large proportion of patients received both aspirin
and statins on discharge, so our analyses may have had insufficient power to reliably detect a difference
between groups.
The findings from this study inform the recent National Framework120 to improve care of people with
OHCA in England. The framework recommends that patients who achieve ROSC are transferred to
recognised centres of care that have the expertise and facilities to provide round-the-clock access to cardiac
catheterisation and an intensive care unit. Although the present study did not find evidence of improved
outcomes based on PCI capability or hospital volume, no harm was seen from increasing transfer distance
from scene to hospital.
DOI: 10.3310/hsdr06140 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 14
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Couper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
Non-modifiable factors
In our study, a number of demographic and medical history variables were associated with both in-hospital
and long-term mortality. Our finding that women were less likely to survive than men conflicts with the
results of a recently published systematic review, which compared male and female survival following
cardiac arrest.121 The meta-analysis of 409,323 patients from 13 studies reported that women were more
likely to survive cardiac arrest (OR for survival 1.10, 95% CI 1.03 to 1.20), despite having worse baseline
characteristics such as increased age and being more likely to have a cardiac arrest at home and be in a
non-shockable rhythm. A sensitivity analysis that was limited to OHCA resulting from a cardiac cause
produced similar findings.
In contrast, female sex in the MI literature is usually associated with worse outcome.122–125 Women who
present with MI are typically older and have more comorbidities, but there is also evidence that women are
less likely to receive evidence-based interventions such as a pre-hospital ECG or PCI, which may explain
the apparent discrepancy in outcome.51,122–124,126,127 In our study, we did not examine sex differences in
relation to demographics or treatment delivery.
Our study found that social deprivation was associated with increased hospital mortality and time
to all-cause mortality. This finding has been reported previously in both the MI and cardiac arrest
literature.128–134 However, this relationship is likely to be complex given that factors such as race and
lifestyle may be associated with both socioeconomic class and risk of cardiovascular disease.135,136 As is
the case with sex, this difference in survival may be partly explained by differences in treatment, such that
patients who are more socially deprived are less likely to receive key interventions such as bystander CPR
and PCI.130,132,134,137–140 For example, an observational study of OHCA undertaken in the north-east of
England reported that bystander CPR rates ranged from 14.5% in the most deprived areas to 23.2% in
the least deprived areas.138 The studies that describe a relationship between PCI and social deprivation
were undertaken in health systems that are markedly different from the UK, such that the generalisability
of these data to the UK setting is unclear. Indeed, a Scottish study found no evidence of an association
between socioeconomic class and use of coronary angiography and intervention following MI.141 Our
analysis found that social deprivation was associated with mortality even after adjustment for baseline and
treatment variables, suggesting that the precise mechanism by which social deprivation is associated with
mortality is likely to be complex.
Study strengths and limitations
The key strength of our study was the use of robust statistical methods on a large national audit data set to
answer an important research question. The inclusion of > 17,000 patients has enabled us to draw important
conclusions about factors that may explain variability in survival following OHCA attributable to ACS.
Nevertheless, the study has a number of limitations.
First, our study examined a cohort of patients who had OHCA secondary to ACS. Our cohort included
17,604 patients, of whom 12,557 (71.3%) survived to hospital discharge. Identification of patients with
ACS following OHCA as ECG findings may be non-specific or difficult to interpret reliably. Over the period
of our study, a total of 1,127,140 individual admissions were included in the MINAP data set. Extrapolating
epidemiological data from the National Out of Hospital Cardiac Arrest registry shows that, over the same
period, there were approximately 210,000 OHCA of presumed cardiac cause that were treated by English
ambulance services, of which approximately 54,100 (26%) achieved ROSC and 16,600 (8%) survived to
hospital discharge. In our cohort, 6225 patients were admitted to an intensive care unit. Over a similar
period (2004–14), there were 29,621 patients admitted to UK intensive care units following OHCA due to
any cause.142 For this reason, the findings of this study cannot be reliably extrapolated to either patients
who have an OHCA secondary to other conditions or patients with myocardial ischaemia who do not have
an OHCA.
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Second, the primary purpose of MINAP is the collection of data on myocardial ischaemia for audit purposes
to assess quality of care. It was not, however, developed for the primary purpose of research, nor was it
intended to be an audit to assess quality of care in OHCA patients. As such, despite MINAP capturing a large
data set, it does not record certain key data relating to both the cardiac arrest event and hospital treatment.
These important missing data items include the location of the cardiac arrest, use of bystander CPR, whether
or not the arrest was monitored or witnessed, and intensive care treatments such as the use of targeted
temperature management.12 There is an urgent need to link the MINAP data set with other relevant data
sets, such as the Out of Hospital Cardiac Arrest Outcomes project and the Intensive Care National Audit and
Research Centre case mix programme, to provide more detailed information about this patient group.143,144
Third, owing to regulations regarding the release of patient-identifiable data, we experienced restrictions in
what data could be released by NICOR. For example, we were not permitted data on the day of the week
of hospital admission, nor were we able to link hospital characteristics to the study data set. The study
group was concerned by a lack of clarity as to precisely what combinations of data could be released and
would welcome the development of guidance around this issue.
Fourth, we are aware of differences between hospitals in relation to the methods used to identify
patients. Anecdotally, some hospitals include only patients admitted to the CCU or who are managed
by a cardiology consultant, while other hospitals take an active approach to identify all patients with
ACS (e.g. follow-up of all positive troponin results reported by the hospital pathology laboratory). This
leads to under-reporting of patients, particularly patients who do not have a STEMI.48,145 This issue has
been recognised by MINAP in annual reports.48 The number of cardiac arrests per year has been relatively
static for the last 10 years, yet we observed that the number of cases recorded in MINAP more than
doubled over this period. Interestingly, the largest rise in cases was among patients who had a STEMI,
which is the group reported by MINAP to be most reliably reported. The precise reason for this increase in
cases is unclear, but may be improved case ascertainment or, alternatively, increasing cardiac intervention
among this cohort. As such, there is a high risk of ascertainment bias, particularly in the early years of data
capture, and this may explain some of the unexplained variability in survival between hospitals.
Finally, and most importantly, this was an observational study. Despite the use of statistical techniques
to adjust for known potential confounders, our results may have been affected by unmeasured residual
confounders (such as those outlined in point two above) for which we were unable to adjust. This is
exemplified by the variable ‘time point of aspirin administration’ in which, in unadjusted analyses, the OR
associated with giving aspirin prior to hospital arrival compared with not giving aspirin was 0.067 (95% CI
0.06 to 0.08). In contrast, the ISIS-2 clinical trial of aspirin in AMI reported that aspirin reduced vascular deaths
by 23%.146 On this basis, we concluded that the variable was likely to be heavily confounded (e.g. patient’s
consciousness level and associated ability to take aspirin) and, thus, not included in the modelling. The extent
to which other variables may have been confounded is unknown. As such, consideration should be given to
testing our key findings in robust clinical trials.
Patient and public involvement
Our clinical academic team was fortunate to be joined by two patient and public involvement (PPI)
representatives who ensured that the interests of patients were central to all study decision-making from
the inception of the project. This included the incorporation of neurological outcome as an outcome, as it
was considered important to patients and is often under-reported in the cardiac arrest literature.54 Bob Ewings
and John Long sat as full members of the study team. Our experience in this project highlighted the value in
engaging PPI representatives at an early stage of the study design with ongoing active involvement
throughout the study period.
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Chapter 6 Conclusions
The number of patients captured in the MINAP database following OHCA has doubled over the lastdecade, with > 2000 cases recorded in 2014. The proportion of patients treated with reperfusion
therapy increased from 20% to 60%. This was primarily attributable to an increase in the proportion of
STEMI patients treated with PCI since 2006 and a concurrent reduction in the proportion treated with
thrombolysis. The overall rate of survival to discharge was 71.3% of patients, but there was variability in
survival between hospitals (range 34–89%; median 71.4%, IQR 60.7–76.9%). Survival with favourable
neurological outcome occurred in 59.1% of cases, which also varied between hospitals (range 13–84%;
median 58.9%, IQR 44.2–66.8%).
Multivariate analysis of patient demographics, medical history, presenting characteristics and care pathway
captured in the MINAP database was able to explain 36% of variation in outcome. The majority of patients
underwent 12-lead ECG prior to hospital admission. The present study found no evidence that the location
where the ECG was recorded affected outcome. Nevertheless, pragmatically, ECG prior to transfer to
hospital facilitates informs decision-making about the most appropriate destination hospital and presents
the opportunity to provide an early alert to the receiving hospital.
The evaluation of modifiable factors in the patient journey produced conflicting results. Although there
was no evidence to suggest harm from increased transfer distances, centre volume and specialist services
(PCI) either had no effect or were associated with worse outcomes. Early reperfusion, whether by
thrombolysis or PCI, was associated with improved outcomes, primarily in patients with evidence of STEMI.
Recommendations for future research
Our research has identified the need for further research in the following areas:
1. The clinical effectiveness and cost-effectiveness of an invasive reperfusion strategy in patients with
resuscitated OHCA of cardiac cause who have not had a STEMI.
2. Factors affecting the decision to use an invasive perfusion strategy by cardiologists following OHCA.
3. Factors that influence survival following OHCA using observational data from multiple data sets
(e.g. MINAP and Out of Hospital Cardiac Arrest Outcomes project).
4. The differences in characteristics and decision-making processes of clinicians at high- and low-performing
hospitals.
5. The risk of adverse clinical events (e.g. rearrest) associated with prolonged transportation following OHCA.
6. Paramedic experiences of decision-making (pre-hospital ECG, transfer destination) in relation to patient
care following ROSC.
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Appendix 1 Overview of the Myocardial
Ischaemia National Audit Project data fields and their
use in the study
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
MINAP data set
Hospital identifier 1.01 – Supplied as anonymised identifier – used to
categorise patients by hospital and in case
identification to identify duplicate cases
– – –
Patient case record number 1.02 – Not used/supplied – – –
NHS number 1.03 – Supplied as anonymised identifier – used in
case identification to identify duplicate
cases
– – –
Patient surname 1.04 – Not used/supplied – – –
Patient forename 1.05 – Not used/supplied – – –
Patient date of birth 1.06 – Supplied as age at time of event ✓ ✓ ✓
Patient sex 1.07 Not known, male, female, not specified Yes ✓ ✓ ✓
Patient administration status 1.09 NHS, private, amenity, unknown Not used/supplied – – –
Patient postcode 1.10 – Supplied as northings–eastings – used to
calculate distance to hospital
✓ ✓ ✓
GP/PCT code 1.11 – Not supplied – – –
Patient ethnicity 1.13 White, black, Asian, mixed, not stated, other,
unknown
Yes ✓ ✓ ✓
Initial diagnosis 2.01 Definite MI, ACS, chest pain? Cause, other
initial diagnosis
Merged with field 2.36 ✓ ✓ ✓
ECG determining treatment 2.03 No acute changes, ST segment elevation,
LBBB, ST segment depression, T-wave
changes only, other acute abnormality,
unknown
Yes ✓ ✓ ✓
Where was aspirin/other
antiplatelet given?
2.04 Already on aspirin/antiplatelet drug, aspirin/
antiplatelet drug given out of hospital,
aspirin/antiplatelet drug given after arrival in
hospital, aspirin/antiplatelet contraindicated,
not given, unknown
Reported in unadjusted analyses. Not used
in modelling as unadjusted result suggested
heavily confounded
– – –
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Previous AMI 2.05 No, yes, unknown Yes ✓ ✓ ✓
Previous angina 2.06 No, yes, unknown Yes ✓ ✓ ✓
Hypertension 2.07 No, yes, unknown Yes ✓ ✓ –
Hypercholesterolaemia 2.08 No, yes, unknown Yes ✓ ✓ –
Peripheral vascular disease 2.09 No, yes, unknown Yes ✓ ✓ ✓
Cerebrovascular disease 2.10 No, yes, unknown Yes ✓ ✓ ✓
Asthma or COPD 2.11 No, yes, unknown Yes ✓ ✓ ✓
Chronic renal failure 2.12 No, yes, unknown Yes ✓ ✓ ✓
Heart failure 2.13 No, yes, unknown Yes ✓ ✓ ✓
Cardiac markers raised 2.14 No, yes, unknown Yes – – –
Serum cholesterol (mmol/l) 2.15 – Yes ✓ ✓ ✓
Smoking status 2.16 Never smoked, ex-smoker, current smoker,
non smoker – smoking history unknown,
unknown
Yes ✓ ✓ ✓
Diabetes 2.17 Not diabetic, diabetes (dietary control),
diabetes (oral medicine), diabetes (insulin),
insulin plus oral medication, unknown
Yes ✓ ✓ ✓
Previous PCI 2.18 No, yes, unknown Yes ✓ ✓ ✓
Previous CABG 2.19 No, yes, unknown Yes ✓ ✓ ✓
SBP (mmHg) 2.20 – Yes ✓ ✓ ✓
Heart rate (b.p.m.) 2.21 – Yes ✓ ✓ ✓
Admitting consultant 2.22 Cardiologist, other general physician, other,
unknown
Yes ✓ ✓ ✓
Place first 12-lead ECG
performed
2.23 Ambulance, in hospital, other health-care
facility, unknown
Yes ✓ ✓ ✓
Beta-blocker use 2.24 No, yes, unknown Not used/supplied – – –
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Angiotensin-converting
enzyme inhibitor or ARB use
2.25 No, yes, unknown Not used/supplied – – –
Statin use 2.26 No, yes, unknown Not used/supplied – – –
Serum glucose (mmol/l) 2.28 – Yes ✓ ✓ ✓
Height 2.29 – Not used/supplied – – –
Weight 2.30 – Not used/supplied – – –
LVEF 2.31 Good, moderate, poor, not assessed, unknown Yes – – –
Family history of CHD 2.32 No, yes, unknown Not used/supplied – – –
Cardiological care during
admission
2.33 No, yes, unknown Yes – – –
Creatinine 2.34 – Yes – – ✓
Haemoglobin (g/dl) 2.35 – Yes ✓ ✓ ✓
Site of infarction 2.36 Anterior, inferior, posterior, lateral,
indeterminate, unknown
See field 2.01 – – –
ECG QRS complex duration 2.37 QRS complex duration ≥ 120 millisecond,
QRS complex duration < 120 millisecond,
unknown
Not used/supplied – – –
Thienopyridine inhibitor use 2.38 No, yes, unknown Not used/supplied – – –
Admission method 2.39 Direct admission via emergency service,
self presenter to this hospital, already in this
hospital, inter-hospital transfer for specific
treatment, repatriation after coronary
intervention, other, unknown
Not used/supplied – – –
Patient location at time of
STEMI
2.40 Onset of STEMI while patient not in hospital
(ST elevation on first ECG), ST elevation first
recorded on a subsequent ECG in (or before
arrival at) a non-interventional hospital, ST
elevation first recorded on a subsequent ECG
in (or before arrival at) the interventional
hospital, not applicable, unknown
Not used/supplied – – –
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Killip class 2.41 No evidence of heart failure, basal
crepitations and/or elevated venous pressure,
pulmonary oedema, cardiogenic shock, not
applicable, unknown
Yes – – –
Stress echo 2.42 No, yes, planned after discharge, not
indicated, unknown
Not used/supplied – – –
Date/time of symptom onset 3.01 – Not used/supplied – – –
Date/time of call for help 3.02 – Used to determine EMS response time with
fields 3.03/3.04
See field 3.39
✓ ✓ ✓
Date/time of arrival of first
responder
3.03 – See field 3.02 – – –
Date/time of arrival of
ambulance
3.04 – See field 3.02 – – –
Ambulance job number 3.05 – Not supplied – – –
Date/time of arrival at hospital 3.06 – Time, month and year supplied
Analyses included term for year slope.
Time categroised as day or night
✓ ✓ ✓
Reason reperfusion treatment
not given
3.08 None, ineligible ECG, too late, risk of
haemorrhage, uncontrolled hypertension,
administrative failure, elective decision,
patient refused treatment, other, unknown
Yes – – –
Date/time of reperfusion
treatment
3.09 – See field 3.39 – – –
D
O
I:10.3310/hsdr06140
H
EA
LTH
SERVICES
A
N
D
D
ELIVERY
RESEA
RCH
2018
VO
L.6
N
O
.14
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
C
ouper
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
105
Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Delay before treatment 3.10 No, sustained hypertension, clinical concern
about recent cerebrovascular event or
surgery, delay obtaining consent, initial ECG
ineligible, cardiac arrest, obtaining consent
for therapeutic trial, hospital administrative
failure, ambulance procedural delay, other,
ambulance, 12-lead ECG not diagnostic of
STEMI, consideration of primary PCI,
ambulance administrative delay,
catheterisation laboratory access delayed,
delay in activating catheterisation laboratory
team, pre-PCI complication, equipment
failure, convalescent STEMI
Not used/supplied – – –
Where was initial reperfusion
treatment given?
3.11 No reperfusion attempted, before admission
to hospital, in A&E, in CCU (direct admission),
in CCU (slowtrack), elsewhere in hospital,
catheterisation laboratory, unknown
Not used/supplied – – –
Cardiac arrest date/time – first
arrest only
3.13 Used in case identification – – –
Cardiac arrest location 3.14 No arrest, before ambulance arrival, after
ambulance arrival, A&E, CCU, medical ward,
elsewhere in hospital, catheterisation
laboratory
Yes ✓ ✓ ✓
Arrest presenting rhythm 3.15 Asystole, VF/pulseless VT, PEA, unknown Yes ✓ ✓ ✓
Outcome of arrest 3.16 No return of circulation, ROSC but died in
hospital, discharged from hospital (with
neurological deficit), discharged from hospital
(no neurological deficit), resuscitation not
attempted, transferred to another hospital,
unknown
Used in case identification and for
neurological outcome
– – –
Admission ward 3.17 CCU, acute admissions unit, general medical
ward, intensive therapy unit, other, died in
A&E, cardiac ward (non CCU), stepdown
ward, unknown
Yes ✓ ✓ ✓
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Peak troponin 3.19 – Not used/supplied – – –
Unfractionated heparin 3.20 No, yes, unknown Not used/supplied – – –
Low-molecular-weight
heparin
3.21 No, yes, unknown Not used/supplied – – –
Thienopyridine platelet
inhibitor
3.22 No, yes, unknown Not used/supplied – – –
IV 2b/3a agent 3.24 No, yes, unknown Not used/supplied – – –
IV beta-blocker 3.25 No, yes, unknown Not used/supplied – – –
Calcium channel blocker 3.27 No, yes, unknown Not used/supplied – – –
IV nitrate 3.28 No, yes, unknown Not used/supplied – – –
Oral nitrate 3.29 No, yes, unknown Not used/supplied – – –
Potassium channel modulator 3.30 No, yes, unknown Not used/supplied – – –
Warfarin 3.31 No, yes, unknown Not used/supplied – – –
Angiotensin-converting
enzyme inhibitor or ARB
3.32 No, yes, unknown Yes – – –
Thiazide diuretic 3.33 No, yes, unknown Not used/supplied – – –
Loop diuretic 3.34 No, yes, unknown Yes – – –
Thrombolytic drug 3.36 Streptokinase, alteplase, reteplase,
tenecteplase
See field 3.39 – – –
Troponin assay 3.37 Troponin I, troponin T, high-sensitivity
troponin T, high-sensitivity troponin I,
unknown
Not used/supplied – – –
Fondaparinux 3.38 No, yes, unknown Not used/supplied – – –
Initial reperfusion treatment 3.39 None, thrombolytic treatment, pPCI in house,
referred for consideration for pPCI elsewhere,
pPCI already was performed at the
interventional hospital, unknown
Used with fields 3.04, 3.06, 3.09, 3,36 to
determine nature and timing of reperfusion
treatment
✓ ✓ ✓
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Additional reperfusion
treatment
3.40 None, rescue PCI in house, referred for
rescue PCI elsewhere, facilitated PCI,
additional dose of thrombolytic
Not used/supplied – – –
Inpatient management of
hyperglycaemia/diabetes
3.41 None, glucose insulin regime, insulin pump,
multidose insulin, other pre-admission insulin
regime, oral medication only, diet only,
unknown
Not used/supplied – – –
Diabetic therapy at discharge 3.42 None, multidose insulin regime, other insulin
regime, oral medication, insulin plus oral
medication, diet only, not applicable,
unknown
Not used/supplied – – –
Oral beta-blocker 3.43 No, yes, unknown Not used/supplied – – –
Aldosterone antagonist 3.44 No, yes, unknown Not used/supplied – – –
Bivalirudin 3.45 No, yes, contraindicated, not indicated,
unknown
Not used/supplied – – –
Date/time of arrival at
non-interventional hospital
3.46 – Not used/supplied – – –
Assessment at
non-interventional hospital
3.47 No contact with a non-interventional
hospital, patient remains in ambulance, A&E,
acute assessment unit, CCU/cardiac facility,
self referral, already in hospital, other,
unknown
Yes – – –
Assessment at interventional
centre
3.48 Assessed in A&E, acute assessment unit,
CCU/cardiac facility, catheterisation
laboratory, already in hospital, unknown
Yes – – –
Intended reperfusion
procedure
3.49 None, primary PCI, rescue PCI, thrombolytic
treatment, other coronary intervention,
unknown
Yes – – –
Procedure performed 3.50 No angiography, angiography but no PCI,
angiography and PCI, unknown
Yes – – –
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Why was no angiogram
performed?
3.51 Not applicable, diagnosis not ACS,
patient refused, patient died, complication
before angiography could be performed,
angiography inappropriate because of
comorbidity, technical failure, laboratory
unavailable, other, unknown
Yes – – –
Why was no intervention
performed?
3.52 Not applicable, patient refused, patient died,
complication before PCI could be performed,
PCI felt to be inappropriate, angiographically
normal coronaries/mild disease/infarct-related
vessel unclear, surgical disease, technical
failure, other, unknown
Yes – – –
Date/time of start of insulin
infusion
3.53 – Not supplied – – –
Date of discharge 4.01 – Used to determine outcomes – – –
Discharge diagnosis 4.02 MI (ST elevation), threatened MI, ACS
(troponin positive)/NSTEMI, ACS (troponin
negative), chest pain of uncertain cause, MI
(unconfirmed), other diagnosis, Takotsubo
cardiomyopathy, PCI related MI
Yes – – ✓
Bleeding complications 4.03 None, intracranial bleed, retroperitoneal
haemorrhage, any bleed with Hb fall of
> 50 g, any bleed with Hb fall of > 30 g and
< 50 g, any bleed with Hb fall of < 30 g,
unknown
Not supplied – – –
Death in hospital 4.04 No, from MI, from complication of treatment,
other non-cardiac-related cause, other
cardiac cause, unknown
Used to determine outcome – – –
Discharged on beta-blocker 4.05 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
Yes – – ✓
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Discharged on angiotensin-
converting enzyme inhibitor
or ARB
4.06 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
Yes – – ✓
Discharged on statin 4.07 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
Yes – – ✓
Discharged on aspirin 4.08 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
Used to determine antiplatelet therapy
strategy on discharge with fields 4.27/4.31
– – ✓
Cardiac rehabilitation 4.09 No, yes, patient declined, not indicated,
unknown
Yes – – ✓
Exercise test 4.10 No, yes, planned after discharge,
not indicated, unknown
Not supplied – – –
Echocardiography 4.11 No, yes, planned after discharge,
not indicated, unknown
Yes – – ✓
Radionuclide study 4.12 No, yes, planned after discharge,
not indicated, unknown
Not supplied – – –
Coronary angiography 4.13 Protocol-driven investigation performed in
this hospital, symptom-driven investigation
performed in this hospital, protocol-driven
investigation performed at another hospital,
symptom-driven investigation performed at
another hospital, planned after discharge,
not applicable, patient refused, not
performed, unknown
Yes – – ✓
Coronary intervention 4.14 PCI, CABG, PCI planned after discharge,
CABG planned after discharge, not
applicable, patient refused, not performed or
arranged, unknown
Yes – – –
Date/time of referral for
investigation/intervention
4.15 – Not used/supplied – – –
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
Discharge destination 4.16 Home, other hospital, convalescence, death,
other speciality in same hospital, unknown
Not used/supplied – – –
Daycase transfer date 4.17 – Not supplied – – –
Angiogram date/time 4.18 – Not used/supplied – – –
Local intervention date 4.19 – Not used/supplied – – –
Interventional centre code 4.20 – Not supplied – – –
Referring hospital code 4.21 – Not supplied – – –
Followed up by 4.23 Cardiologist, non cardiologist, no follow up,
not applicable, unknown
Yes – – ✓
Reinfarction 4.24 No, yes, unknown Not used/supplied – – –
Date of return to referring
hospital
4.26 – Not supplied – – –
Discharged on a
thienopyridine inhibitor
4.27 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
See field 4.08 – – –
Discharged on an aldosterone
antagonist
4.28 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
Not supplied – – –
What procedure was
performed at the
interventional hospital
4.29 No angiography or primary reperfusion
treatment performed, angiography only,
primary angioplasty, rescue angioplasty,
CABG, thrombolytic treatment, unknown
Not used/supplied – – –
Delay to performance of
angiogram
4.30 None, delay due to comorbid clinical
condition/competing clinical issue, capacity
issues, patient preference, other, unknown
Not used/supplied – – –
Discharged on ticagrelor 4.31 No, yes, contraindicated, patient declined
treatment, not applicable, not indicated,
unknown
See field 4.08 – – –
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Field name
MINAP
field
number Response options Variable used
Used in modelling
In-hospital
mortality
Neurological
outcome
Time to
all-cause
mortality
High risk NSTEMI 4.32 No, yes, unknown Not supplied – – –
Smoking cessation advice
given
5.1 No, yes, planned in rehabilitation,
not applicable, unknown
Yes – – –
Dietary advice given during
this admission
5.2 No, yes, planned in rehabilitation,
not applicable, unknown
Yes – – –
ONS data
Survival status and days to
censorship
– – Yes – – –
IMD score – – Yes ✓ ✓ ✓
Other data items
Hospital northings–eastings – – See field 1.10 – – –
Mini-GRACE score – – Derived from other supplied fields – – –
PCI centre – – Determined using field 3.39 for each
hospital
✓ ✓ ✓
Cardiac arrest volume – – Yes ✓ ✓ ✓
A&E, accident and emergency; ARB, angiotensin receptor blocker; b.p.m., beats per minute; CHD, coronary heart disease; GP, general practitioner; Hb, haemoglobin; IV, intravenous;
PCT, primary care trust; SBP, systolic blood pressure.
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Appendix 2 Imputation iteration performance:
models of convergence
Iteration
Mean X.1.07Gender SD X.1.07Gender
Mean EthnicityNewCat SD EthnicityNewCat
Mean SmokingNewCat SD SmokingNewCat
Mean DiabetesBin SD DiabetesBin
Mean X.3.14Wherecardiacarrest SD X.3.14Wherecardiacarrest
Mean LogCholesterol SD LogCholesterol
Mean LogSystolicDP SD LogSystolicDP
0 5 10 15 20 25 30 0 5 10 15 20 25 30
Mean LogHeartRate SD LogHeartRate
4.43
0.28
0.30
0.245
0.260
0.310
0.325
0.44
0.48
0.33
0.35
0.37
0.492
0.496
0.95
1.00
1.05
0.2
0.3
0.4
0.5
4.45
4.77
4.79
1.43
1.45
1.47
1.3
1.4
1.5
1.13
1.15
1.17
1.54
1.58
1.55
1.60
1.65
1.6
1.7
1.8
1.9
FIGURE 11 Imputation iteration performance: models of convergence – first group of variables.
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Mean LogGlucose SD LogGlucose
Mean LogHaemoglobin SD LogHaemoglobin
Mean LogCreatinine SD LogCreatinine
Mean DiagnosisSite SD DiagnosisSite
Mean X.3.15PresentingRhythm SD X.3.15PresentingRhythm
Mean X.2.01AdmissionDiagnosis SD X.2.01AdmissionDiagnosis
Mean ECGDeterminingTrtNewCat SD ECGDeterminingTrtNewCat
Mean X.2.31LVEF SD X.2.31LVEF
Iteration
0 5 10 15 20 25 30 0 5 10 15 20 25 30
1.90
2.00
2.00
2.10
1.0
2.0
3.0
4.0
2.74
2.78
2.82
2.10
2.20
4.60
4.70
2.54
2.58
2.62
2.24
2.30
2.36
0.79
0.81
0.83
0.74
0.78
0.52
0.58
0.96
0.98
0.38
0.42
0.46
0.16
0.18
0.43
0.45
FIGURE 12 Imputation iteration performance: models of convergence – second group of variables.
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Mean LogEMSresponse SD LogEMSresponse
Mean LogEMSdistanceKm SD LogEMSdistanceKm
Mean AdmConsultantBin SD AdmConsultantBin
Mean X.2.33CardiologicalCareduringAdmission SD X.2.33CardiologicalCareduringAdmission
Mean AdmWardNewCat SD AdmWardNewCat
Mean AspirinGivenNewCat SD AspirinGivenNewCat
Mean X.2.23PlaceECGPerformed SD X.2.23PlaceECGPerformed
Mean EchocardiographyNewCat SD EchocardiographyNewCat
Iteration
0 5 10 15 20 25 30 0 5 10 15 20 25 30
1.54
1.58
1.85
1.95
2.05
2.75
2.85
2.8
3.0
3.2
1.3
1.5
1.7
1.30
1.40
1.50
2.25
2.35
2.45
2.20
2.24
2.28
0.490
0.496
0.80
0.90
1.14
1.18
0.95
1.05
1.15
0.35
0.45
0.46
0.48
0.50
0.80
0.84
0.66
0.70
FIGURE 13 Imputation iteration performance: models of convergence – third group of variables.
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Mean CoronaryAngioNewCat SD CoronaryAngioNewCat
Mean CoronaryInterventionNewCat SD CoronaryInterventionNewCat
Mean DischargeDiagnosisNewCat SD DischargeDiagnosisNewCat
Mean X.4.23Followedup SD X.4.23Followedup
Mean X.4.09CardiacRehab SD X.4.09CardiacRehab
Mean ThienoTicagrelor SD ThienoTicagrelor
Mean GeoIMDScore SD GeoIMDScore
Iteration
0 5 10 15 20 25 30 0 5 10 15 20 25 30
20
21
22
23
24
25
1.50
1.60
1.74
1.76
1.78
1.80
1.9
2.0
2.1
1.80
1.90
2.00
1.42
1.46
1.62
1.66
1.70
14.0
15.0
16.0
17.0
0.52
0.56
0.60
0.41
0.43
0.45
0.55
0.60
0.65
0.0
0.1
0.2
0.3
0.4
0.56
0.58
0.60
0.80
0.82
0.84
FIGURE 14 Imputation iteration performance: models of convergence – fourth group of variables.
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